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 Abstract 
Patient involvement with healthcare provision is limited, particularly in treatment 
outcomes measurement. This is even more critical in substance misuse treatment, where 
patients tend to be stigmatised and their perspectives devalued. There are calls for a paradigm 
shift towards a greater patient involvement and personalisation of outcome measurement in 
substance misuse treatment. Responding to such call, this project implemented an idiographic 
outcome measurement approach in substance misuse treatment, through the use of 
individualised patient-reported outcome measures (I-PROMS). Unlike the traditional 
nomothetic method, which relies on standardised measures with pre-set items, I-PROMS are 
tailor-made tools with items created by patients, in their own words. I-PROMS do not only 
increase patient involvement with outcome measurement, by asking patients to actively 
contribute for the generation of items, but also permit a personalisation of measurement by 
focusing on topics of relevance for each individual case. The findings of our five articles 
showed that patients welcomed the freedom provided by I-PROMS to express their personal 
concerns, mainly in the presence of their therapists. I-PROMS allowed the identification of 
qualitative information that standardised measures targeting general psychological distress and 
drug-related problems missed to capture. On psychometrics, I-PROMS produced good reliable 
scores but were not strongly correlated with standardised outcome measures. Overall, our 
project suggests that, in substance misuse treatment, I-PROMS are a potential strategy to 
successfully increase patient involvement with outcome measurement and to personalise the 
evaluation of treatment outcomes. The combined use of I-PROMS with standardised measures 
is recommended for optimal results.  
Keywords: substance misuse treatment, patient involvement, patient perspectives, 
outcome measurement, idiographic approach, personalised health assessment, I-PROMS.  
 Resumo 
O envolvimento dos pacientes com a prestação de cuidados de saúde é limitado, em 
particular na avaliação dos resultados do tratamento. Esta situação torna-se mais crítica na área 
do tratamento para a dependência de substâncias, onde os pacientes tendem a ser 
estigmatizados e as suas perspectivas desvalorizadas. A comunidade científica tem apelado 
para uma mudança paradigmática no sentido de um maior envolvimento dos pacientes e uma 
maior personalização da avaliação do tratamento para a dependência de substâncias. 
Respondendo directamente a tal apelo, este projecto implementou uma estratégia idiográfica 
de avaliação do tratamento, através do uso de medidas individualizadas de avaliação dos seus 
resultados (I-PROMS, do inglês individualised patient-reported outcome measures). 
Contrariamente ao método tradicional nomotético, que se baseia em medidas estandardizadas 
com itens pré-definidos, as I-PROMS são instrumentos feitos à medida do paciente com itens 
criados por si, nas suas próprias palavras. As I-PROMS não só aumentam o envolvimento dos 
pacientes com a avaliação do tratamento, ao permitirem que os pacientes contribuam 
activamente para a criação dos itens, como também personalizam a avaliação ao atender aos 
aspectos que são relevantes para cada caso individual. Os resultados obtidos nos cinco artigos 
demonstram que os pacientes apreciam a liberdade dada pelas I-PROMS para expressar os seus 
problemas pessoais, principalmente na presença dos seus terapeutas. As I-PROMS 
possibilitaram a identificação de informação qualitativa que as medidas estandardizadas 
focadas no sofrimento psicológico ou na dependência de substâncias não conseguiram captar. 
A nível psicométrico, as I-PROMS produziram avaliações (scores) fiáveis para quantificar o 
sofrimento dos pacientes, mas não se correlacionaram fortemente com as medidas 
estandardizadas. Em suma, o nosso projecto sugere que, no tratamento para a dependência de 
substâncias, as I-PROMS são uma estratégia potencialmente bem-sucedida para aumentar o 
envolvimento dos pacientes com a avaliação do tratamento e para personalizar a avaliação dos 
 seus resultados. O uso combinado de I-PROMS com medidas estandardizadas é recomendado 
para uma maior optimização dos resultados.   
Palavras-chave: tratamento para a dependência de substâncias, envolvimento dos 
pacientes, perspectivas dos pacientes, avaliação dos resultados, estratégia idiográfica, 
avaliação personalizada da saúde, medidas I-PROMS.  
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BACKGROUND OF THE PROJECT 
 
 2 
General introduction  
 “It is a truth universally acknowledged, that a single man in possession of a good 
fortune, must be in a want of a wife”, wrote Jane Austen in her worldwide acclaimed novel 
Pride and Prejudice, released in 1873. Even though literary masterpieces such as this are not 
to be compared with psychological manuscripts, this quote illustrates how important it is for 
us to understand the universal laws of human behavior, so that individuals’ actions can be 
predicted as accurately as possible.   
 For decades, searching for what is common across individuals, using objective and 
quantifiable variables, has been the preferred approach to psychological science. The concept 
of “psychological experiment” was born with the works of Wundt at the end of the ninetieth 
century. Back then, Wundt dedicated himself to the study of social phenomena, but soon this 
so-called positivist approach spread to other fields of psychology, including the evaluation of 
psychological treatment outcomes. Resembling what occurs in other health-related fields, the 
evaluation of psychological treatment outcomes has traditionally followed a nomothetic 
approach. This nomothetic approach focusses on “dimensions that are common to all people, 
in varying degrees, (…) to locate the patient on those universal dimensions by comparing his 
or her score with population norms” (Sales & Alves, 2016, p. 266). When treatment evaluation 
has a nomothetic scope, the measurement is based on standardised questionnaires, containing 
pre-set items that are applicable to a large group of individuals. According to Möller (2009), 
the majority of psychology and psychiatry research and practice has relied on standardised 
measures to assess changes in patients’ psychological status, which may occur with or without 
clinical interventions. These measures serve this purpose because they not only allow an 
objective quantification of psychological phenomena, but also facilitate data analysis with 
statistical methods and communication of findings to wider audiences (Möller, 2009). Because 
of this, standardised measures, which tend to be driven by experts and professionals, have 
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become the gold standard to evaluate the outcomes of psychological treatments (Paul, Sanson-
Fischer, & Carey, 2013).  
 However, when it comes to evaluating the outcome of psychological treatments, the 
nomothetic approach has received a major criticism from the literature: overlooking subjective 
and distinctive characteristics of individuals (Elliott et al., 2016; Möller, 2009; Sales & Alves, 
2012; 2016). In other words, standardised measures have minimal input from patients, who are 
poorly involved in the selection of topics that are relevant for their own reality.  
 To improve this situation, the use of alternative methods capturing the individual 
features of patients started to emerge, leading to the so-called idiographic measurement 
approach, which was first introduced in the 1930’s by authors such as Allport and Shapiro (cit. 
Elliott et al., 2016). By definition, the idiographic approach targets the particular features of 
patients, taking into account the uniqueness of each individual and what differentiates him/her 
from the population (Elliott et al., 2016; Sales & Alves, 2012; 2016). As such, the idiographic 
measurement approach relies on individualised tools, which are tailor-made instruments where 
patients have the opportunity to freely define the aspects, or items, that have personal relevance, 
without the pre-definition of investigators or clinicians (Fitzpatrick et al., 1998).  
 The present work aimed to contribute with knowledge about the idiographic approach 
to outcome measurement, through the use of individualised measures, and in comparison with 
the traditional nomothetic strategy. We focussed on patients in substance misuse treatment 
settings as our target population, which is one of the clinical settings where patients’ 
individualities tend to be less considered (Orford, 2008). In the next pages we present the 
theoretical, empirical and ethical principles that guided the research reported henceforth.  
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Treatment outcome measurement and the role of patient-reported outcome measures 
(PROMS)  
 The impact, or value, of psychological interventions is generally estimated according 
to the outcomes that they generate (Schulte, 1995). Hence, evaluating the outcomes of 
treatment is a way of comprehending the utility and the effect of such treatment, namely, how 
patients are feeling, functioning, or even surviving (Walton et al., 2015).  
 Nearly 20 years ago, Schulte (1995) proposed a three-step classification system to 
consider in the outcome measurement process. The first refers to “operationalization”, i.e., 
choosing the method(s) to capture information and the most relevant data sources to capture 
information from. There are methods that can be used for this purpose, including self-report 
questionnaires, observations, interviews or even biological markers. All these methods have 
been extensively used in many clinical contexts and, to date, there is an incommensurable 
number of measures available for researchers and practitioners to use, depending on their 
objectives. More challenging is to decide who constitutes the best source of information to 
collect data from: patients, staff members (e.g. therapist), significant others or neutral observers 
(e.g. researchers). The second step in outcome measurement is, to Schulte (1995), the 
“definition of success criteria”, i.e. determining which aspects should be measured and with 
which norms or references they should be compared against. This comparison (e.g. pre-post 
treatment evaluation) will inform us about the outcome of treatment. The third step to consider 
in outcome measurement is the “design of data collection”, i.e. the procedure by which the 
study is conducted, including aspects such as the points in time where the evaluation is to be 
carried out. From a theoretical perspective, our research focussed on the two first steps of 
Schulte’s (1995) classification. 
 Let us concentrate on how outcome measurement should be operationalised, namely, 
which data sources provide us with relevant, useful and reliable knowledge about psychological 
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treatments. Health professionals have expertise that gives them authority and autonomy to 
make decisions about treatment, based on their own clinical judgement (Bower & Gilbody, 
2010). Similarly, the expertise of researchers in a given field also tends to play a key role in 
determining the research agendas of clinical services and university centres. Assuming that this 
is correct, i.e. that professionals and researchers are those who best know how to detect 
psychological changes, methods such as observational scales or staff-targeted check lists of 
behaviours/symptoms would be enough for professionals to measure those changes. This 
assumption is not entirely true. It is unquestionable that professionals and researchers possess 
a vast level of experience about delivering treatment. But patients themselves are in a privileged 
position to inform us about their concerns and how they are feeling; and we will never have 
access to this information – unless we ask them (Devlin & Appleby, 2010).  
 Until very recently, patients’ reports about their own clinical status and well-being were 
seldom collected as a routine procedure in health services (Snyder et al., 2011). In 2010, an 
innovative outcome measurement approach was introduced by the United Kingdom’s National 
Health Service that would lead to a paradigm shift: the patient-reported outcome measures 
(PROMS) initiative (Devlin & Appleby, 2010). This initiative gave patients a key role in 
outcome measurement, by providing them with an opportunity to contribute for the evaluation 
of their condition. PROMS can be defined as questionnaires, or tools, that are meant to be 
completed by patients and aim to gather their own perception about how they are feeling and 
the impact of treatment on their health (Greenhalgh et al., 2014). By following this 
measurement strategy, we are therefore assuming that patients are, indeed, a valuable source 
of information about their condition (Bren, 2006). 
 PROMS follow a nomothetic approach and, according to Devlin and Appleby (2010), 
share a common feature: they are based on a pre-set, standardised series of structured questions 
for patients to report on their current health. Two main types of PROMS have been identified 
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in the literature (Sales, 2016): generic PROMS, targeting general health and unspecific health-
related topics, such as quality of life or level of functioning, and that are potentially relevant to 
patients with various clinical conditions (e.g. EuroQol; http://www.euroqol.org/); and specific 
PROMS, targeting a particular type of disorder, and which are only relevant to a certain patient 
group (e.g. Beck Depression Inventory; Beck, Steer, & Garbin, 1988).  
 One of the greatest criticisms that PROMS have received throughout the years is the 
subjectivity of their data, for being generated directly by patients. But as Devlin and Appleby 
(2010) put it, this is exactly the purpose of PROMS: to understand the patients’ views. One 
advantage of PROMS is their potential to improve the communication between patients and 
clinicians, ultimately leading to better care delivery and outcomes (Valderas et al., 2008). For 
instance, even though Flückiger and collaborators (2012) did not use PROMS in their study, 
they showed that asking patients to provide their views about treatment was likely to increase 
the quality of the therapeutic relationship, which is widely acknowledged as one of the 
variables that most contributes to treatment success. Other benefits of PROMS include the 
screening of problems, monitoring patients’ progress throughout treatment or at follow-up 
appointments and, most importantly, to facilitate the delivery of a more patient-centred care 
(Snyder et al., 2011). But there is a challenge that traditional, standardised PROMS are not able 
to surpass: capturing the unique features of each individual patient (Sales & Alves, 2016).   
 
The emergence of the individualised patient-reported outcome measures (I-PROMS) 
 PROMS emerged as a direct response to the necessity of involving patients in the 
evaluation of their healthcare. This was a positive move, by inviting patients to rate their level 
of distress. There are, though, a growing number of authors stating that this nomothetic 
approach to measurement, through the use of standardised PROMS, is not enough if we aim 
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for a truly patient-centred outcome measurement (Valderas, 2008; Basch, Abernethy, & 
Reeve, 2011). 
  For outcome measurement to focus on the particularities of each patient, it must follow 
an idiographic approach. In such circumstances, patients are asked not only to quantify their 
distress, but also to define the contents of the instrument itself. When instruments are based in 
contents directly generated by patients, they are designed as individualised outcome measures. 
Therefore, unlike their standardised counterparts, individualised outcome measures do not rely 
on pre-set lists of questions, selected by others, but are instead comprised of items generated 
by patients, about whichever domains that are important and meaningful to them (Basch, 
Abernethy, & Reeve, 2011; Fitzpatrick, 1988).  
 Individualised outcome measures arose in 1937 when authors such as Allport reported 
that “as long as psychology deals with universals and not with particulars, it won’t deal with 
much” (cit. Elliott et al., 2016). Since then, individualised outcome measures have emerged in 
many different fields, receiving different, yet similar designations, such as “patient-generated 
outcome measures” (PGOMS; Ashworth et al., 2004), “client-generated outcome measures” 
(CGOMS; Elliott et al., 2016) and also “individualised patient-reported outcome measures” (I-
PROMS; Sales, 2016). These designations have been used as synonyms in the literature, based 
on the authors’ preferences, the field of study and also the time of publication. The 
interchangeable use of these terms is also present in this compilation of articles, to meet 
publication requirements. However, hereafter, we shall be using the term I-PROMS since, to 
our belief, it is currently the most accurate designation for these type of instruments. 
 I-PROMS have not yet become “normal science”, as Kuhn (1962) would have put it. 
This is mainly due to the fact that I-PROMS are focussed on what is specific about a single 
person, hindering the aggregation of data about common features among patients in a certain 
population, service, or even at a national/international level. However, there are several signs 
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showing that we are now potentially entering an “extraordinary science” period (Kuhn, 1962), 
which is calling out for a new paradigm in outcome measurement. Using McNamara’s (2007) 
words, now our “challenge is to [understand how to] make the important measurable, not the 
measurable important”. I-PROMS are not necessarily innovative by providing patients with an 
opportunity to talk about their problems. In fact, listening to patients’ complaints is part of any 
therapeutic intervention, particularly in the first treatment sessions when therapists are learning 
about what brought patients to treatment. However, this individualised information tends to be 
mostly used for clinical-related tasks, such as treatment planning or decision-making, and is 
usually lost for the purposes of outcome measurement. This is where the greatest advantage of 
I-PROMS lies: generating individualised information about patients, in the format of items, 
that can be scored by patients and be used to evaluate clinical changes that patients undergo 
whilst in treatment, as standardised measures do (Elliott et al., 2016; Sales & Alves, 2016). 
This is a step forward in outcome measurement, by providing an opportunity for patient’s 
concerns to be heard and, simultaneously, transformed into numbers that can be shared with 
clinical staff, service managers and funding agencies, for data management purposes. 
 
Moving towards a personalised outcome measurement approach  
To this point, we have demonstrated that standardised and individualised outcome 
measures are both advantageous and necessary for a successful and meaningful outcome 
measurement process. Hence, instead of opposing strategies to evaluate treatment, it has been 
advocated that they can and should be used to complement each other (Möller, 2009).  
 In 2000, an international and multidisciplinary group of researchers and therapists 
formed a practice-based research network to investigate how to increase patient involvement 
with outcome measurement in mental health treatments. After a decade of fruitful 
collaboration, this group was designated as International Research Network on Personalised 
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Health Assessment (IPHA Group; Sales, Alves, Evans & Elliott, 2014). To date, the IPHA 
Group integrates dozens of professionals coming from countries such as Portugal and the 
United Kingdom, who have been collaborating to develop, implement and reflect about I-
PROMS and how they can be integrated with standardised measures.  
 The co-joint work of the IPHA Group has resulted in the proposal of a new strategy for 
outcome measurement: the personalised measurement approach. More than a method, this 
approach is an evaluation philosophy, rooted in the assumption that it is possible to reach a 
successful compromise between nomothetic and idiographic measures. The first attempt to 
translate this approach into practice emerged in 2010, with the development of the 
Individualised Patient-Progress System (IPPS; Sales & Alves, 2012; Sales, Alves, Evans, & 
Elliott, 2014). This system is a web-based patient progress tracking software that includes one 
standardised PROM about general psychological distress, the Clinical Outcomes Routine 
Evaluation – Outcome Measure (CORE-OM; Evans, Connell, Barkham, Mellor-Clark, & 
Audin, 2002) and one I-PROM focusing on patients’ target complaints, the Personal 
Questionnaire (PQ; Elliott et al., 2016). IPPS derived from the well-stablished CORE-Net 
system (Mellor-Clark, 2007), which included CORE-OM only, and illustrates the movement 
towards the integration of standardised and individualised PROMS in the same evaluation 
protocol (Barkham, Mellor-Clark, & Stiles, 2015). 
 With the development of IPPS, the personalised measurement approach was introduced 
in several therapeutic contexts and clinical populations, with positive results (Sales, Alves, 
Evans, & Elliott, 2014). This included university counselling services (Lucas, Soares, Oliveira, 
Sales, & Alves, 2012), general hospitals (Vieira, Torres, & Moita, 2013) and also private 
psychotherapy practices (Cruz, 2014).  
 According to its preliminary users, the personalised measurement approach has several 
helpful and hindering aspects. On the positive side, therapists reported that this methodology 
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‘highlights situations that represent patients’ distress or harm’, ‘supports clinical decision 
making’, ‘helps patients to re-think about themselves and their problems’ and provide a ‘quick 
picture of patients’ psychological distress’ (Sales, Alves, Evans, & Elliott, 2014). As 
downsides, therapists stated that using this measurement approach is “a lengthy process, 
particularly at the pre-treatment evaluation’ (Sales, Alves, Evans, & Elliott, 2014).  
 Within such panorama, there is a need to continue exploring I-PROMS and what we 
can gain by combining them with standardised measures, from a qualitative and quantitative 
point of view. The present project was a step in this direction. 
 
The status of outcome measurement in substance misuse treatment  
Unless there is a pre-treatment evaluation with diagnostic purposes, it is impossible to 
predict what motivated patients to psychological treatment when they arrive for their first 
clinical session. This is not what occurs in specialist services, though, which are focussed in a 
particular target population. In these services, professionals are expecting to address a primary 
behaviour, and co-occurring, or secondary problems may be disregarded or perceived as a 
“dilemma” (Drake, Mueser, & Brunette, 2007). Such is the reality of specialist treatment 
services for substance misuse disorders. 
It has been stated that problem screening and outcome measurement is essential and 
should be a routine practice in substance misuse treatment services (British Psychological 
Society, 2008; Deady, 2009). To Deady (2009), this measurement is particularly important for 
case formulation purposes, i.e. “gathering information about factors that may be relevant to 
treatment planning, and formulating a hypothesis as to how these factors fit together to form 
the current presentation of the client’s symptoms” (p. 9), as well as identifying “symptoms that 
may require further investigation and treatment” (p. 9). According to the British Psychological 
Society (2008), the purposes of substance misuse treatment measurement are clear and include 
 11 
the following: to confirm substance misuse; to evaluate the severity of dependence; to identify 
complications of substance misuse and related risk-behaviours; to identify medical, social and 
mental health problems; to evaluate expectations of treatment and motivation to change; to 
determine the most appropriate treatment pathway and expertise required; to evaluate the need 
for substitute medication; and to refer/liaise with other services and forms of care. 
Despite general recommendations, information about how the measurement procedure 
should be conducted and which tools should be used is diffuse. However, when patients are 
referred to or request treatment at substance misuse treatment services, they tend to be provided 
with brief evaluation forms that focus on topics related to history of substance misuse and 
typically associated behaviours, such as criminality. An example is the Treatment Outcomes 
Profile (TOP; Marsden et al., 2008), which is widely used in the United Kingdom 
(http://www.nta.nhs.uk/healthcare-TOP.aspx) and targets the following sections: ‘substance 
use’, ‘injecting risk behaviour’, ‘crime’ and ‘health and social functioning’. In Portugal, even 
though no instrument in itself is recommended by health authorities, patients tend to be invited 
for an induction session with a key worker and an initial evaluation with a psychologist or 
psychiatrist, which includes topics such as previous history of substance use and treatment 
(Serviço de Intervenção nos Comportamentos Aditivos e Dependências, see 
http://www.sicad.pt/PT/Intervencao/TratamentoMais/SitePages/ModelosRespostas.aspx).  
From a research point of view, international large-scale outcome studies have targeted 
similar criteria. The most popular were the National Treatment Outcome Research Study 
(NTORS; http://www.ntors.org.uk/), conducted in the United Kingdom, evaluating aspects 
such as ‘substance use’, ‘risk behaviours’, ‘health’ and ‘personal/social functioning’; the 
Australian Treatment Outcome Study (ATOS; Ross, Teesson, Darke, Lynskey, Ritter, & 
Cooke, 2004), that included ‘treatment experiences’, ‘heroin and other drug use’, ‘mental 
health’ and ‘criminal activity’; and the Drug Abuse Treatment Outcome Studies (DATOS; 
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http://www.datos.org/), conducted in the United States of America, which evaluated 
‘employment status’, ‘criminal status’, ‘mental health’, ‘medical and health-related data’, level 
of drug/alcohol use’, ‘primary drug and patterns of dependence’ and ‘HIV risk behaviours’. 
Even though these studies identified positive outcomes, the reality showed a different picture, 
presenting a high number of treatment drop-outs, relapse and a low percentage of treatment 
success (Gordon, 2003). Such findings call out for a reflection about how outcomes are being 
measured in substance misuse treatment. Are we missing something?  
 
Patient involvement with substance misuse treatment measurement  
 As in other mental health settings, patients in substance misuse treatment are powerful 
sources of information when it comes to identifying relevant outcomes or success criteria. In 
line with this, in 2006, the United Kingdom’s National Treatment Agency advocated that 
‘service users should be involved in all key aspects of decision making in relation to their care’ 
(p. 1). However, patients in substance misuse treatment tend to be poorly engaged with most 
clinical-related tasks, including evaluation of treatment (Orford, 2008; Trujols et al., 2011).  
 One of the main reasons behind the poor engagement of substance misusers with 
treatment-related tasks is the stigmatisation of the addictive behaviour. The literature shows 
that substance misusers are likely to be criminalised and discriminated for their behaviour, and 
perceived as ‘tainted’, ‘discounted’ and ‘undeserving’ persons whose views tend to be 
discredited and/or not even requested (Fischer et al., 2007; Ti, Tzemis, & Buxton, 2012; Trujols 
et al., 2011). Also, as Fischer and Neale (2008) highlighted, several health professionals 
‘disregard’ the concerns of patients in this population, which reduces their involvement with 
treatment and weaken their self-worth and self-confidence as individuals. This view is also 
supported by Cheng and Smith (2009), who claim that the controversies over the moral, 
criminological and bio-medical aspects of addiction hinders the development of initiatives to 
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improve the engagement of patients with clinical services. According to Fischer and 
collaborators (2007), other barriers impeding the involvement of substance users in their 
treatment include power imbalances between professionals and patients; patients’ vulnerability 
or lack of interest to participate in treatment-related tasks; and patients’ beliefs that therapists 
are experts and know how to make the best decisions for them.  
For authors such as Fischer and colleagues (2007), the movement towards a greater 
involvement of users was slower in substance misuse treatment in comparison with other health 
fields (e.g. cancer treatment). However, the increasing body of literature that emerged in the 
past decades suggests a stronger interest in including the patients’ voices in areas such as 
treatment evaluation and development of clinical guidelines (Fischer et al., 2007; Trujols et al., 
2011). As Trujols and collaborators (2011) pointed out, this paradigm is likely to have derived 
from the general tendency to modify the hierarchised relationship between doctors and patients, 
which underlined a biased assumption of substance misusers as non-competent individuals.  
It is now widely acknowledged that for services to be improved and more relevant for 
substance misusers, they must take the needs of patients into account (Ti, Tzemis, & Buxton, 
2012). Otherwise, there is a risk that services will not be sensitive to this population’s problems 
and preferences (Fischer et al., 2007). Asking for patients’ involvement is also a means of 
increasing their empowerment, confidence and self-esteem as individuals, which are likely to 
be impaired in substance misusers; as well as potentially increasing the level of acceptability 
and utilization of services by patients (Fischer et al., 2007; Ti, Tzemis, & Buxton, 2012). A 
study conducted in Scotland (cit. Fischer, 2007) illustrated the potential benefits of involving 
patients more actively with their clinical interventions. In this study, patients who had been 
involved in treatment-related decisions reported being more satisfied with their care, had longer 
treatment stays and presented more positive outcomes than their counterparts who were less 
engaged with treatment. Moreover, as Crawford et al. (2002) put it, it is a democratic right and 
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ethical obligation to involve substance misusers in the treatment they are receiving; otherwise, 
they will continue to be dehumanised and condemned for their behaviour. This is of particular 
importance in countries such as Portugal, whose decriminalisation policy adopted 15 years ago 
(Law nr. 30/2000) states that individuals who misuse drugs are referred to treatment, instead 
of being convicted with a crime sentence or even incarcerated.  
 Despite the appeal for a greater involvement of patients with substance misuse 
treatment (Orford, 2008), there is little guidance on how to translate this recommendation to 
practice. This work aimed to fill this gap by proposing, testing and gathering patients’ 
experiences with a methodology to include patient perspectives in the measurement of 
treatment outcomes.  
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Project rationale  
In our literature review, we highlighted the critical situation of outcome measurement 
in substance misuse treatment services, where 1) it is uncertain whether the “right” criteria are 
being used to measure treatment; and 2) patients’ perspectives tend to be neglected. I-PROMS 
have been introduced in several mental health fields with promising results. Therefore, this 
research project was an extension of IPHA group previous work, by introducing I-PROMS in 
substance misuse treatment and exploring their potential towards a greater patient involvement 
and personalisation of outcome measurement in this specific field.  
For our project, we devised a naturalistic cross-sectional study, where a personalised 
evaluation protocol was administered to patients entering substance misuse treatment services 
in Portugal, which resulted in two empirical articles; a focus group qualitative study to 
investigate patients’ experiences with that evaluation protocol, leading to one empirical article; 
and a scoping review to explore how relevant the existing outcome measures for substance 
misuse treatment are for this patient group, which resulted in our last empirical article.  
The evaluation protocol combined I-PROMS with standardised outcome measures. 
Using standardised tools was necessary not only for comparison purposes, but also to 
investigate the benefits and drawbacks of using both type of measures co-jointly, as the 
literature advocates (Sales & Alves, 2016; 2012; Sales, Alves, Evans, & Elliott, 2014). 
Addiction researchers (Neale & Strang, 2015) have also promoted the complementary use of 
personalised, qualitative information with standardised data about patients.  
Two I-PROMS were included in the evaluation protocol, namely, the Personal 
Questionnaire (PQ; Elliott, 2016) and the Psychological Outcome Profiles (PSYCHLOPS; 
Ashworth et al., 2005). Even though both PQ and PSYCHLOPS have an idiographic scope, 
these differ in the method for item generation (interview vs. self-report) and quantity of 
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individualised items requested (unlimited vs. three). To our knowledge, no previous study had 
ever compared the similarities and differences between these two I-PROMS.  
As standardised measures, we opted for including tools that addressed the commonest 
psychological, physical and social problems of this population. Psychological health, including 
depression, anxiety, personality disorders and post-traumatic stress are reported to be amid the 
most important areas to tackle in substance misuse treatment (Wanigaratne, Davis, Pryce, & 
Brotchie, 2005). Psychological distress has been considered in previous large-scale outcome 
studies (e.g. DATOS, NTORS and DTORS), in particular depression and suicidal ideation. 
Because of this, we selected the Clinical Outcome Routine Evaluation – Outcome Measure 
(CORE-OM; Evans, Connell, Barkham, Mellor-Clark, & Audin, 2002), a self-report measure 
about general psychological distress; and the Patient Health Questionnaire – 9 (PHQ-9; 
Kroenke, Spitzer & Williams, 2001), another self-report measure targeting mood disorders, in 
particular, depression. To evaluate substance misuse and related behaviours, the researcher-
administered Treatment Outcomes Profile (TOP; Marsden et al., 2008) was added to our 
evaluation protocol, which is one of the most popularly used measures targeting drug-related 
problems.  
To sum up, this research project was designed to improve outcome measurement in 
substance misuse treatment, through the personalisation of the evaluation process with I-
PROMS; and to increase patient involvement with outcome measurement, by actively asking 
for their collaboration in the selection of topics to be evaluated. We endeavoured that this work 
could contribute to the development of a new methodological approach to measure substance 
misuse treatment outcomes. Can we shift the current paradigm? 
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Aims and overview 
Our main goal was to explore the potential of I-PROMS as a strategy to personalise the 
outcome measurement process in substance misuse treatment services, following a mixed-
methods (qualitative and quantitative) approach. More specifically, we aimed to explore the 
nature of qualitative information and the scorings generated by I-PROMS, as well as their 
practicability and adequacy as outcome measures. Additionally, we also explored the 
perspectives of patients about I-PROMS.  
The outputs of our work were divided into five scientific articles. The first article had a 
theoretical scope and aimed to provide a literature-based foundation for our measurement 
philosophy and to present it to the scientific community, since there were no accounts of 
individualised measures in substance misuse treatment. For this article, we followed a critical 
literature review approach to reinforce the importance of patient involvement, and to overview 
the methods currently used to increase this involvement in healthcare. I-PROMS were 
suggested as a method to involve patients more actively in treatment. In particular, we 
discussed how asking patients in substance misuse treatment to complete individualised 
measures is likely to reduce the stigmatisation of these individuals, humanise the outcome 
measurement process and value the perspectives of those who have first-hand experience with 
substance misuse. This article was concluded by enhancing the challenges in using I-PROMS 
in this field, as well as future research needed to make this approach a more feasible, reliable 
and robust method.  
The second article presented a qualitative study, using a focus group approach, in which 
we interviewed a sub-sample of patients (N = 10) who completed the evaluation protocol. Its 
main goal was to explore patients’ experiences and thoughts about the I-PROMS and 
standardised measures that were part of the protocol and to comprehend how relevant and 
appropriate those measures were for this population, from their point of view. We expected to 
 18 
learn from patients what is necessary to increasingly make outcome measurement a more 
meaningful and comfortable experience. From an ethical point of view, and particularly in a 
project about patient involvement, it was imperative to consult patients about our measurement 
approach. Otherwise, it would have been contradictory to our research philosophy to suggest a 
methodology to improve patient involvement without involving them in this process as well.  
 After learning that I-PROMS were positively perceived by patients, we proceeded to 
the third article. This study explored if I-PROMS generated additional information about 
patients that standardised measures overlooked. For this, we categorised 489 I-PROMS items, 
generated by 93 patients. Items were categorised according to their underlying sub-theme, 
based on a classification system proposed by Ashworth and collaborators (2007). A thematic 
comparison was made between these sub-themes and the contents of pre-set items provided in 
the three standardised measures. Our aim was to understand if, from a qualitative perspective, 
I-PROMS were a valuable complement to standardised measures. 
 The fourth article had a quantitative scope and its aims were twofold: first, to investigate 
the practicability of I-PROMS in substance misuse treatment services, based on quantitative 
parameters (e.g. administration times, response rates); and second to explore the scorings of I-
PROMS from a psychometric point of view. In other words, we wanted to investigate to what 
extent I-PROMS could be used to quantify patients’ distress in a reliable and valid manner, in 
addition to providing relevant qualitative information about patients. The findings of this study 
were meant to build on preliminary reports about the psychometrics of I-PROMS and its 
potential as outcome measures.  
To this point, our studies were limited to the comparison of I-PROMS with three 
standardised measures. For that reason, the fifth and final article had a more general scope, by 
exploring how outcome measures currently recommended in Europe for substance misuse 
treatment reflect the concerns of patients. This study followed a scoping review methodology 
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and derived from the findings of the third article using the I-PROMS sub-themes that emerged 
from our naturalistic sample. The aims were to identify the domains covered by outcome 
measures and to contrast them with I-PROMS sub-themes. We intended to take a step further 
from the findings obtained in our project, potentially demonstrating that even when a broader 
range of PROMS is considered, I-PROMS are still needed to capture patients’ individual 
concerns.  
 This work is concluded with a general discussion of the main findings that emerged 
from the five articles, having in mind the objectives of the research project. We also sought to 
discuss the meaning of our research outputs in light of what is already reported in the literature 
and directions for future research. Lastly, we aimed to highlight preliminary recommendations 
on how to use I-PROMS in substance misuse treatment settings, which derived from our 
findings. Figure 1 provides a visual diagram that summarises our research tasks, their 
sequenced implementation and the timeframes in which each task was performed.  
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Notes: * refers to the time interval where the article / research study was conducted. For 
empirical articles, the first date refers to the beginning of data collection, and the last 
corresponds to the submission of the article to scientific journals.   
  
Figure 1. Outline of the main research question, tasks and outputs of this project. 
Task 1 (2012-2013)*
•To propose a personalised outcome 
measurement approach to the scientific 
community
•Output: Theoretical article published at 
International Journal of Drug Policy  (5-
year impact factor: 3.04; Q1)
Task 2 (2013-2014)
•To explore the experiences of people with 
the personalised outcome measurement
protocol
•Output: Empirical article published at
Substance Abuse Treatment, Prevention
and Policy (5-year impact factor: 2.03; Q3)
Task 3 (2013-2016)
•To investigate the qualitative gains of 
integrating I-PROMs with standardised 
PROMs
•Output: Empirical article (submitted for 
publication)
Task 4 (2012-2016)
•To study the practicability and 
psychometrics of I-PROMS
•Output: Empirical article (submitted for 
publication)
Task 5 (2016)
•To explore if the existing PROMS in 
substance misuse treatment cover the 
topics of relevance to patients (identified 
in Task 3)
•Output: Empirical article invited for 
revision and resubmission at Drug and 
Alcohol Dependence (5-year impact 
factor: 3.72; Q1)
Main research question 
Can we move towards a personalised outcome measurement approach in substance 
misuse treatment? 
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Personalising the evaluation of substance misuse treatment: a new 
approach to outcome measurement¤ 
Paula C. G. Alvesa,b*, Célia M. D. Salesc, & Mark Ashworthb 
 
Patient involvement in healthcare, in general, and in substance misuse in particular, has 
become a topic of paramount importance (Rutter et al., 2004). Patient involvement can be 
conceptualised as listening to the patients’ perspective and encouraging patients to take an 
active role in the care they are receiving. This approach is advocated by international authorities 
in health and social care such as the United Kingdom’s National Institute for Health and Care 
Excellence (NICE), which recommends “person-centred care” that takes into account the 
patient’s “needs, preferences and strengths” (Crawford, 2011). According to Orford (2008), the 
perspectives of patients in substance misuse treatment tend to be overlooked and their 
involvement with treatment is limited. However, the evidence on how patient involvement can 
be improved within the context of substance misuse programmes are scarce. Can we do 
something to shift this reality?  
 In healthcare, patients can become actively involved by collaborating with treatment 
outcome evaluation. In psychological treatments the commonest approach to this involves the 
use of standardised outcome measures (SOM), whose pre-set items, developed by research 
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experts or professionals are rated by patients. The majority of SOM, both in psychological 
treatments (e.g., CORE-OM; Evans, Connell, Barkham, Mellor-Clark, & Audin, 2002) and in 
substance misuse (e.g., TOP; Marsden et al., 2008), have had their psychometric properties 
extensively explored and their results are widely acknowledged as valid and reliable to evaluate 
treatment. However, due to their universal scope and applicability to both healthy populations 
and those with mental health conditions, SOM are unlikely to cover all the subjective concerns 
of patients, their priorities and their personal experiences in treatment.  
There is a different approach to evaluate treatment, which is based on patient-generated, 
or individualised, outcome measures (PGOM). PGOM include items that are created by 
patients, resulting in personalised tailor-made scales that can be rated for severity, just like 
SOM (Sales & Alves, 2012). There are several protocols to generate these personalised scales: 
for instance, the Personal Questionnaire (PQ; Elliott, Mack, & Shapiro, 1999) is a semi-
structured interview where patients are asked to say which are “the main problems that led 
them to treatment” and then to rank order them by importance; or PSYCHLOPS (Ashworth et 
al., 2004), a self-report instrument where patients write down the two main problems they are 
currently experiencing and one thing that has become difficult to do because of those problems. 
When PGOM are used, the level of patient involvement with treatment evaluation increases 
substantially, which is important not only because patients and clinicians tend to appraise 
treatment differently, but also because most measurements are developed without direct input 
from patients (Crawford et al., 2011). Also, PGOM data is not fixed in time and allows patients 
to revise, delete obsolete problems or add new ones that might have arisen during therapy. 
PGOM are becoming increasingly popular in psychological treatments, given their 
advantages for outcome evaluation and clinical practice. As outcome measures, PGOM include 
patient case-specific information, as well as scores that quantify the distress caused by such 
problems, allowing a personalised evaluation of outcome (Sales & Alves, 2012); one of the 
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properties of PGOM is greater sensitivity to clinical change when compared with SOM; the 
trade-off is that PGOM have slightly lower levels of test-retest reliability and internal reliability 
(Lacasse et al, 1999). Nevertheless, the reliability levels of PGOM are satisfactory and this 
should not detract their role as highly sensitive measures of change (Ashworth et al., 2008; 
Elliott et al., 2014). Also, PGOM allow outcome measurement to take patient’s perspectives 
into account, making them feel more valued as individuals (Alves, Sales, & Santos, 2014). As 
clinical tools, PGOM have been considered to be useful to complement diagnoses, case 
formulation and clinical-decision making (Sales et al., 2007; Sales, Alves, Evans, & Elliott, 
2014); and recently, patients reported satisfaction with the freedom that PGOM give them to 
focus on the topics which they prioritise during the evaluation process (Alves, Sales, & Santos, 
2014).  
But there are downsides to using PGOM. For instance, they have been considered time-
consuming and are difficult to use with patients with certain impaired cognitive functions (e.g. 
memory). Moreover, PGOM hinder the comparison between patients (Sales et al., 2007; Soares 
et al., 2012), making it difficult to interpret their scores against population norms since each 
‘individualised’ measure is, in effect, offering a score for unique, individually defined items. 
Hence, PGOM are not the “holy grail” of outcome assessment and cannot provide, alone, all 
the information that is needed to evaluate patients’ clinical situation.  
It has been recently suggested that PGOM should be added to standardised data for 
optimal results, in a strategy called personalised outcome measurement approach (Sales & 
Alves, 2012). In practice, this approach implies the combination of PGOM and SOM in the 
same evaluation protocol. Here is one example: to use, at the pre-treatment evaluation session, 
PQ or PSYCHLOPS, followed by CORE-OM. With SOM, therapists can quickly assess the 
patient’s level of distress based on clinical cut-offs; whilst PGOM identify the specific concerns 
of patients, giving more insight about how they perceive their own clinical situation. According 
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to the characteristics of the service, personalised outcome protocols can be administered pre 
and post treatment; or on a session-to-session basis, to monitor the progress of patients 
throughout treatment. In such cases, as aforementioned, patients are able to update the contents 
contained in their PGOM, as many times as desired. 
The personalised outcome measurement approach has already been implemented in 
various mental health settings, from university-based counselling centres to day psychiatry 
units and also group therapy interventions, with positive results. These studies have been 
conducted as part of a practice-based research network, dedicated to personalised assessment, 
the IPHA Group (Sales, Alves, Evans, & Elliott, 2014).  
As earlier stated, failing to include the patient’s perspective has been identified as one 
of ten areas which require a paradigm shift in psychological addiction treatment (Orford, 2008). 
If the personalised outcome measurement approach seems to work, on the one hand, and is, on 
the other, a potential strategy to increase patients’ involvement in treatment, could we extend 
it to this specific context? What would we gain from doing so? 
In substance misuse, improvements in mental health are among the most important 
treatment goals (Wanigaratne, Davis, Pryce, & Brotchie, 2005). However, psychological health 
tends to be evaluated with SOM such as the SF Health Survey (see Drug Treatment Outcomes 
Research Study, Jones et al., 2009 for an example), where the level of patient involvement is 
minimal, as previously explained. Also, as shown in previous reviews (e.g. Livingston et al., 
2011), substance misuse disorders tend to be more stigmatized in comparison with other health 
problems. This may not only act as a barrier for seeking healthcare, but also to poor and 
inadequate provision of care, potentially leading to early treatment drop-out and poor 
adherence (Livingston et al., 2011). 
From a clinical perspective, we believe that substance misuse treatment services could 
benefit from adopting the personalised measurement approach. First, the use of PGOM 
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potentially allows clinicians to better understand how patients perceive their own situation. 
This is particularly relevant at the pre-treatment stage, because it helps clinicians preparing 
treatment plans that take the priorities of patients into account, instead of adopting “by-the-
book”, or protocol driven interventions. Also, in a population where drop-out rates are 
relatively high, to formally ask for patients’ help to evaluate their own situation might increase 
their motivation to continue with the treatment programme. 
 Second, adding PGOM to outcome measurement encourages patients to select and 
prioritise their own problems, regardless of whether these are drug-related or not. In this 
context, the tools used for screening and outcome measurement purposes focus primarily on 
drug use and drug-related risk behaviours (e.g. TOP; Marsden et al., 2008). However, patients 
may have other concerns that are perceived as equal or of greater importance than their drug 
use (e.g. recent death of a relative). As a female patient put it in focus group recently conducted 
in Portugal, “This questionnaire [PSYCHLOPS, a PGOM] helps people to think about all their 
difficulties in life. It is not just the alcohol” (Alves, Sales, & Santos, 2014). Thus, even though 
PGOM do not substitute for diagnostic interviews or disorder-specific scales (e.g. Beck 
Depression Inventory; Beck, Steer, & Garbin, 1988) they may serve as flag alerts for clinical 
practice and further assessments.  
We also hope that using PGOM will contribute to diminishing, to some extent, the 
stigmatization of patients with substance misuse problems. It is not uncommon for these 
patients to be perceived as manipulative and untruthful, which may be related to reasons why 
their own perspectives tend to be overlooked. However, as illustrated in the previous paragraph, 
asking patients’ opinions about their own problem priorities enables health care workers to 
offer more holistic care (cf. above: “it’s not just the alcohol”). 
The personalised outcome assessment approach is also a potential tool to influence 
policies regarding treatment provision in this field. On the one hand, this measurement 
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approach provides an action plan, ultimately in the format of guidelines, for therapists to 
understand how to put the principle of “patient-centred” care into practice, as a means of 
improving quality of care in general. This is of importance at the time being, when health care 
budgets are increasingly constrained and funding decisions are dependent upon evidence of 
effectiveness judged both by professionals and patients.  
Second, personalised outcome measurement is a strategy that reconciles the existing 
approach to outcome assessment, with personalised questionnaires that serve not only as 
complementary outcome measures, but also as clinical tools that are useful to practice, and 
humanize the assessment procedure that is often regarded as impersonal ‘tick-box’ measures. 
As PGOM reflect the patient’s perspectives, we believe that they might provide insights 
about the problems which are most relevant to this population, so that we know, through the 
patient’s eyes, which areas should be more emphasized in drug misuse treatment programs. For 
instance, if the majority of patients report that unemployment is what concerns them the most, 
it might be necessary to revise the policies regarding social rehabilitation of patients in drug 
misuse treatment (e.g. increasing the number of partnerships between treatment centres and 
employment agencies). 
Also, adding PGOM to traditional outcome measures will lead to more comprehensive 
policies of treatment evaluation and delivery, for it includes the point of view of all the parties 
involved in healthcare, namely, the voice of patients who are likely to be unheard in substance 
misuse settings.  
Finally, as aforementioned, the use of tools to include the perspective of patients will, 
ultimately, contribute to a greater humanization of the substance misuse treatment system. All 
in all, from an ethical point of view, it is imperative to enhance patient autonomy in patient 
care. By valuing what patients have to say, and involving them as actively as possible in the 
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delivery of health care, we consider that this approach will maximize the potential benefit of 
treatment programmes.  
There are, however, several steps that need to be taken before this approach is fully 
acknowledged as feasible and reliable in substance misuse treatment. These include: 1) piloting 
the personalised assessment approach in several international treatment agencies, to increase 
its robustness; 2) discussing, with international drug monitoring agencies, the appropriateness 
of developing and disseminating international guidelines for personalised assessment, to 
reduce the gap between treatment delivery and outcome assessment across countries; and 3) 
creating practice-based networks for drug treatment services to collaborate and share their 
experiences with personalised assessment, extending the cooperation between therapists, 
researchers and patients towards the improvement of healthcare (e.g. International Exchange 
Platform for Personalising Substance Misuse Treatment; Alves, Sales, & Ashworth, 2013). 
 To sum up, in this paper we have presented the personalised outcome measurement 
approach as a potential strategy to increase patient involvement with substance misuse 
treatment, an area in need of an urgent paradigm shift. Overall, this strategy potentially allows 
us to better accommodate the diversity and the idiosyncrasies of each patient that enters each 
consultation room. There is, however, the danger of becoming so individualized that it becomes 
difficult to have an overview about the population’s heterogeneity, rendering it harder to plan 
services at a population level. Hopefully, the compromise that we propose between 
personalised and standardised measures is the ideal strategy to bridge these two worlds, but 
only further testing of where the balance lies will enable us to maximize the benefit from both 
approaches.  
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“It is not just about the alcohol”: service users’ views about individualised 
and standardised clinical assessment in a therapeutic community for 
alcohol dependence¤ 
Paula C. G. Alvesa,b*, Célia M. D. Salesc, & Mark Ashworthb 
 
Abstract 
The involvement of service users in health care provision in general, and specifically in 
substance use disorder treatment, is of growing importance. This paper explores the views of 
patients in a therapeutic community for alcohol dependence about clinical assessment, 
including general aspects about the evaluation process, and the specific characteristics of four 
measures: two individualised and two standardised. A focus group was conducted and data 
were analysed using a framework synthesis approach. Service users welcomed the experience 
of clinical assessment, particularly when conducted by therapists. The duration of the 
evaluation process was seen as satisfactory and most of its contents were regarded as relevant 
for their population. Regarding the evaluation measures, patients diverged in their preferences 
for delivery formats (self-report vs. interview). Service users enjoyed the freedom given by 
individualised measures to discuss topics of their own choosing. However, they felt that part 
of the standardised questions were difficult to answer, inadequate (e.g. quantification of health 
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status in 0-20 points) and sensitive (e.g. suicide-related issues), particularly for pre-treatment 
assessments. Patients perceived clinical assessment as helpful for their therapeutic journey, 
including the opportunity to reflect about their problems, either related or unrelated to alcohol 
use. Our study suggests that patients prefer to have evaluation protocols administered by 
therapists, and that measures should ideally be flexible in their formats to accommodate for 
patient preferences and needs during the evaluation.  
Keywords: user involvement, clinical assessment, personalised assessment, evaluation 
measures, patient views, individualised measures, qualitative research. 
 
Introduction 
Most mental health literature is based on a professional perspective, generated by 
researchers or practitioners (Rose & Thornicroft, 2006). However, service users have expertise 
by experience, which is why their involvement is increasingly acknowledged as a crucial part 
of the health care agenda (INVOLVE Strategy, 2012; Rose, 2014; Tait & Lester, 2005; Wu, 
Snyder, Clancy, & Steinwachs, 2010).  
One area where service user involvement is paramount is the selection of measures to 
evaluate the patient’s clinical condition (Blount, Evans, Birch, Warren, & Norton, 2002; 
Crawford et al., 2011; Ennis & Wykes, 2013). Evaluation measures are helpful for clinical 
work at different points in time during treatment. At treatment intake, they allow the assessment 
of patients’ distress, and if administered at pre-post treatment, they provide data for outcome 
assessment purposes. Several authors have suggested that, to maximize their clinical utility, 
these measures should be relevant, acceptable and valuable for both professionals and service 
users (Blount, Evans, Birch, Warren, & Norton, 2002; Slade, Thornicroft, & Glover, 1999). 
The reality, though, is that many popularly used measures do not reflect the service users’ 
perspective (Gilbody, House, & Shelton, 2013; Perry & Gilbody, 2009; Rose, Evans, Sweeney, 
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& Wykes, 2011). Consequently, we have little information on whether the existing evaluation 
tools are meaningful, personally relevant, and expressed in terms which make sense to users 
(Blount, Evans, Birch, Warren, & Norton, 2002; Ennis & Wykes, 2013; Rose, 2011). 
 User involvement in health care is even more challenging among socially excluded 
and stigmatised groups, since their views tend to be discredited, undermined and regarded as 
unworthy (Bryant, Saxton, Madden, Bath, & Robinson, 2008; Hayter, 2011; Livingston, Milne, 
Fang, & Amari, 2012; Ti, Tzemis, & Buxton, 2012). This often applies to patients in substance 
use disorder treatment services, who seldom participate actively in shared decision-making 
activities (Alves, Sales, & Ashworth, 2015; Bryant, Saxton, Madden, Bath, & Robinson, 2008; 
Orford, 2008). Just as with patients in general, patients in substance use disorder treatment 
services have first-hand knowledge about their clinical condition and are in a privileged 
position to inform providers about which outcomes of interest best reflect their reality (Bryant, 
Saxton, Madden, Bath, & Robinson, 2008; Neale et al., 2015). According to the European 
Monitoring Centre for Drugs and Drug Addiction, there are currently over 50 tools to measure 
treatment outcomes in this population. The vast majority of these are standardised, and do not 
take the patients’ perspective into account. A recent study gathered 76 variables commonly 
used by professionals to evaluate recovery from substance use disorder, and service users were 
asked their views about those criteria (Neale et al., 2015). Patients reported that some variables 
were unrealistic and hard to achieve (e.g. to be completely anxiety-free). This study also 
highlighted the frustration expressed by patients that most existing variables did not capture 
individual idiosyncrasies and personal preferences, stating that service providers “had no idea 
of their experiences” (p. 31).  
 There has been a recent call for the use of individualised data in the evaluation of 
substance use disorder treatment (Alves, Sales, & Ashworth, 2015; Neale & Strang, 2015; 
Trujols, Iraurgi, Batlle, Durán-Sindreu, & Pérez de Los Cobos, 2015). Such data can be 
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collected with individualised measures, which are tailor-made lists of items (problems or 
goals), generated in patients’ own words (Sales & Alves, 2016). Similarly to pre-set 
standardised measures, these individualised items are rated for intensity in quantitative scales 
(e.g. Likert scales). This allows an evaluation of patients’ level of distress, based on their 
unique problems.  
 Our study sought to address three main concerns in this field. First, there are a 
growing number of studies exploring what users of mental health services think about clinical 
assessment, including views about the measures and the process by which they are 
administered (Gordon, Ellis, Siegert, & Walkey, 2013). With the exception of the study by 
Neale and colleagues (2015), little is known about what patients in substance use disorder 
treatment think about clinical assessment. Second, a pioneer study published by Duong et al. 
(2016) has compared patients’ perspectives about standardised and individualised measures in 
school mental health. To the best of our knowledge, there are no reports on the use of 
individualised measures in the field of substance use disorder treatment, nor do we know how 
this population perceives such measures. Third, the literature has suggested that the majority 
of measures and patient-focussed materials in substance use disorder treatment tend to require 
literacy skills above the average level of literacy among this population (Greenfield, Sugarman, 
Nargiso, & Weiss, 2005; McHugh et al., 2014). However, those who are most likely to have 
low reading / writing skills (e.g. low socio-economic status, limited education, marginalised 
populations, and rural settings) are seldom asked to contribute with their views on clinical 
assessment.  
 We were interested in understanding what patients in substance use disorder 
treatment services, with low literacy skills, think about clinical assessment, in general, and in 
particular about standardised and individualised measures. More specifically, our aims for this 
study were two-fold: to explore patients’ overall perspectives about their experience with the 
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evaluation process; and to investigate patients’ views about what is helpful and hindering about 
each of the four measures in the evaluation protocol. Ultimately, our goal was to understand 
what makes patients engage, feel (de)motivated or (un)comfortable whilst using evaluation 
measures as part of their treatment.  
 
Method 
A single focus group with 10 service users was conducted in a therapeutic inpatient 
community for females with alcohol dependence, based in a rural area of northern Portugal. 
This service targets women with severe alcohol dependence problems, who are referred to this 
facility by local drug and alcohol outpatient units, child protection and social security services 
and general practitioners. The treatment programme in this facility lasts approximately for 8 
months.  
On sample characteristics, service users had a mean age of 45 years (SD = 7). Six had 
completed primary school (i.e. 4 years of education, from the age of 6 to 10, also known as the 
1st cycle of basic education in Portugal), whilst the remaining 4 were illiterate. The majority 
were unemployed (6 participants) and nearly all (8 participants) had a previous history of 
substance use treatment episodes. The group took place in the community and was moderated 
by the first author (PA), assisted by the community’s therapist. Ethical approval was granted 
by the community’s clinical director. As explained earlier, we opted for a sample with these 
characteristics (i.e. severe addiction problems, disadvantaged socio-economic status, low 
literacy skills) since this is likely to represent patients with greater difficulties understanding 
evaluation measures.  
The evaluation protocol used in the therapeutic community consisted of four measures. 
Two were standardised measures, namely, Treatment Outcomes Profile (TOP; Marsden et al., 
2008) and Clinical Outcome Routine Evaluation – Outcome Measure (CORE-OM; Evans, 
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Connell, Barkham, Mellor-Clark, & Audin, 2002); and two were individualised, Psychological 
Outcome Profiles (PSYCHLOPS; Ashworth et al., 2004) and Personal Questionnaire (PQ; 
Elliott et al., 2016) (see Table 1 for more information). These measures were chosen for being 
widely used in an international context.  
The focus group was conducted in December 2013 and lasted for 2.5-3 hours. Eight 
participants completed the measures at treatment intake only (between October-November 
2013). The remaining two completed the measures twice i.e. at treatment intake (June 2013) 
and 7 months after (December 2013). 
The group discussion was guided by a semi-structured interview focusing on patients’ 
views about: 1) the evaluation process, i.e. overall satisfaction, duration in time, administration 
and adequacy of contents of the evaluation protocol; and 2) the helpful and hindering 
characteristics of each measure in the evaluation protocol i.e. questionnaire length, delivery 
format and topics covered by the items. 
The session was audio-recorded and transcribed verbatim. The transcripts were 
analysed following a framework synthesis approach (Carroll, Booth, Leaviss, & Rick, 2013), 
based on categories, created a priori, that reflected the information which we aimed to extract 
(i.e. general aspects about the evaluation process and helpful and hindering aspects of each 
measure). Data extraction and synthesis was made by one of us (PA) and later discussed with 
two senior academics (CS and a senior lecturer in Philosophy with expertise in health ethics). 
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Results 
General views about the evaluation process 
 
The evaluation process was reported by most service users as a positive experience, 
because it helped them to reflect about their clinical situation. The overall duration of the 
evaluation protocol was considered as adequate (“The bigger it is, the more we discover things 
that we did not know about ourselves”, P7). Patients found it helpful to have their own therapist 
administering the measures, since “these things are very intimate… if it wasn’t our therapist, 
we wouldn’t have cared” (P4).  
Among those that completed the questionnaires twice, patients felt that certain topics 
had been difficult to address at treatment intake (“The questions are not wrong, but we’re not 
used to being honest with ourselves, I was still sort of numb”, P9). However, when answering 
later in treatment, another patient reported that the questionnaires made her aware of how much 
she had changed since starting the therapeutic community programme (“It made me think about 
how different I am. When I arrived I was at the bottom and now I am a new woman”, P7). 
Patients also considered that all evaluations performed after treatment intake should have been 
focussed on other aspects besides their personal problems, particularly their progress in 
treatment and the changes that they perceive (“We were given the chance to talk about the 
problems that we still had, but we could also talk about how we were recovering (…) and I 
have come such a long way”, P7). 
 
Helpful and hindering aspects of the evaluation measures 
 
Nearly all measures in the protocol were deemed as adequate in their length, except for 
CORE-OM, which was considered as “too big” (P4). There was some variability regarding the 
preferred delivery format, with some patients finding the self-report structure to be more 
appealing, as “it was easier to tick boxes… we don’t have to think so hard about our problems” 
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(P9) and that “we can be more honest by using a pen” (P3); and others reporting that “if we are 
forced to talk, it is better because we end up saying something” (P7). Regarding the topics 
covered by the items, particularly among the standardised measures, there were certain 
questions that patients found impropriate and hard to answer. Table 2 summarizes the helpful 
and hindering aspects of each measure as identified by patients. 
 
Table 2 
Summary of measures used in the research protocol 
 Helpful Hindering 
Key aspects Patients’ voices Key aspects Patients’ voices 
TOP Raises awareness 
about the quantity of 
drugs / alcohol used 
Promotes emotional / 
breakthrough 
experiences  
“It is a way of getting 
yourself together, we 
have no idea about 
how much alcohol we 
used to drink and the 
money we spent”, P3 
0-20 scale questions to 
rate psychological/ 
physical health and 
quality of life difficult to 
understand and 
meaningless    
“When I was asked 
about this I answered 
by chance. It meant 
nothing to me. Later 
we are able to answer 
in another way”, P5 
 
CORE-OM User-friendly  
Contents relevant to 
this population 
Enhances self-
awareness 
“This instrument is 
related to what we 
are”, P7 
 
Large number of items 
Contains questions about 
sensitive topics (e.g. 
suicide) 
Items not generated by 
patients 
 
“The questions were 
made by other people 
and the words didn’t 
come from inside of 
us”, P7 
 
PSYCHLOPS Easy to understand 
Helps reflecting 
about personal 
difficulties  
Provides freedom of 
expression to talk 
about any topic, 
related or not to 
substance use 
Makes patients feel 
like “normal” people 
 
“It not just about the 
alcohol, we feel bad 
about many other 
things in life. My 
sister doesn’t drink 
alcohol but could 
answer this too, 
because everyone has 
problems”, P8 
Requires personal 
exposure   
The self-completion 
format may lead to 
misleading or incomplete 
answers 
 
“We want to hide our 
real problems for 
fears of being judged 
(…) if the words are 
already written by 
someone else, it is 
easier to just say yes 
or no”, P7 
PQ Opportunity for self-
reflection  
Oral format 
encourages to talk 
about personal 
problems 
“When a person 
encourages us to talk, 
we become more 
comfortable and 
open. I talked about 
my drinking problem 
but on paper I 
wouldn’t have said a 
thing” P7 
Patients reported none.   “It is fine as it is”, P1 
 
Notes. “P”, followed by a number (e.g. “P3”) is an anonymous designator for each focus group 
participant. 
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Discussion 
The purpose of this study was to explore the thoughts of a sample of patients in 
substance use disorder treatment about the process of clinical assessment. It also aimed to hear 
those patients’ voices about the characteristics of four evaluation measures that all of them used 
at treatment intake, and some also later in treatment. Among these were two individualised 
measures, in addition to two traditional and widely used standardised measures.  
Our first goal was to investigate patients’ general views about the evaluation process 
and the findings were encouraging. We learned that patients not only welcomed clinical 
assessment, but also perceived it as a valuable task for their therapeutic journey. Patients were 
satisfied with the duration of the evaluation protocol (which included six A4 size pages) and 
there was even openness for the inclusion of further items. Previous studies (Blount, Evans, 
Birch, Warren, & Norton, 2002; Crawford et al., 2011) have shown that patients tend to be 
concerned about the brevity of several measures, for being “too simplistic”. In contrast, studies 
of services and therapists, report that evaluation measures can become a burden for patients 
and potentially interfere with the time assigned for the consultations and treatment (Sales, 
Goncalves, Fragoeiro, Noronha, & Elliott, 2007). 
There was a general preference to have therapists administering the evaluation protocol, 
making it a meaningful part of the therapeutic process and potentially leading to a greater 
commitment with the task. As such, we believe that clinical assessment could be formally 
included as part of treatment, which has already been proposed by authors such as Valderas 
(2008). The major advantage of this is that using evaluation measures would not require extra 
human and time resources from the service, making it a potentially more feasible task in real 
clinical settings. As a downside, one must bear in mind that when therapists administer the 
protocol directly, patients’ answers are likely to be biased, particularly in oral interviews. In 
such cases, patients may feel the need to provide desirable answers and underreport undesirable 
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behaviours, to satisfy their therapist, as reported by Bowling (2005). However, unless patients 
are under court-ordered treatment, they tend to be disposed and motivated to disclose personal 
and clinically relevant information to their therapists. Hence, we believe that if the interviewer 
is also the therapist, the risk of offering socially desirable answers is likely to decrease. 
Considering that most research about social desirability in mental health has been conducted 
with non-clinical samples (Bowling, 2005) further studies are needed to ascertain the pros and 
cons of having therapists as interviewers in clinical assessment, which is something that, as we 
have seen, patients seem to prefer.  
Our second main goal was to learn what was helpful and hindering about the measures 
in the evaluation protocol, from the patient perspective. There was a tension regarding service 
users’ preferences about the delivery format of measures, with some favouring the simplicity 
of ticking boxes, and others keener on talking about their problems. This suggests that a one-
size-fits-all approach to evaluation is not enough and flexibility is desirable, so that patients’ 
preferences can be considered. Such flexibility had already been suggested by Gordon and 
colleagues (2013). As such, we need to further explore to what extent the psychometric 
properties of an instrument remain unaltered in multiple formats of application, i.e. allowing a 
flexible administration of measures while providing reliable information for treatment 
evaluation.  
However, when it came to eliciting personalised information, most patients in our group 
preferred the dialogue, oral format of PQ, rather than describing their problems in writing, as 
required by the PSYCHLOPS questionnaire. This is consistent with the study by Ashworth and 
colleagues (2005), where therapists felt that PSYCHLOPS was challenging because patients 
not only had to identify problems on their own, but also to use their own words to write their 
problems down.  
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In our study, standardised and individualised measures were seen as relevant for clinical 
assessment, despite having certain disadvantages. TOP and CORE-OM were perceived as 
useful and relevant for this population, suggesting a good level of acceptability among patients. 
Nevertheless, not all contents covered by these two standardised measures were regarded as 
meaningful or appropriate (e.g. rating psychological health in a 20-point scale). Also, service 
users expressed some reservations about the disclosure of sensitive personal information in 
certain TOP and CORE-OM items, as shown in other studies (Stone & Elliott, 2011). One 
potential consequence of patients feeling uncomfortable or dissatisfied with the evaluation 
questionnaires is the likelihood of misleading responses and/or missing. Thus, further research 
is needed to ascertain which topics are likely to trigger negative reactions to the evaluation 
process.  
As expected, patients appreciated the freedom given by both individualised measures, 
PSYCHLOPS and PQ, to express any type of personal concern, regardless of topic. This was 
in line with Duong and colleagues (2016), who demonstrated that recipients of mental health 
care consider individualised measures to be less confining than their standardised counterparts. 
Hence, our findings indicate that accommodating a great diversity of topics is important to 
patients, since misusing substances can lead to / or be the consequence of problems that drug-
focussed instruments might not address. Future research should compare the topics elicited 
from standardised and individualised measures, so that we understand if the former tend to 
overlook aspects of relevance for patients that the latter are able to capture.  
Finally, it is also worth emphasizing that patients who responded to the evaluation 
measures at treatment intake and later in treatment valued the opportunity to focus on other 
aspects besides outcomes. This could be overcome by including items about the treatment 
process, giving patients the opportunity to share their thoughts about the care they are 
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receiving. Such feedback about treatment could be used by clinicians to adjust the intervention 
to match the patient’s needs, as well as to increase therapeutic alliance (Flückiger et al., 2012).  
This study is not without limitations. To have a female only, small sample size means 
that the findings are less generalisable and conclusions should be interpreted with caution. 
Also, the presence of the patients’ therapist in the group may have overstated their positive 
views about the evaluation process and the measures included in our study.   
 
Conclusions 
This study suggests that service users can actively contribute to improving the process 
of clinical assessment, guiding researchers and professionals towards developing evaluation 
measures that are more meaningful and relevant for patients with alcohol dependency. 
Individualised outcome measures have the potential to broaden the range of viewpoints 
captured from patients compared to the more narrowly focussed standardised instruments.  
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“There are things I want to say but you don’t ask”: a thematic comparison 
between standardised and individualised outcome measures in substance 
misuse treatment ¤ 
Paula C. G. Alvesa,b*, Célia M. D. Salesc, Mark Ashworthb, & Luís Faíscad 
 
Abstract 
In healthcare in general, and substance misuse treatment in particular, there have been 
increasing calls for patients to be more actively involved with outcome assessment. Such 
involvement can be achieved through the use of individualised outcome measures, where 
patients are asked to contribute with their own criteria for evaluation. This is an alternative 
strategy to the traditional approach based on standardised measures, whose contents are 
developed by experts and universality used with all patients, in a nomothetic approach. 
However, little is known about the extent to which individualised measures add information to 
standardised measures. A cross-sectional survey was conducted, in which we contrasted the 
problems defined by patients using two individualised measures against the contents of three 
widely used standardised measures using a thematic comparison approach. We found that 80% 
of the themes reported in individualised measures were included in at least one of the 
standardised measures. Nevertheless, half of our sample generated at least one problem whose 
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theme was not covered by any of the three standardised measures. Our study suggests that 
individualised measures appear to be a potential strategy to capture issues of importance to 
substance misuse patients, which may be underestimated by standardised measures.   
Keywords: personalised assessment, standardised measures, individualised measures, 
substance misuse treatment evaluation. 
 
Introduction 
A growing body of literature suggests that personalising the assessment of outcome in 
substance misuse treatment is of central importance (Alves, Sales, & Ashworth, 2015; Neale 
& Strang, 2015; Trujols et al., 2015). Recent reports have also shown that patients in this 
population appreciate being actively engaged in outcome assessment (Alves, Sales, & 
Ashworth, 2016; Neale et al., 2015). Individualised outcome measures are tools that gather 
each patient’s unique perspective about their clinical condition. However, there is little 
evidence about the extent to which individualised outcome measures may complement 
traditional standardised questionnaires. In this study we will contrast the contents elicited by 
patients in individualised outcome measures with standardised measures, as well as comparing 
two measures with different methods for generating individualised data. 
 
Outcome assessment in substance misuse treatment  
The evaluation of patients in substance misuse treatment has been discussed in several 
international guidelines (e.g. the European Monitoring Centre for Drugs and Drug Addiction, 
EMCDDA). According to these, evaluation aims “to determine individual needs, to obtain 
standard somatic, mental and psychological information”, and to focus on “the consequences 
of treatment for the clients” (EMCDDA, 2007). Furthermore, the EMCDDA recommends that 
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evaluation, including outcome assessment, should be based on “instruments that are available 
and validated” (EMCDDA, 2007).  
The instruments recommended for outcome assessment in this field tend to be 
standardised scales containing quantitative pre-determined items (see the Evaluation 
Instruments Bank available at http://www.emcdda.europa.eu/eib). These instruments are 
mostly based on criteria selected by experts, which do not always coincide with what patients 
deem important (Pulford, Adams, & Sheridan, 2009; Thurgood et al., 2014). A recent study 
has attempted to overcome this limitation by including patients in the development of a 
standardised outcome measure, involving them in topic selection (Neale et al., 2016). However, 
even when patients are involved in such a task, the universal scope of standardised measures 
limits the understanding of patients’ personal problems. More specifically, these measures do 
not give patients the freedom to express their personal views and they may contain questions 
that are not relevant for each patient, or omit questions of relevance. 
 
Why use individualised outcome assessment? 
In outcome assessment, capturing the personal issues, concerns or problems is 
important for several reasons. For instance, Wagner (2002) showed that, in a psychotherapeutic 
context, nearly 60% of personalised data were not equivalent to any item included in two 
standardised measures used as comparators. Hunter et al. (2004) carried out a similar study in 
mental health services, showing that 25% of the information provided by patients was not 
represented in standardised measures. In 2007, Ashworth and colleagues found that, in the 
primary care setting, 44% of items in a personalised measure were not covered by a commonly 
used standardised measure of psychological well-being. These findings indicate that 
standardised outcome measures potentially fail to capture information about patients that is 
relevant for evaluation purposes.  
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Gathering personalised data involves the use of individualised outcome measures. 
These are open-ended questionnaires, tailored to each individual, and whose items (problems 
or goals) are generated by patients, in their own words (Ashworth et al., 2004). By doing this, 
items in the individualised questionnaire reflect the patient’s reality (e.g. “I haven’t spoken 
with my daughter for two years”), unlike standardised questionnaires which contain issues that 
apply to the whole population (e.g. “Talking to people has felt too much for me”). There are 
two main processes for gathering individualised items: the self-report method, where patients 
are invited to write their concerns in a pen-and-paper format (e.g. Psychological Outcome 
Profiles, PSYCHLOPS; Ashworth et al., 2004); and open-ended interviews, where patients are 
asked, in a dialogue, to talk about their problems (e.g. Personal Questionnaire, PQ; Elliott et 
al., 2016). Researchers believe that both formats have their own advantages and disadvantages. 
For instance, self-report individualised measures tend to be briefer, to demand less staff/service 
resources (e.g. presence of researcher / staff member not necessary), are flexible when it comes 
to the context of application (e.g. waiting room, private consultation room) and can be 
administered to multiple patients in the same event (e.g. group therapy). However, as they are 
meant for self-completion, patients are required to have a minimum level of literacy skills and 
be physically able to complete the questionnaire unaided. On the other hand, interview-based 
individualised protocols can be administered to any patient able to communicate verbally, since 
data collection is conducted by the interviewer. Nevertheless, interview-based individualised 
outcome measures are normally lengthy (e.g. 30-60 minutes), and require completion in a one-
to-one format between patient and interviewer (for a review about individualised outcome 
measures, see Sales & Alves, 2016). 
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Using individualised outcome measures in substance misuse treatment  
Individualised outcome measures have already been used in other health contexts with 
promising findings, such as primary care mental health (e.g. Ashworth et al., 2007), counselling 
and psychotherapy services (e.g. Elliott et al., 2016). However, the use of individualised 
outcome measures has only recently been applied to substance misuse treatment, and little is 
known about their potentialities in this field.  
We believe that individualised outcome measures may broaden the understanding of 
outcome assessment in substance misuse treatment. Patients in this population tend to be 
stigmatised (Livingston, Fang, & Amari, 2012), their perspectives about treatment are seldom 
taken into account (Orford, 2008) and they are rarely involved in outcome assessment (Alves, 
Sales, & Ashworth, 2015). In a recent study, we found that patients valued the freedom 
provided by individualised outcome measures to express personal concerns, even when the 
topic of concern was unrelated to substance misuse (Alves, Sales, & Ashworth, 2016). Patients 
also reported that they preferred an interview-based procedure, especially if the interviewer 
was their own therapist. In contrast, they admitted having difficulties identifying personal 
problems in self-complete individualised outcome measures (Alves, Sales, & Ashworth, 2016). 
 
Study rationale  
In this study, we sought to explore the extent to which individualised outcome measures 
add personalised information to traditional measures of outcome assessment, in substance 
misuse treatment. Our aims were the following: 1) to explore the personal problems of patients 
with individualised outcome measures; 2) to compare the problems elicited from individualised 
and standardised outcome measures, investigating whether individualised data added 
information to that obtained from their standardised counterparts; and 3) to contrast the 
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problems elicited from two types of individualised measures (self-report vs. interview-based 
protocol). 
  
Method 
This study followed a cross-sectional design and is part of a larger project (Alves, Sales, 
& Ashworth, 2013) that aimed to implement the personalised assessment approach in the field 
of substance misuse treatment. Data were collected in four drug and alcohol treatment services 
in Portugal; three as outpatients and one an inpatient therapeutic community. Ethics approval 
was obtained at the Committee for Health of Lisbon and surrounding areas (ARSLVT, Ref. 
8251/CES/2012).  
 
Participants  
Our sample included patients starting treatment for substance misuse. During the 
recruitment period, all new patients at the four study sites, who met the inclusion criteria, were 
invited to participate. The inclusion criteria were: 1) aged 18 years and over; 2) admitted for a 
first or new treatment episode (i.e. treatment of a relapse); and 3) fluency in Portuguese. A total 
of 102 patients were invited for the study. Of these, 8 people declined participation and one 
was excluded on the basis of incomplete data collection. The final sample consisted of 93 
respondents, corresponding to a 91% response rate.   
 
Measures  
The evaluation protocol included the following outcome measures: 1) Psychological 
Outcome Profiles (PSYCHLOPS; Ashworth et al., 2004), a self-report individualised outcome 
measure in which patients are invited to answer three open-ended questions: “Choose the 
problem that troubles you the most”, “Choose another problem that troubles you” and “Choose 
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one thing that is hard to do because of your problem(s)”. PSYCHLOPS includes a fourth 
standardised 6-point scale question about overall well-being; 2) Personal Questionnaire (PQ; 
Elliott et al., 2016), an interview-based individualised outcome measure whose items are 
elicited in a semi-structured format. In the interview, the patient is asked to brainstorm his / her 
current problems, prompted by the question “Describe the main problems that you are having 
right now that led you to seek treatment”; 3) Clinical Outcome Routine Evaluation – Outcome 
Measure (CORE-OM; Evans, Connell, Barkham, Mellor-Clark, & Audin, 2002), a 
standardised self-report measure about generic psychological distress, which contains 34 items 
covering four domains: well-being, problems / symptoms, functional capacity and risk/harm; 
4) Patient Health Questionnaire – 9 (PHQ-9; Kroenke, Spitzer, & Williams, 2001), a 9-item 
standardised self-report questionnaire to measure depression; and 5) Treatment Outcomes 
Profile (TOP; Marsden et al., 2008), a standardised staff-administered scale focusing on drug-
related aspects of treatment, i.e., drug and alcohol use, injecting risk behaviours, offending and 
criminal involvement and health and social functioning.  
PQ and PSYCHLOPS were chosen because they are the most frequently used 
individualised outcome measures in the mental health field (Sales & Alves, 2016); CORE-OM 
and PHQ-9 are widely used measures of general psychological distress, and have already been 
administered in combination with PQ and PSYCHLOPS with satisfactory/good convergent 
validity scores (PQ vs. CORE-OM r =.80 and PQ vs. PHQ-9 r = .44; Elliott et al., 2016; 
PSYCHLOPS vs. CORE-OM r =.60; Ashworth et al., 2015); and TOP is one of the most 
frequently used measure for outcome evaluation in substance misuse treatment (see 
http://www.nta.nhs.uk/top-world-map.aspx). 
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Data collection   
Data were collected between July 2013 and May 2015 by the first author and five 
research assistants. All selected participants were asked to complete the evaluation protocol 
prior to their first treatment session, in a private room. Patients were given a Patient Information 
Leaflet and consent was obtained before proceeding with questionnaire completion. The four 
measures of general psychological distress (PQ, PSYCHLOPS, CORE-OM and PHQ-9) were 
presented in random order. TOP was the final measure to be presented and was not randomised 
because it focussed mainly on drug-related issues. Randomisation was achieved through the 
use of numbered evaluation packs with each of the 24 possible questionnaire combinations 
labelled as pack #1 to #24. A random number generator was used to select which pack was 
administered to each participant.  
 
Data analysis    
To achieve our first aim (exploring patients’ individualised problems), we analysed the 
free-text items in PQ and PSYCHLOPS. These were categorised according to their content, or 
sub-theme, based on a previously validated thematic classification system which comprised of 
65 mutually exclusive sub-themes of problems (Robinson et al., 2006; Sales et al., submitted). 
Use of this classification system allowed us to compare our findings with previous studies. The 
categorisations were made independently by three researchers, followed by inter-rater 
reliability calculations. Whenever there was disagreement, discussions with an independent 
expert in individualised measures took place until consensus was reached.  
 For the second aim (matching the content of individualised and standardised measures), 
we categorised the sub-themes found in individualised items according to whether their content 
overlapped with each standardised item in CORE-OM, PHQ-9 and TOP. A binary yes/no scale 
was used, where “no” meant “individualised item vague, general or completely different from 
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the standardised item” and “yes” meant “individualised item connected, clearly related or 
completely overlapped with the standardised item”. Content overlap was categorised 
independently by two researchers and inter-rater reliability was also computed. Frequencies of 
sub-themes with and without overlap with the three standardised measures were calculated.  
The third aim (contrasting the two individualised measures) was attained by comparing 
the number of items and the type of contents generated in PQ and PSYCHLOPS. The similarity 
between patients’ responses in both measures was explored using Jaccard’s similarity index (J) 
(Real & Vargas, 1996) to estimate the percentage of patients that reported the same sub-themes 
in the two measures. We considered values of J > 0.3 to indicate strong similarity. Significance 
of Jaccard’s index was determined using Fisher’s exact test.  
Finally, we investigated whether prior exposure to standardised measures could 
influence (or not) the contents of patient-generated items. To explore this hypothesis, we 
selected a sub-sample of people (n = 29) who responded to standardised measures in between 
individualised measures (i.e. in the following order: one individualised measure – one or two 
standardised measures – one individualised measure). Then, we focussed on sub-themes 
elicited from individualised measures that were and were not featured in standardised 
measures; and when they were, we analysed if patients mentioned them before or after having 
contact with the standardised measure. If there was no influence, the proportion of featured 
sub-themes spontaneously mentioned in individualised measures prior to completing the 
standardised measure would be at least 50%. To test this hypothesis, we used the one sample t 
test (within-subject analysis). 
 
Results 
The mean age of our final sample (N = 93) was 43 years old (SD = 11) and more than 
half (57%) were male (see Table 1 for a full summary of socio-demographic information). 
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Among the study participants, 92 generated a total of 275 items from PQ (one patient did not 
complete PQ) and 89 generated 214 items from PSYCHLOPS (four patients did not complete 
the Problem section of PSYCHLOPS). 
 
Table 1  
Socio-demographic characteristics of study sample (N = 93)  
Socio-demographic criteria M (SD) n (%) 
Age  42.9 (11.0) n/a 
Gender  
 
 
  Male  n/a 55 (59.1) 
  Female  n/a 38 (40.9) 
Marital status    
  Single  n/a 45 (48.4) 
  Married  n/a 19 (20.4) 
  Divorced  n/a 28 (30.1) 
  Widowed  n/a 1 (1.1) 
Educational level 
 
 
  Illiterate n/a 3 (3.2) 
  Literate, but not completed primary school (years 1-4)  n/a 1 (1.1) 
  Middle school (years 5-9)  n/a 64 (68.8) 
  Secondary school (years 10-12)  n/a 15 (16.1) 
  Undergraduate student  n/a 6 (6.5) 
  University degree  n/a 4 (4.3) 
Employment status  
 
 
  Full-time employment  n/a 21 (22.6) 
  Occasional / part-time employment  n/a 5 (5.4) 
  Unemployment <1 year  n/a 18 (19.4) 
  Unemployment >1 year  n/a 36 (38.7) 
  Medically unfit to work  n/a 6 (6.5) 
  Student  n/a 1 (1.1) 
  Retired  n/a 6 (6.5) 
Treatment status  
 
 
  First treatment episode  n/a 49 (52.7) 
  Experience of previous treatment episodes  n/a 44 (47.3) 
 
Notes. In Portugal, the first year of school (which is called primary school) starts at the age of 
6. Secondary education ends on the 12th school year. The mean (SD) and number, n (%) 
values are given where applicable.    
 67 
What problems do patients report in individualised measures?  
Individualised items generated from PQ and PSYCHLOPS were classified into 54 of 
the available 65 sub-themes, with good inter-rater reliability results (Cohen’s kappa between 
raters ranged from .88 to .93). Altogether, the sub-themes most frequently elicited by patients 
in individualised measures were ‘addiction’ (73%), ‘work-related problems’ (47%), ‘general 
relationship difficulties with family’ (22%), ‘money worries’ (19%) and ‘relationship 
difficulties with family that involve worrying about another person’ (16%) (see Table 2). 
 
Table 2.  
Sub-themes elicited from patients’ responses (N=93): comparison between individualised and 
standardised outcome measures 
Sub-themes Number of patients 
reporting each sub-
theme (%) 
Jaccard’s 
similarity index 
(p) 
Content overlap between standardised 
measures and sub-themes 
CORE-OM PHQ-9 TOP 
Addiction  68 (73.1) 0.54 (0.01)    
Work-related problems 44 (47.3) 0.20 (0.45)    
Relationships difficulties: 
family-general 
20 (21.5) 0.05 (1.00)    
Money worries 18 (19.4) 0.17 (0.07)    
Relationship difficulties: 
family - worry about 
another 
15 (16.1) 0.0 (0.99)    
Justice-related problems 13 (14.0) 0.15 (0.09)    
Worries about health 13 (14.0) 0.31 (0.01)    
Self image/self worth 12 (12.9) 0.0 (0.99)    
Coping: daily living 11 (11.8) 0.0 (0.99)    
Loneliness/being alone 11 (11.8) 0.0 (0.99)    
Global 10 (10.8) 0.10 (0.27) 
 
  
Depression/Anxiety 9 (9.7) 0.0 (0.99)    
Motivation 9 (9.7) 0.11 (0.24)    
Emotions – unspecified 8 (8.6) 0.0 (0.99)    
Relationship difficulties: 
family - breaking up 
8 (8.6) 0.13 (0.18)   
 
Relationships-general 8 (8.6) 0.0 (0.99)    
Relationship difficulties: 
family - conflict 
7 (7.5) 0.14 (0.12)    
Socialising 7 (7.5) 0.14 (0.12)    
Agression/irritability 6 (6.5) 0.17 (0.10)    
Housing worries 6 (6.5) 0.50 (0.01) 
 
  
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Sub-themes Number of patients 
reporting each sub-
theme (%) 
Jaccard’s 
similarity index 
(p) 
Content overlap between standardised 
measures and sub-themes 
CORE-OM PHQ-9 TOP 
Relationship difficulties 
partner - breaking up 
6 (6.5) 0.17 (0.12)    
Communication 5 (5.4) 0.0 (0.99)    
Relationship diffculties: 
family – caring 
5 (5.4) 0.0 (0.99) 
 
  
Being happy 4 (4.3) 0.0 (0.99)    
Dependence on other 
people 
4 (4.3) 0.0 (0.99)    
Guilt 4 (4.3) 0.0 (0.99)    
Suicidal thoughts 4 (4.3) 0.0 (0.99)    
Understanding self/events 4 (4.3) 0.0 (0.99)    
Existence/existential 3 (3.2) 0.0 (0.99)    
Future 3 (3.2) 0.0 (0.99)   
 
Relationship difficulties: 
partner - conflict 
3 (3.2) 0.0 (0.99)    
Concentration 2 (2.2) 0.0 (0.99) 
 
  
Coping: general 2 (2.2) 0.0 (0.99)    
Fears/panics 2 (2.2) 0.0 (0.99)    
Moving on 2 (2.2) 0.0 (0.99)    
OCD 2 (2.2) 0.50 (0.02)    
Personal development 2 (2.2) 0.0 (0.99)    
Sleep problems 2 (2.2) 0.0 (0.99)    
Studies-related problems 2 (2.2) 0.0 (0.99)    
Victim of abuse/sexual 
violence 
2 (2.2) 0.0 (0.99)    
Achievement 1 (1.1 0.0 (0.99)    
Attempted suicide 1 (1.1) 0.0 (0.99)    
Bereavement 1 (1.1) 0.0 (0.99)    
Coping: feelings 1 (1.1) 0.0 (0.99)  
 
 
Eating problems 1 (1.1) 0.0 (0.99)    
Going out/travelling 1 (1.1) 0.0 (0.99)    
Having positive outlook 1 (1.1) 0.0 (0.99)    
Having time 1 (1.1) 0.0 (0.99)    
Outlook on life 1 (1.1) 0.0 (0.99)    
Relationship difficulties: 
partner - development 
1 (1.1) 0.0 (0.99)    
Relationship difficulties: 
partner - general 
1 (1.1) 0.0 (0.99)    
Relationship difficulties: 
partner - worry about 
another 
1 (1.1) 0.0 (0.99)    
Self-acceptance 1 (1.1) 0.0 (0.99)    
Sexual problems 1 (1.1) 0.0 (0.99)    
Another person illness 0 (0) n/a    
Avoiding issues 0 (0) n/a    
Making decisions 0 (0) n/a    
Relationship difficulties: 
family – development 
0 (0) n/a    
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Sub-themes Number of patients 
reporting each sub-
theme (%) 
Jaccard’s 
similarity index 
(p) 
Content overlap between standardised 
measures and sub-themes 
CORE-OM PHQ-9 TOP 
Relationship difficulties: 
partner - forming 
0 (0) n/a    
Relaxing 0 (0) n/a    
Self-harm 0 (0) n/a    
Somatic symptoms 0 (0) n/a    
Thinking rationally 0 (0) n/a    
Thoughts 0 (0) n/a   
 
Traumatic event 0 (0) n/a    
 
Notes: In this table, ‘n/a’ refers to sub-themes that are included in the classification system 
but were not present in any item elicited by this sample.  * indicates strong (J > 0.3) and 
significant (p < 0.05) similarity values. 
 
Do individualised measures add information to standardised measures? 
For the process of analysing content overlap between individualised and standardised 
outcome measures, all categorisations achieved satisfactory inter-rater reliability results 
(Cohen’s kappa between raters ranged from .66 to 1.0).  
Just over two thirds (38 out of 54) of sub-themes captured by individualised measures 
were absent from TOP. Among these were sub-themes frequently reported by patients such as 
‘money worries’ (19%), ‘relationship difficulties with family – worry about another’ (16%) 
and ‘self-image/self-worth’ (13%). Among the measures of general psychological distress, a 
little over one third (19 out of 54) of sub-themes captured by individualised measures were not 
covered by CORE-OM. A large proportion of sub-themes (40 out of 54) were not covered by 
PHQ-9. Sub-themes not featuring in CORE-OM and PHQ-9 included topics frequently 
reported by patients, namely, ‘addiction’, mentioned by 73% of patients, ‘work-related 
problems’ (47%) and ‘money worries’ (19%). 
 When considered as a whole, 43 out of 54 sub-themes reported by patients on 
individualised measures were captured by one or more of the standardised instruments (see 
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figure 1). However, almost half of the patients in our sample (49%) described at least one 
individualised problem whose content was not covered by any of the three standardised 
measures. This indicates that even with the inclusion of three standardised measures, certain 
types of personal problems (e.g. ‘money worries’) were only covered by an individualised 
measure (see figure 2).  
 
 
Figure 1. Content overlap between standardised and individualised outcome measures, 
represented by number of sub-themes (n = 54). 
 
 
Figure 2. Number of patients (N = 93) with additional problems identified by individualised 
outcome measures and not featured in standardised measures. 
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Are there any differences between the two individualised measures?  
The mean number of items elicited in PQ was 2.9 (SD = 2.1; range 1 to 12) and in 
PSYCHLOPS was 2.4 items (SD = 0.7; range 0 to 3); this difference was significant [t (91) = 
3.2, p < .002; Cohen’s d = 0.44]. Twenty-five patients (27%) reported the same number of 
items in both instruments; 41% (n = 38) reported more items in PQ and 32% (n = 30) reported 
more items in PSYCHLOPS.  
There was little content overlap between the two individualised instruments. Most sub-
themes (72%) present in patient-generated items had a Jaccard’s similarity index of 0. This 
means that the responses elicited by PQ tended not to coincide with those elicited by the same 
patient in PSYCHLOPS, and vice versa. A strong overlap was only found for the following 
sub-themes: ‘addiction’ (J = .5), ‘housing worries’ (J = .5), ‘obsessive compulsive disorder’ (J 
= .5) and ‘worries about health’ (J = .3).  
Our study showed no evidence that prior completion of a standardised measure 
influenced the items reported by patients in individualised measures. We found that the 
proportion of CORE-OM and PHQ-9 sub-themes that were mentioned in patient-generated 
items prior to completing a standardised measure was 68% (SD = 38%). This result was 
statistically superior to 50% [t (28) = 2.5, p < .02], showing that patients spontenously reported 
items regardless of their content being covered or not by standardised measures. 
 
Discussion 
Our study suggests that using individualised measures in substance misuse treatment is 
a powerful strategy to collect personalised information about patients that would otherwise be 
overlooked by standardised outcome measures.  
It was expected that a sample of patients being admitted for drug and alcohol treatment 
would be mainly concerned about their addiction problem. However, as patients put it in a 
 72 
previous study (Alves, Sales, & Ashworth, 2016), it was not “just about the alcohol” (p. 4) and 
drugs. Besides their substance use, people made use of individualised outcome measures to 
express other concerns, such as their financial situation or difficulties in relating with their 
family members. To learn that patients who seek substance misuse treatment report problems 
beyond drug use is a major finding of our study. On the one hand, it confirms the importance 
of having outcome evaluation protocols that include other aspects, such as psychosocial 
functioning or stress (Tiffany, Friedman, Greenfield, Hasin, & Jackson, 2012). Both of these 
domains were expressed by patients in our sample in individualised measures. Moreover, our 
study also reinforced that is worth involving patients in the selection of criteria to evaluate 
treatment success, so that it focuses on topics of relevance for patients. As stated by Lee and 
Zerai (2010), “assuming that [treatment] success itself can be defined, one must accept that is 
nuanced and, (at least in part), participant-defined” (p. 2423). 
When comparing individualised and standardised measures, we were primarily 
interested in TOP. We expected this measure to have a high content overlap with individualised 
measures, because it is focussed on problems specific to this population. However, the majority 
of problems freely reported by patients were overlooked by TOP. By adding two measures of 
general psychological distress (CORE-OM and PHQ-9), we extended the range of problems 
covered by the standardised module of the evaluation protocol. We included these measures 
based on the work of previous authors (Wanigaratne, Davis, Pryce, & Brotchie, 2005) which 
emphasised the importance of psychological health as a major factor in recovery from drug and 
alcohol dependence. But even with the inclusion of these three measures, 20% of problems 
reported by patients were not captured by the standardised measures. These findings have 
various implications for treatment evaluation in this patient group. The failure of standardised 
instruments to capture a substantial proportion of reported problems implies that current 
evaluation protocols may need to be revised in order to accommodate the needs of this 
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population. The wide range of reported problems illustrate the importance of including broadly 
defined psychosocial criteria in evaluation protocols and not merely focusing on drug and 
alcohol issues. Additionally, our study indicates that individualised measures can be a valuable 
increment to the existing evaluation protocols, by capturing aspects that are overlooked by 
standardised measures, but relevant at an individual level. In other words, the burden of 
individualised measures (which tend to be lengthy) is potentially overcome by the type, amount 
and relevance of the information gathered from a clinical perspective.  
Patients reported a greater number of items in PQ than in PSYCHLOPS. This finding 
was expected because PQ imposes no limits on the number of items that patients can create, 
whereas PSYCHLOPS asks people to generate up to a maximum of three items. This suggests 
that, if time constraints are not important, one might opt for a questionnaire without a cap on 
item number. However, although significant, the difference between the mean number of items 
in PQ and PSYCHLOPS was small (2.9 vs. 2.4, respectively), indicating that the choice of 
format might be dependent on available resources. Moreover, we found that in self-report 
individualised measures, some patients did not describe any problems at all, resulting in 
missing data for outcome assessment. In a previous study, patients reported a preference for 
someone “pushing them” to facilitate a discussion about their problems rather than 
documenting their own problems in writing, and thus preferred the format of PQ rather than 
PSYCHLOPS (Alves, Sales, & Ashworth, 2016).  
The two individualised measures elicited different concerns. This discrepancy may 
have arisen because patients found it easier to express certain problems in one format rather 
than another. For example, patients may prefer to report sensitive topics, e.g. expression of 
suicidal thoughts, in a therapist-administered questionnaire; whereas others may prefer a 
written format to report e.g. communication difficulties. Another explanation is that patients 
may not have wanted to duplicate reporting across the two measures. If this was the case, we 
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do not know which of the measures elicited the topics of greatest concern for patients. Further 
research using think-aloud testing would enable us to explore reasons for the unexpected 
differences in responses elicited by the two individualised measures administered 
consecutively (Charters, 2003).  
This study has several strengths and limitations. Our findings provide the first thematic 
comparison in substance misuse patients between the contents reported in individualised 
measures and traditional standardised questionnaires. The comparison of items generated in 
PQ and PSYCHLOPS has not been previously reported and provides information about their 
similarities and differences. We were also able to test for contamination of individualised 
measure completion through prior use of standardised measures, although our findings suggest 
little if any evidence of bias arising from this source. However, further testing of individualised 
measures is required in order to establish whether reported differences are related to the 
structure of the measures or to the mode of administration. Also, it is likely that target problems 
and treatment goals may change during treatment, hence, future studies should focus of 
analysing how problems vary after treatment entry, by comparing session-to-session or pre-
post data. Even though we chose standardised comparators that were of common use both in 
mental health and substance misuse treatment, it is possible that other measures, not included 
in this study, may have a greater content overlap with PQ and PSYCHLOPS than those used 
in this sample. Another concern relates to the oral administration of self-report measures and 
the degree to which non-verbal cues may have influenced responses. 
 
Conclusions 
Overall, we have demonstrated that individualised measures have the potential to 
capture qualitative information about personal problems, which is likely to be excluded from 
standardised psychological outcome measures, even when they are specific to drug and alcohol 
related problems. This shows that there are benefits, from a qualitative point of view, to 
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combine these measures with traditional standardised tools, so that patient-relevant information 
is included in outcome assessment and used to personalise treatment provision.  
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Personalising outcome measurement in substance misuse treatment: the 
practicability and psychometrics of two individualised outcome measures ¤ 
Paula C. G. Alvesa,b*, Célia M. D. Salesc, & Mark Ashworthb, & Luís Faíscad 
 
Abstract 
Individualised information in substance misuse treatment complements standardised 
outcome measures. However, few studies investigate the use of individualised measures and 
their robustness in terms of quantifying outcomes. In this study we analysed the psychometrics 
and practicability of two individualised outcome measures (PQ and PSYCHLOPS). We 
followed a cross-sectional methodology, administering the individualised measures and three 
additional standardised measures (CORE-OM, PHQ-9 and TOP) to a sample of 93 patients 
entering substance misuse treatment in four clinical services. The results showed high levels of 
patient acceptability of the two individualised measures (response rates > 95%). The internal 
reliability was good for both PQ and PSYCHLOPS (Cronbach’s alpha, .79 and .72, 
respectively). The correlation between PQ and standardised measures was weak: TOP 
(psychological health) r = .21, PHQ-9 r = .22 and CORE-OM r = .27. In contrast, convergent 
validity of PSYCHLOPS was moderate: r = .40, r = .39 and r = .50 (TOP, PHQ-9 and CORE-
OM, respectively). Convergence between PQ and PSYCHLOPS was weak (r = .28). 
Experience of previous treatment episodes was associated with higher PQ and PSYCHLOPS 
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scores; PSYCHLOPS but not PQ scores were higher among those opting to complete the 
questionnaires in written rather than verbal format. Our findings demonstrated that PQ and 
PSYCHLOPS are reliable and practical individualised outcome measures for use in substance 
misuse treatment units, even though convergent validity with standardised measures was only 
weak to moderate. Optimal outcome measurement may involve combining individualised and 
standardised measures.  
Keywords: substance misuse treatment, individualised outcome measures, personalised 
assessment, PQ, PSYCHLOPS. 
 
Introduction 
The evaluation of treatment outcomes has, until recently, been dominated by a 
nomothetic approach. However, a growing body of expert opinion has recommended that 
idiographic, or individualised, information should also be used for outcome measurement 
purposes (Alves, Sales & Ashworth, 2015; Neale & Strang, 2015). Combining nomothetic and 
idiographic approaches has been described as an “optimal way of understanding and measuring 
patient reported outcomes of addiction and its related constructs” (Neale & Strang, 2015, p. 
1216). However, little is known about whether individualised outcome measures are a viable 
method for collecting idiographic information and producing reliable quantitative estimates of 
outcomes in substance misuse treatment.  
 Broadly speaking, outcome measures aim to quantify changes that occur in a patient’s 
clinical status over the course of treatment. The commonest strategy involves the use of 
standardised outcome measures, based on pre-set questions administered to a general group of 
patients. The standardised structure of these measures allows for a mechanisation of the 
outcome measurement process, since all individuals are presented with the same pre-
determined questions (OECD, 2013). The generation of large scale data from standardised 
 81 
instruments has given these measures a golden status in the field of outcome evaluation (Evans, 
Greenhalg & Connelly, 2000).  
In recent years, individualised measures have gained ground in healthcare, due to a 
number of reasons (Fitzpatrick, Davey, Buxton & Jones, 1998). First, they provide patients 
with an opportunity to indicate items to evaluate the outcome of their treatment (Barkham, 
2016); second, they allow patients to rate the intensity or level of distress caused by their own 
problem, which correspond to their priorities (Elliott et al., 2016; Sales & Alves, 2012; 2016); 
third, they have a greater sensitivity to clinical change than standardised outcome measures 
(Ashworth, Evans, & Clement, 2008; Elliott et al., 2016); fourth, they are likely to capture 
information overlooked by standardised measures (Alves, Sales, Ashworth, & Faísca, 
submitted); and fifth, patients value the opportunity to define and express their own range of 
concerns (Alves, Sales, & Ashworth, 2016).  
To be appropriate, outcome measures must be “psychometrically strong, applicable and 
practical” (Lambert & Hawkins, 2004, p. 493). A growing body of literature has explored these 
properties among individualised outcome measures. These studies have focussed mostly on the 
Personal Questionnaire (PQ; Elliott et al., 2016) and the Psychological Outcome Profiles 
(PSYCHLOPS; Ashworth et al., 2004). PQ and PSYCHLOPS are individualised measures 
targeting general psychological distress, based on items generated by patients, and widely used 
in mental health care (Sales & Alves, 2016).  
Previous findings stated that PQ and PSYCHLOPS are clinically useful, since they 
contain items of high relevance for patients (Ashworth et al., 2005; Sales et al., 2007). 
Therapists have also reported their satisfaction using these two measures for several clinical 
tasks, including outcome assessment (Sales et al., 2007; Sales & Alves, 2012). On 
psychometrics, both PQ and PSYCHLOPS have produced reliable and valid scores to measure 
treatment outcomes in general mental health settings (e.g. university counselling units, mental 
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health primary care) (Ashworth et al., 2008; Elliott et al., 2016). However, further studies, 
ideally in other clinical populations, are required to decrease the scepticism about 
individualised measures (Elliott et al., 2016). 
Substance misuse treatment is one of the areas where individualised measures have 
been little explored. In this field, outcome measurement tends to focus on specific drug-related 
issues, as well as psychosocial variables, including general psychological distress and specific 
problems such as depression or suicidal thoughts (Darke, Ross, & Teesson, 2007; Gossop, 
Marsden, Stewart, & Kidd, 2003, Jones et al., 2009; Wanigaratne, Davis, Pryce, & Brotchie, 
2005). However, these outcomes tend to be assessed with standardised instruments and it is 
unknown whether individualised outcome measures are also practical and psychometrically 
robust for outcome measurement purposes (Alves, Sales, & Ashworth, 2015). 
To our best knowledge, PQ and PSYCHLOPS were firstly introduced in substance 
misuse treatment in 2013, in a larger project where this present study is included (Alves, Sales, 
& Ashworth, 2013). Preliminary findings demonstrated that patients value these measures by 
being easy to understand; helping them to reflect about personal difficulties; providing them 
with freedom to talk about problems, related or not to substance misuse; and making them feel 
like normal people (Alves, Sales, & Ashworth, 2016). As a downside, patients admitted that 
the level of self-exposure that these instruments require can be hindering (Alves, Sales, & 
Ashworth, 2016). This project also revealed that PQ and PSYCHLOPS elicited problems 
overlooked by standardised measures (Alves, Sales, Ashworth, & Faísca, submitted). For 
instance, more than two thirds of sub-themes indicated by patients in these individualised 
measures were absent from the Treatment Outcomes Profile (TOP; Marsden et al., 2008), 
including problems such as ‘money worries’ and ‘self-image/self-worth’ (Alves, Sales, 
Ashworth, & Faísca, submitted). The present study builds on these findings by exploring the 
practicability of PQ and PSYCHLOPS, as well as their psychometric properties in this sample. 
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Study rationale  
The current study focussed mainly on the practicability of PQ and PSYCHLOPS, in 
contrast with their standardised comparators; and in the psychometric properties of PQ and 
PSYCHLOPS in this population. Additionally, we also explored potential factors that may 
influence PQ and PSYCHLOPS scores (e.g. socio-demographic, substance misuse, treatment 
history and other variables of interest), to gain further knowledge about the quantitative value 
of these instruments. We also aimed to contrast the scorings obtained with PQ and 
PSYCHLOPS, since both are individualised measures albeit with different characteristics (e.g. 
mode of administration). To our knowledge, this is the first study to explore these questions 
within the context of substance misuse services. 
 
Method 
This was a cross-sectional study with a sample of adult patients entering treatment in 
four services for drug and alcohol substance misuse in Portugal, between July 2013 and May 
2015. Approval was granted by the Committee for Health of Lisbon and surrounding areas 
(ARSLVT, Ref. 8251/CES/2012). 
 
Participants   
The sample comprised of patients aged 18 years and older, who were starting a 
treatment episode (i.e. first episode or treatment of a relapse) and were fluent in Portuguese. 
We excluded patients that were not motivated to participate or were too distressed to complete 
the evaluation protocol. This decision was made by researchers in consultation with the 
administrative/clinical staff available. We calculated our sample size based on previously 
reported alpha scores of .80 for PSYCHLOPS, with 114 patients, and .86 for PQ, with 72 
patients (Ashworth, Evans, & Clement, 2008; Elliott et al., 2016). Based on these findings, we 
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aimed to recruit a sample of approximately 100 patients. Of the 102 individuals who met the 
inclusion criteria, 94 (92%) consented to participate. One was excluded because of non-
completion of PQ and PSYCHLOPS, resulting in a final sample of 93 patients.  
 
Instruments 
Personal Questionnaire (PQ; Elliott et al., 2016). A semi-structured interview-based 
individualised outcome measure that asks patients to describe the main problem(s) that resulted 
in them seeking treatment. The intention is to prompt patients to elicit an unlimited number of 
personalised items, without any limitations on topic, where each item represents a unique 
problem of the patient expressed in their own words. After the item generation process, the 
patient is asked to rate each item/problem according to how much it troubled him/her over the 
last week using a 7-point scale (ranging from “1 = not at all” to “7 = maximum possible”); and 
for how long the problem has been of concern, also recorded on a 7-point scale (from “1 = less 
than 1 month” to “7 = more than 10 years”). PQ total score corresponds to the sum of the 
scorings of all items elicited by each patient.  
Psychological Outcome Profiles (PSYCHLOPS; Ashworth et al., 2004). A self-
report individualised measure in which patients are invited to write down one or two 
personalised problems in free-text boxes, in response to the question, “choose the problem that 
troubles you most” (P1) and “choose another problem that troubles you” (P2). Each problem 
is rated according to how much it has affected him/her over the last week, on a 6-point scale 
(from “0 = not at all affected” to “5 = severely affected”); and for duration in time on a 5-point 
scale (from “0 = under one month” to “4 = over five years”). PSYCHLOPS includes a third 
personalised item prompted by the question, “choose one thing that is hard to do because of 
your problem or problems” (Functioning), also rated on a 6-point scale (from “0 = not at all 
hard” to “5 = very hard”). There is a final pre-set item where patients are asked to rate the 
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question “how have you felt in yourself this last week” on a 6-point scale (from “0 = very 
good” to “5 = very bad”) (Well-being). PSYCHLOPS total score corresponds to the sum of the 
scores of the two problems, in addition to the scores of functioning and well-being items. In 
case P2 is missing, the score of P1 should be doubled; whenever P1 and/or the functioning and 
well-being items are missing, the total score cannot be computed.  
Clinical Outcomes in Routine Evaluation – Outcome Measure (CORE-OM; 
Evans, Connell, Barkham, Mellor-Clark, & Audin, 2002). A self-report standardised 34-
item tool to assess the level of psychological distress in four domains: problems (depression, 
anxiety, physical problems and trauma), functioning (general daily functioning, relationships), 
subjective well-being (feelings about self and optimism about the future), and risk behaviours 
(risk to self and to others). All items are scored on a 5-point scale (from “0 = not at all” to “4 
= most or all the time”, or the opposite, for reversed items) based on the number of times that 
each item was experienced by patients in the previous week. CORE-OM total score 
corresponds to the sum of the 34 items. If more than three items are missing, the total score 
cannot be computed. Regarding the four domains, if more than one item is missing from 
problems and well-being, these total scores cannot be computed as well.  
Patient Health Questionnaire – 9 (PHQ-9; Kroenke, Spitzer, & Williams, 2001). A 
self-report standardised 9-item questionnaire to evaluate depression. In this measure patients 
are asked to score each item in a 4-point scale (from “0 = not at all” to “3 = nearly every day”), 
according to the frequency that each problem troubled the patient in the last two weeks. PHQ-
9 total score corresponds to the sum of the 9 items.  
Treatment Outcomes Profile (TOP; Marsden et al., 2008). A standardised 
questionnaire orally administered by researchers, in an interview, that includes 20 questions 
about key aspects of substance misuse treatment: substance use, injecting risk behaviour, crime, 
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health and quality of life. In TOP, the items are rated in number of days, yes/no questions and 
scaling items on 20-point scales.  
 
Procedure   
Researchers invited patients attending the treatment centres to take part in the study 
prior to commencing treatment. Consent was obtained and participants completed the 
evaluation protocol immediately prior to the first treatment session. 
Patients were presented with the evaluation protocol containing the five outcome 
measures, followed by a socio-demographic and treatment history form. All measures were 
administered according to their original instructions, unless patients required assistance to 
complete the questionnaires. We randomised the order in which measures about psychological 
distress (PQ, PSYCHLOPS, CORE-OM and PHQ-9) were presented to patients. With this, we 
aimed to control for order effects and avoid patients’ responses to be influenced by the contents 
elicited in the other measures with similar purposes. The presentation order of TOP was not 
randomised. TOP was invariably presented at the end of the protocol because it focusses 
specifically in drug-related topics and little or no influence was expected.  
 
Data analysis 
Practicability. We focussed on three main parameters to evaluate the practicability of 
individualised measures: administration duration in minutes (note: we opted for timing the 
entire protocol, instead of each measure separately, to interfere as little as possible with the 
evaluation process, considering that only one researcher was present in the room); 
acceptability, i.e. proportion of patients who completed each instrument; and the preferred 
mode of administration, i.e. proportion of patients who were able to complete by self-report or 
who required assistance from an administrator (upon patient’s request).  
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Descriptive analyses of PQ and PSYCHLOPS. PQ and PSYCHLOPS data were 
analysed in terms of mean number of patient-reported items, mean severity of distress and 
mean problem duration since onset. Because of the unpredictability of the number of patient-
reported items in PQ, overall mean severity and duration was based on the individual PQ mean 
score for each patient. Data on problem duration was also recorded for the longest duration 
reported in PQ and PSYCHLOPS.  
Internal reliability of PQ and PSYCHLOPS. For PQ, we computed consecutive 
Cronbach’s alpha values, starting with 2 items (PQ item #1 and PQ #2) and then consecutively 
re-calculating new alphas by adding the next PQ item (one at a time) to the calculation. A total 
of four alphas were computed until the last item mentioned by at least 15 patients (i.e. PQ item 
#5) was added. The mean (and respective standard deviation) of the alpha for PQ represents 
the mean of the four alphas that resulted from this procedure, following the method described 
by Elliott et al. (2016). For PSYCHLOPS, we opted for two alpha values, one for the three 
individualised items and one for the total score.  
Convergent validity of PQ and PSYCHLOPS. Correlations between instrument 
scores were calculated using Pearson’s r.  The mean scores of PQ and PSYCHLOPS were 
correlated with CORE-OM, PHQ-9 and TOP (psychological health, physical health and quality 
of life scale items). As in Elliott et al. (2016), we expected moderate to strong correlations 
between individualised and standardised measures. Unlike CORE-OM and PHQ-9, the scale 
items of TOP have their scores reversed (i.e. “0 = very bad” and “20 = very good”) in contrast 
to PQ and PSYCHLOPS; hence convergent validity would be indicated by a negative 
correlation. 
In addition to practicability and psychometrics of the individualised measures, we also 
explored the association between PQ and PSYCHLOPS scores with socio-demographics, 
substance misuse and treatment history variables. The objective of these further analyses was 
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to extend our knowledge about the quantitative data generated by individualised instruments, 
as well as investigating potential variables that might influence these quantitative scores. PQ 
and PSYCHLOPS scores were also contrasted according to their mode of administration 
(interview vs. self-report) and order of instrument administration (severity of scores in the first 
and second individualised completed by patients). For binary variables, the student’s t-test was 
used; for nominal variables with more than two values, one-way ANOVAs (followed by 
Bonferroni post hoc analyses) were computed; for continuous data, Pearson’s r was calculated.  
All analyses were conducted in IBM SPSS Statistics 22. 
 
Results 
The 93 patients who participated in our study consisted of a higher proportion of men 
(59%); the mean age was 43 years (SD = 11). Tables 1 and 2 (2a and 2b) show further 
characteristics of the sample, as well as their substance use and treatment history, respectively 
 
Table 1 
Patient characteristics (N = 93)  
Variable  n % 
 
Relationship status  
 
Single 
 
45 
 
48.4 
 Married/cohabiting  19 20.4 
 Divorced/separated  29 31.2 
Educational level  Illiterate  3 3.2 
 Literate, but not completed primary 
school  
1 1.1 
 Basic school (years 1-9) 64 68.8 
 Secondary school (years 10-12) 15 16.1 
 University (years >12) 10 10.8 
Employment status    
 Paid work (full-time/part-time) 26 28.0 
 Unemployed  52 55.9 
 Retired  8 8.6 
 Other (e.g. housewife) 7 7.5 
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Variable  n % 
Accommodation 
status 
 Rented/owned house  84 90.3 
 Temporary accommodation                    
(e.g. guesthouse) 
1 1.1 
 Homeless 2 2.2 
 Shared supported accommodation     
(e.g. community shelters) 
6 6.5 
 
Table 2a  
Substance misuse – age of onset and usage in the last 12 months (N = 93) 
Type of substance  Years: Mean 
(Standard 
deviation) 
n (%) 
 
Alcohol Age of onset  16.5 (7.7)   
Used in the last 12 months (yes) 58 (62.4) 
Heroin  Age of onset  20.2 (6.7)   
Used in the last 12 months (yes) 10 (10.8) 
Cocaine (powder) Age of onset  20.3 (6.7)   
Used in the last 12 months (yes) 4 (4.3) 
Crack cocaine  Age of onset  28.0 (12.8)   
Used in the last 12 months (yes) 1 (1.1) 
Cannabis  Age of onset  14.7 (2.5)   
Used in the last 12 months (yes) 14 (15.1) 
Ecstasy  Age of onset  16.3 (1.7)   
Used in the last 12 months (yes) 1 (1.1) 
LSD Age of onset  16.2 (1.5)   
Used in the last 12 months (yes)   0 (0) 
Tobacco  Age of onset  14.1 (3.3)   
Used in the last 12 months (yes)   58 (62.4) 
 
Table 2b  
Substance misuse treatment history 
Substance misuse treatment history  Yes 
n (%) 
 First treatment episode  
 
49 (52.7) 
Type of previous treatment Psychological treatment  15 (17.4) 
 Opioid substitution treatment 7 (8.1) 
 Alcohol dependence medication 11 (12.8) 
 Inpatient therapeutic community  13 (15.1) 
 Detoxification unit 17 (19.8) 
 Self-help groups 4 (4.7) 
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Practicability of individualised vs. standardised outcome measures  
 The mean time required for completion of the evaluation protocol, including the 
individualised measures, was 30.1 minutes (SD = 11.4, range 10-61 minutes). Regarding the 
acceptability, the proportion of patients who responded to each tool was as follows: PQ, 92 
(99%); PSYCHLOPS, 88 (95%); CORE-OM, 92 (99%); PHQ-9, 93 (100%); and TOP, 90 
(97%). Concerning the mode of administration, PQ and TOP were delivered in an interview-
based format, as required by their instructions. The self-report tools often required 
administrator completion. PSYCHLOPS was administered orally to 37 (41%) patients; CORE-
OM to 36 (40%) patients; and PHQ-9 to 35 (39%) patients. Patients requested assistance 
because of literacy issues, self-reported anxiety and poor sight.  
 
Descriptive analyses of PQ and PSYCHLOPS mean scores 
 The mean number of items in PQ was 2.9 (SD = 2.1), range 1 to 12. The mean severity 
score for PQ items was 5.3 (SD = 1.7). Eighty-two (89%) patients had mean PQ severity scores 
above the clinical cut-off value of 3.25 points, as defined in Elliott et al. (2016). Problems 
described in PQ had lasted 1 to 2 years (M = 4.2 points; SD = 1.6); however, the longest duration 
problem was 3 to 5 years (M = 5.3 points; SD = 1.8).  
For PSYCHOPS, the mean number of patient-generated items (P1 + P2 + Function) 
was 2.3 (SD = .8), range 0 to 3 items. The mean item severity scores were: problems, 7.1 (SD 
= 2.9, range 0-10); function, 3.4 (SD = 1.7, range 0-5); well-being, 2.3 (SD = 1.8). The mean 
total PSYCHLOPS score was 13.8 (SD = 4.9, range 0-20). Even though we collected 92 
PSYCHLOPS, the total score could only be computed for 58 patients because of insufficient 
data (i.e. two problems missing and/or function, and/or well-being item missing). The problems 
reported in PSYCHLOPS had been troubling patients for a duration of 3 months to 1 year         
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(M = 3.4 points, SD = 1.3). In this sample, the PSYCHLOPS problem of the longest duration 
was 1 to 5 years (M = 3.6 points, SD = 1.4).  
 
Internal reliability of PQ and PSYCHLOPS mean scores  
Both individualised measures showed good internal reliability, with alpha scores for 
PQ of α = .79 (mean) and for PSYCHLOPS α = .72 (Table 3).  
 
Table 3  
Internal reliability (Cronbach’s alpha) of PQ and PSYCHLOPS  
Cronbach’s alpha PQ items 
1-2 
PQ items 
1-2-3 
PQ items 
1-2-3-4 
PQ items 
1-2-3-4-5 
Mean (SD) 
PQ .69 .75 .83 .88 .79 (.09) 
PSYCHLOPS Problem 
items 1-2 
Problem + functioning 
items 1-2-3 
(individualised 
component) 
All items 1-2-3-4 
(individualised items + 
standardised item) 
.42 .69 .72 
 
Notes. In PQ, item #1 corresponds to the first item in the PQ item list, i.e. the item identified 
by the patient as being the problem he/she is most concerned about; item #2 is the second 
problem that most concerns the patient, etc.  
 
Convergent validity of PQ and PSYCHLOPS vs. standardised outcome measures 
 Table 4 shows the correlation matrix between the five instruments. We found a weak 
and significant convergence between PQ and PSYCHLOPS (r = .28) scores. Correlations 
between PQ and PSYCHLOPS problem scores were similar when self-completed (r = .28) in 
contrast to researcher administered (r = .25). The correlations between PQ scores and the 
standardises measures were weak, namely, CORE-OM r = .27, PHQ-9 r = .22 and TOP 
(psychological health) r = .21 (see Table 4). In contrast, correlations between CORE-OM, 
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PHQ-9 and TOP (psychological health) with PSYCHLOPS were moderate at r = .50, r = .39 
and r = .40, respectively. 
 
Table 4  
Convergent validity of PQ and PSYCHLOPS with CORE-OM, PHQ-9 and TOP  
Measures 
(Pearson’s r) 
 PQ PSYCHLOPS 
 Domains  Problems Functioning Well-being Total 
score 
PQ       
PSYCHLOPS Problems .35**     
 Functioning .23 .53**    
 Well-being .17 .39** .27*   
 Total score .28** .89** .73** .70**  
CORE-OM Problems .31** .39** .38** .49** .48** 
 Functioning .12 .20 .31* .53** .39** 
 Well-being .30** .41** .35** .52** .49** 
 Risk .19 .32** .16 .37** .37** 
 Total score  .27** .38** .37** .54** .50** 
PHQ-9   .22* .39** .28* .52** .39** 
TOP Psychological 
health 
-.21 -.33** -.12 -.60** -.40** 
 Physical health -.12 -.15 -.004 -.26* -.07* 
 Quality of life -.24* -.30** -.30* -.48 -.44** 
 
Notes. * p ≤ .05; ** p ≤ .01. The values highlighted in bold indicate the correlation between 
PQ and PSYCHLOPS (total, 4 items) and the total scores of the other measures.  
 
 
Association between PQ/PSYCHLOPS scores, demographic and clinical variables   
Socio-demographic data. There were no significant differences in PQ and 
PSYCHLOPS scores according to gender, educational level, type of accommodation and 
employment status. No correlation was found between item severity and patient age.  
Substance use and treatment history. PQ and PSYCHLOPS scores were correlated 
with the age of first substance misuse. The later in life people started to use certain substances, 
the higher were their distress scores on individualised outcome measures. Specifically, we 
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found that PQ mean scores were moderately and positively correlated with the age of first use 
of LSD (r = .38) and had a perfect positive correlation with crack (r = 1.0); and were 
moderately, yet negatively related with age of first use of cannabis (r = -.40). Regarding 
PSYCHLOPS, scores were strongly and positively correlated with age of first use of ecstasy (r 
= .90) and negatively with age of first use of LSD (r = -.76). 
Patients who had received previous treatment for substance misuse were more likely to 
report a higher level of psychological distress both in PQ [t (90) = -1.9, p < .05] and 
PSYCHLOPS [t (56) = -2.5, p < .02]. Regarding the type of treatments received, patients with 
previous psychological outpatient treatment [t (50) = 2.0, p < .04] and in therapeutic 
communities [t (50) = 2.4, p < .02] had significantly higher problem scores in PSYCHLOPS 
than those who did not. These effects were not observed in PQ. There were no differences 
between the mean scores of PQ and PSYCHLOPS problems in those receiving the remaining 
treatment modalities.  
Mode of administration. PSYCHLOPS scores were significantly higher among those 
who reported free-text items about problems [t (84) = 2.5, p < .01] and functioning [t (56) = 
2.4, p < .02] in a written format.    
Order of instrument administration. There were no significant differences in 
problem severity scores relating to the order of individualised instrument completion [t (85) = 
.69, p < .49].  
 
Discussion 
Previous findings have demonstrated the importance of PQ and PSYCHLOPS as a 
source of qualitative, personalised information about patients undergoing treatment for 
substance misuse (Alves, Sales, Ashworth, & Faísca, submitted). The present study adds to that 
body of literature by providing estimates about the practicability, reliability and validity of such 
individualised outcome measures in this context.  
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Are individualised measures practicable for use in substance misuse treatment?  
We found that the administration of the whole evaluation protocol took approximately 
30 minutes (i.e. approximately half the typical duration of a clinical session). This means that 
individualised measures were completed relatively quickly, suggesting that adopting these 
measures might not be a burden in real clinical settings. Replicating previous findings in a 
primary care mental health setting (Ashworth et al., 2005), the completion rates of 
individualised measures were above 90%, demonstrating high levels of patient acceptability. 
The completion rates of individualised and standardised measures were similar, showing that 
both types of measures were equally received by patients. However, nearly half of our sample 
missed at least two responses in PSYCHLOPS, hindering the calculation of its total score and 
questioning its practicability. This was a low number in comparison with previous studies, 
where more than 90% of patients’ responses to PSYCHLOPS allowed the calculation of its 
total scores (Ashworth et al., 2004; Ashworth et al., 2007; Ashworth et al., 2008).  
Regarding the mode of administration, although designed to be self-completed, almost 
half the sample asked for PSYCHLOPS to be administered orally. This may be due to low 
literacy skills, high levels of patient distress on entering treatment and patients may have felt 
more supported by being able to talk about their problems during assessment. On the other 
hand, patients reported higher severity scores in the written format, implying that they might 
feel less comfortable verbalising their distress or that responses may be moderated by 
perceptions of socially disapproved, or even illegal, behaviours. Although contradictory, our 
results were consistent with Bowling’s observation (2005) that interviewer-based methods are 
likely to increase response accuracy, but self-report questionnaires may encourage the sharing 
of more sensitive information. No difference was observed between self-report or oral format 
scores on the standardised measures CORE-OM and PHQ-9.  
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Overall, our findings indicate PQ and PSYCHLOPS are practicable in substance misuse 
treatment settings. Nearly all patients invited to participate in the study were motivated to 
complete the individualised measures, even though not all responded to them in the expected 
format. In particular, there were many patients requesting the instruments to be administered 
verbally. This suggests that even when self-report measures such as PSYCHLOPS are selected, 
researchers and clinicians may have to enhance their interview skills to ensure that data 
collection is not negatively affected, should patients require assistance in this task.  
 
Do individualised measures generate quantitatively robust information? 
Both PQ and PSYCHLOPS elicited fewer items than when used in other clinical 
populations. For instance, in Elliott et al. (2016), the mean number of items created across five 
samples of patients in general mental health treatment was 10, compared with three items in 
the present study. Similar findings were reported in the previous section, when we observed 
that patients in our sample tended to miss PSYCHLOPS items more often than other samples 
(Ashworth et al., 2004; Ashworth et al., 2007; Ashworth et al., 2008). When combined, these 
results indicate that substance misuse patients provided less information in individualised 
measures than other clinical populations. Further research is needed to explore why this 
occurred. However, we hypothesize that being admitted for a specialist treatment, targeting a 
specific behaviour, might have led patients to think that it was inappropriate, or unnecessary, 
to disclose too much information about their lives. On the other hand, item scores and mean 
problem duration were similar to those reported in previous studies (Ashworth et al., 2005; 
Elliott et al., 2016), indicating that patients experience similar levels of psychological distress 
as in other generalist mental health samples, emphasising the importance of addressing 
psychological health in this population (Wanigaratne, Davis, Pryce, & Brotchie, 2005). 
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Concerning psychometric properties, our analyses revealed good internal reliability for 
PQ and PSYCHLOPS in the context of substance misuse therapy. Such reliability values were 
similar to those previously reported in Elliott et al. (2016) (α = .86) and Ashworth et al. (2005)       
(α = .79). On the other hand, the convergence between individualised and standardised outcome 
measures was weak to moderate. This might reflect the nature of problems experienced by our 
sample of patients, often unrelated to health and including concerns such as housing or finances 
not covered by the standardised comparators used (Alves, Sales, Ashworth, & Faísca, 
submitted). PSYCHLOPS correlated more strongly with standardised measures than PQ did. 
This might be a feature of the structural characteristics of PSYCHLOPS which is a hybrid 
instrument containing one standardised well-being item which correlated more strongly with 
standardised measures; whilst PQ is a pure patient-generated instrument, only containing 
personalised items.                        
A weak correlation was found between the two individualised measures. This was 
expected for several reasons: the different structure of PQ and PSYCHLOPS may have 
prompted patients to respond differently to both measures; a previous study (Alves, Sales, 
Ashworth & Faísca, submitted) had already found that patients tend not to repeat 
items/problems when answering both instruments as part of the same evaluation protocol. 
Moreover, the original self-report format of PSYCHLOPS was altered to an interview in 
approximately half of the sample. Considering that the information provided in a questionnaire 
depends on its administration (Bowling, 2005), it is unknown how much PSYCHLOPS 
responses were affected when provided orally.  
To sum up, even though individualised measures produce reliable measurements, their 
weak to moderate correlation with standardised measures suggests that they should 
complement standardised instruments rather than being used alone. This proposal had already 
been suggested by authors working in other treatment contexts (Barkham, 2016; Sales & Alves, 
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2012; 2014). Combining both types of measures may enhance their potential for outcome 
measurement. As Möller put it (2009), whilst standardised measures can objectively quantify 
psychological constructs, individualised information is able to capture “distinctive 
characteristics of individuals” (p. 2016), giving a more meaningful context to the numbers 
obtained with standardised tools.  
 
Which individual/treatment characteristics may influence PQ and PSYCHLOPS scores?  
Patients with past experience of substance misuse treatment were more likely to present 
higher distress in PQ and PSYCHLOPS, in comparison with those starting their first treatment 
episode. On the one hand, relapse may be particularly associated with distress and disruptive 
situations; also, patients who dropped out of previous treatment episode(s) without a successful 
therapeutic result may be more likely to have unresolved personal issues which they report as 
problems in individualised measures. Ramos & Brown (2008) identified that, among substance 
misusers, the main reasons leading to substance misuse and relapse are social situations, coping 
with negative emotions and interpersonal conflicts. These type of concerns were reported by 
our sample in PQ and PSYCHLOPS (Alves, Sales, Ashworth, & Faísca, submitted), which is 
in line with what we found in this study.   
Regarding the age of onset of drug use, our study was partly in line with the literature, 
which has reported that the younger individuals start to use drugs, the more severe their drug-
related problems are (Hser, Longshore, & Anglin, 2007). In support of this was the negative 
correlation between age of first use of cannabis and PQ; and first use of LSD and 
PSYCHLOPS. However, for crack and LSD in PQ, and ecstasy in PSYCHLOPS the reverse 
was true. For these patients, it is likely that other bio-psycho-social factors may have 
contributed for their dependence disorder, reinforcing the importance of a multidimensional 
evaluation of clinical status (Alves, Sales &, Ashworth, submitted).  
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Hence, even though PQ and PSYCHLOPS severity scores were higher in patients with 
previous treatment history, we found that the age in which patients starting using certain 
substances had different effects in PQ and PSYCHLOPS scores. This is another finding 
supporting the fact that PQ and PSYCHLOPS do not tend to converge in what they measure 
and in how their scorings are influenced by other variables, showing that, despite having similar 
purposes, they may actually be measuring different aspects of patients’ distress.  
 
Limitations 
The biggest limitation of our study is that it overlooks post-treatment scores. 
Contrasting pre-post treatment data would have permitted an estimation of further 
psychometric parameters of PQ and PSYCHLOPS, such as sensitivity to change and temporal 
structure. Practicability could be further explored by comparing patient and staff preferences 
for different combinations of instruments. We only collected the administration time for the 
entire protocol. Separate times would have provided a better estimate of individualised 
measures’ length and how they compare to their standardised counterparts. Moreover, we did 
not evaluate the quality of the items produced by patients in PQ and PSYCHLOPS. We 
hypothesise that differences between the quality of the items may have accounted for the 
divergence in the results obtained between these two measures.  
 
Conclusions 
With this study we have confirmed that individualised measures are practical and 
reliable to use as outcome measures in substance misuse treatment, in line with previous studies 
on psychometrics of PQ and PSYCHLOPS (Ashworth et al., 2005; Ashworth, Evans, & 
Clement, 2008; Elliott et al., 2016). Convergent validity between PQ and PSYCHLOPS and 
standardised measures was not strong, suggesting that individualised measures may be 
measuring different aspects of patient’s distress.  
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One of our biggest findings was the weak correlation between PQ and PSYCHLOPS 
and the variability of results produced by them, when in fact these measures were expected to 
measure similar constructs – patient’s individual concerns. Researcher and self-administered 
modes of completion may have influenced item generation, potentially leading to the 
differences between the scorings of PQ and PSYCHLOPS. 
Overall, our study suggests that PQ and PSYCHLOPS scoring can be used to measure 
patient’s distress in substance misuse treatment. Due to their low to moderate convergence, 
individualised measures should ideally be used in combination with standardised measures for 
optimal results. Further research is required to shed light to the psychometric properties of 
individualised measures, namely, in regards to their validity. Also, future pre-post studies are 
still needed to clarify whether PQ and PSYCHLOPS are valid, reliable and sensitive to measure 
clinical changes, a question that our cross-sectional study with pre-treatment data was not able 
to respond. 
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Does substance misuse treatment outcome assessment reflect the personal 
concerns of patients? A scoping review of measures recommended in 
Europe ¤ 
Paula C. G. Alvesa,b*, Célia M. D. Salesc, & Mark Ashworthb 
 
Abstract 
In substance misuse treatment, outcome measurement tends to rely on estimates of 
substance misuse and related behaviours (e.g. crime). There is a growing number of authors 
stating that outcome measurement should go beyond substance misuse and include other bio-
psycho-social variables of interest. However, little is known about which topics tend to be 
covered by outcome measures targeting this specific population, and whether they reflect the 
typical concerns of this patient group. This study followed a scoping review methodology in 
which 42 outcome measures were selected for review. Thirty-one domains of problems were 
identified across 42 measures, with ‘substance use’ and ‘psychological health’ among the 
commonest. The majority of the measures were similar between each other and 
multidimensional, suggesting a broad understanding of substance misuse disorders. Almost all 
domains of problems identified in the outcome measures corresponded to concerns reported by 
patients. On the other hand, we found that several topics of relevance for patients were not 
covered by any of the measure included in our study. This suggests that existing outcome 
measures do not always target aspects that affect patients’ lives. Our study shows that outcome 
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assessment needs to adopt a more flexible and comprehensive approach, by taking on board 
the problems experienced by patients in this population.  
Keywords: outcome measurement, evaluation tools, substance misuse treatment, patient 
perspectives, thematic analysis. 
 
Introduction 
In substance misuse treatment, as in any other mental health intervention, outcome 
assessment plays a crucial role in understanding how interventions work. To date, one of the 
largest outcome studies in this field was the National Treatment Outcome Research Study 
(NTORS; Gossop, Marsden, Stewart, & Kidd, 2003), conducted in the United Kingdom in the 
early 2000s. This study investigated the outcomes of community and residential treatment in a 
national sample of 418 individuals misusing illicit drugs and alcohol. It revealed reductions in 
drug use and risk-taking behaviours, as well as improvements in psychological and physical 
health. Other large scale outcome studies have reported similar findings (e.g. ATOS; Darke, 
Ross, & Teesson, 2007; DTORS; Jones et al., 2009). Gossop (2008) also referred to a “clinical 
fallacy”, which considers that numerous successful cases are overlooked in reports due to 
patients leaving the services voluntarily after self-perceived improvements. Although treatment 
drop-out can also represent treatment failure, these findings indicate that substance misuse 
treatment works, at least to a certain extent, and for a certain group of patients. 
However, for a relatively large proportion of people, substance misuse treatment is not 
as successful as desired. For instance, in NTORS, after a 5-year follow-up, there was still a 1% 
mortality rate and the levels of alcohol consumption remained unchanged among those that 
took part in the study. Moreover, an increase in frequency of alcohol use was observed in 
patients receiving residential treatment (Gossop, 2003). The latest report published by the 
National Drug Treatment Monitoring System of Public Health England (PHE, 2015) showed 
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that approximately one third of patients (with opiate, non-opiate, non-opiate/alcohol or alcohol 
problems only) dropped out of treatment prior to its completion. It also revealed that one third 
of patients with opiate and/or non-opiate dependence problems remain unchanged after six 
months in treatment; and considering solely the alcohol problems, nearly half of all patients 
failed to improve. The reasons for these discouraging results are unclear, but unsuccessful 
treatment may negatively affect patients’ mental, physical and social status, and contribute to 
mortality excess in this group. With such contradictory findings the first question is: how are 
we evaluating substance misuse treatment? In other words, there is a need to reflect about the 
value and relevance of the information which is being used for outcome assessment purposes.  
In 2012, Tiffany and colleagues stated that, to be effective, substance misuse treatment 
outcome measurement should 1) focus on the consequences or strong, concurrent correlates of 
excessive drug use; 2) cover aspects that are common across abused substances and widespread 
among people dependent on those substances; and 3) have documented and strong 
psychometric properties that produce replicable evidence that the outcome can be altered 
following treatment. Despite providing a good framework, or strategy, for substance misuse 
treatment evaluation, this proposal does not suggest which aspects should be covered by 
outcome measures in this field.  
There is a great diversity of outcome criteria proposed for substance misuse treatment. 
However, the literature lacks consensus, with many international organisations (e.g. European 
Monitoring Centre for Drugs and Drug Addiction, EMCDDA) and authors suggesting different 
domains, or outcome measurement criteria (Table 1).   
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Table 1 
Examples of domains (i.e. outcome criteria) to use in substance misuse treatment assessment, as 
suggested by experts  
Type of 
publication 
Authors/year  Source  Criteria suggested for outcome assessment  
International 
guidelines 
EMCDDA, 
2007 
EU Agency  Addictive behaviour/consumption of substances, 
retention/time in treatment, status at discharge 
(planned / drop-out), risk-taking behaviours for 
drug-related infection, somatic and psychiatric 
health, social reintegration (housing, employment, 
social network, life style, delinquency), and quality 
of life 
 
Scientific 
literature 
Tiffany, 
Friedman, 
Greenfield, 
Hasin, & 
Jackson, 2012 
 
Addiction research 
experts  
Self-efficacy, psychosocial functioning, 
network/social support, craving and quality of life 
 
Scientific 
literature 
Donavan et 
al., 2011 
Addiction research 
experts  
Behavioural functioning and quality of life  
 
 
Scientific 
literature 
Neale et al., 
2015 
Addiction research 
experts  
Substance use, treatment/support, psychological 
health, physical health, use of time, 
education/training/employment, income, housing, 
relationships, social functioning, offending/anti-
social behaviour, well-being, identity/self-
awareness, goals/aspirations and spirituality 
 
Moreover, there is a gap between what is proposed in the literature and what is actually 
evaluated in research studies and/or practice. Most evaluation protocols focus on drug and/or 
alcohol use and related behaviours, e.g. injecting, criminal activities (Donavan et al., 2011; 
Tiffany, Friedman, Greenfield, Hasin, & Jackson, 2012), overlooking psychosocial variables 
that many authors believe to be highly relevant for patients’ recovery (Table 1). These data 
could be used as markers to adjust the intervention according to treatment response (Tiffany, 
Friedman, Greenfield, Hasin, & Jackson, 2012), as well as allowing a better understanding of 
the mechanisms underlying recovery. 
The outcome assessment process in this patient group faces another major challenge: 
most measures are expert-driven, and not primarily sourced from patient perspectives. Failure 
to involve patients in the process of outcome measurement raises the possibility of overlooking 
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aspects of relevance for patients (Alves, Sales, & Ashworth, 2016) and having over-optimistic 
reporting of outcomes (Thurgood et al., 2014). Increasingly, studies are seeking the views of 
patients about outcome assessment criteria (e.g. Ruefli & Rogers, 2004; Neale et al, 2016; see 
Table 1). For instance, Ruefli and Rogers (2004) revealed that patients in treatment stated the 
importance of domains covering: ‘making money’, ‘getting something good to eat’, ‘being 
housed’, ‘relating to family’, ‘getting needed programs/benefits/services’, ‘handling health 
problems’, ‘handling negative emotions’, ‘handling legal problems’, ‘improving oneself’ and 
‘handling drug-use problems’. In a similar study conducted in 2015, Neale and colleagues 
asked patients to define what “being recovered” meant for them. Patients reported that 
treatment recovery should include improvements in ‘substance use’, ‘material resources’, 
‘outlook on life’, ‘self-care’ and ‘relationships’. Another example is the recently developed 
SURE, a standardised outcome measure for substance misuse treatment (Neale et al., 2016). In 
this measure, items were generated in collaboration with former and current drug and alcohol 
service users (Neale et al., 2016). Similarly, our own research group has sought the views of 
substance misuse patients through the use of individualised outcome measures, enabling 
patients to report their personal concerns at treatment entry (Alves, Sales, Ashworth & Faísca, 
submitted). We found that patient priorities were ‘addiction’, ‘work-related problems’, ‘general 
relationships with family’, ‘money’ and ‘worries about another person’. Additionally, we found 
that most of the patient-reported topics were not captured by widely used standardised outcome 
measures of psychological well-being, such as CORE-OM or PHQ-9, or drug-related outcome 
measures, namely TOP (Alves, Sales, Ashworth & Faísca, submitted). These findings suggest 
that patients may contribute with new evidence to outcome assessment, providing insight into 
contradictory findings reported in the literature about the outcomes of substance misuse 
treatment. 
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Study rationale  
The principal aim of this study was to explore the thematic content of items used by 
outcome assessment tools in substance misuse treatment in Europe and to understand the extent 
to which these measures are perceived as relevant to this population. We hope that our findings 
will contribute to a broader understanding of the attributes of outcome measures and their 
ability to capture the personalised problems reported by patients.  
  
Method  
This study was comprised of three analytical steps. The first was a scoping review (Arksey 
& O’Malley, 2002) to search for outcome measures and to identify the domains covered by those 
measures. Secondly, we explored the similarity between the measures according to their domains. 
Finally, a thematic comparison analysis was conducted to compare the domains covered by 
standardised instruments with “problem” domains generated by patients, which derived from 
individualised measures in previous literature (Alves, Sales, Ashworth, & Faísca, submitted). 
 
Search strategy, selection of measures and data extraction  
A scoping review is a charting technique used to extract information, from relevant 
sources, according to key issues or topics (Arksey & O’Malley, 2002). In this study, the key 
aspects used to chart our data were the general characteristics and domains covered by the 
outcome measures. We started by hand searching for outcome measures in the Evaluation 
Instrument Bank (http://www.emcdda.europa.eu/eib) of EMCDDA, until August 2016. This data 
source was selected because it operates as an information hub collating data about substance 
misuse across 30 European countries. Twenty-six national agencies for drug and alcohol 
monitoring were also contacted by e-mail to ensure that all measures recommended for outcome 
assessment had been identified. No additional tools were identified by the six national agencies 
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that responded to our request. Outcome measures were selected for review according to two 
inclusion criteria: 1) used to evaluate the outcome of treatment; and 2) used in adults as the target 
population. The measures were excluded if: 1) they did not target the patient (e.g. measures 
focusing on significant others); and 2) were not available in English. After selecting the outcome 
measures, a charting form was created for data recording. We extracted data describing general 
characteristics of the measures, by identifying their authors, year of publication, focus (drugs, 
alcohol, drug/alcohol, health, other), type of measure (standardised, individualised, hybrid), 
delivery format (self-report, interview, mixed) and number/type of items (Likert scales, nominal 
scales, number of days/times, other).  
 
Data analysis  
Part 1: Identification of domains covered by outcome measures. We started by reading 
the Evaluation Instruments Bank’s “User information” sheet of each measure, which included a 
section about “Domains measured/life areas/problems assessed”. If unavailable, the 
accompanying instructions or main references were consulted. A preliminary list of domains was 
then created, containing all domains included in each selected measure. In this list, domains were 
recorded verbatim as provided in the description of the measure. We removed duplicate domains 
and grouped those that referred to similar/equivalent topics, until a complete list of domains was 
obtained. For instance, ‘illegal activities’ and ‘criminal involvement’ were both integrated in the 
domain ‘crime’. In the particular case of ‘psychological health’, we opted for creating several sub-
domains, due to the existence of instruments that either focussed on general or single aspects of 
psychological health (e.g. ‘self-esteem’). This procedure was performed by the first author and 
the results were discussed with a researcher, independent to the study, until consensus was 
reached.  
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Part 2: Similarity between outcome measures in terms of domains covered. Next, we 
grouped the measures according to the similarity of the domains which they contained, to 
understand how convergent the tools were. To achieve this goal, we used the MF similarity index 
(Sales & Wakker, 2009; Sales, Wakker, Alves, & Faísca, 2015) to obtain a similarity matrix, based 
on the ‘absence’ or ‘presence’ of each domain, in each tool. The similarity matrix was analysed 
with the Hierarchical Cluster Technique (centroid method) in order to obtain groups of measures 
that shared common features. We used IBM SPSS Statistics 22 and the freeware online MF 
calculator (http://mfcalculator.celiasales.org/) to conduct this analysis.   
Part 3: Matching between outcome measure domains and the problems relevant for 
patients. The third part of our analysis comprised a thematic comparison between the domains 
extracted from the outcome measures and 54 previously defined domains of patient-generated 
problems. These problems represented patient concerns identified in individualised outcome 
measures, which are tools where patients are asked to report the concerns that led them to 
treatment, in an open-ended fashion and in their own words. The list of 54 patient-generated 
domains was identified by patients entering substance misuse treatment in a previous study (Alves, 
Sales, Ashworth & Faísca, submitted). The thematic comparison was made independently by two 
researchers using a binary coding system to rate each outcome measure domain as “yes” (i.e. 
topics connected, clearly related or completely overlapped with patient-generated domains) and 
“no” (i.e. topics completely different from patient-generated domains). This procedure was 
followed by calculations of inter-rater reliability, based on Cohen’s kappa values. Certain outcome 
measures selected for review contained sections about socio-demographic/treatment history and 
treatment process (e.g. readiness for treatment). These sections were excluded from our thematic 
comparison, as we were interested in outcome criteria only. After completing the content 
matching, we calculated the number and percentage of patient-generated domains included in each 
of the outcome measures.  
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Finally, for data reduction purposes, we re-analysed the data obtained from the 
aforementioned thematic comparison of patient concerns to identify the presence of underlying 
constructs featured in the selected outcome tools. We only included those patient-generated 
domains which were identified in at least a tenth of the outcome measures; less frequently featured 
domains were not included. This produced a cohort of 20 domains; the remaining 34 domains 
were discarded from this part of the analysis. In order to explore the structure of underlying 
constructs in selected domains, we used Multiple Correspondence Analysis (MCA; Carvalho, 
2008). MCA is a multivariate technique used to detect underlying dimensions among a group of 
nominal/categorical data. Factor analysis can also be used for a similar purpose; however unlike 
factor analysis, MCA makes no assumptions of normality and can be used with categorical data 
(Carvalho, 2008; Philips, 2009). Using MCA, dimensions are identified on the basis of their 
discriminatory and contribution values, in a range varying from zero to one.                                                                                                        
 
Results 
After removing the duplicates, 74 outcome measures were screened in this study, of which 
42 fulfilled the selection criteria (see selection flowchart in Figure 1).  
 
 
 
 
 
 
 
 
Figure 1. Flowchart showing the selection of outcome measures for review. 
Measures identified in EMCDDA 
Evaluation Instruments Bank (n = 75) 
Measures excluded (n = 32): 
Not for adult population (n = 18) 
Not addressed outcome of treatment (n = 4) 
Not focusing on the patient (n = 3) 
 Not available in English (n = 7) 
Not available online (n = 1) 
 
Measures screened after 
removing duplicates (n = 74) 
Total number of measures 
included for review (n = 42) 
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Main characteristics of the outcome measures  
Among the 42 outcome measures, 25 (60%) focussed on drugs/alcohol, seven (17%) 
focussed on drugs, six (14%) on alcohol, one (2%) on general health and three (7%) on other 
aspects (i.e. depression, self-esteem and quality of life). All but one measure were standardised, 
and only one differed by having an individualised scope, i.e. non-pre-set defined items. On 
delivery format, 21 (50%) were interview-based protocols, 19 (46%) were self-report measures, 
one (2%) was an observational scale and one (2%) followed a mixed-methods approach. The mean 
number of items was 54 (SD = 57, range 1-223). Among these measures, 23 (55%) contained 
nominal items and 34 (81%) had scale-type items (see Table 2). 
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Domains identified and similarity between outcome measures according to domains 
covered  
From a preliminary group of 196 domains of problems identified across the measures, 
we obtained a final list of 31 domains by excluding all domains which had overlapping content. 
The full list of these domains is presented in Figure 2. 
 
 
 
Figure 2. List of domains (N = 31) ordered by frequency of outcome measures featuring each 
domain. 
 
The mean number of domains per measure was 4 (SD = 4, range 1-18); and 43% of 
measures (n = 18) covered only one domain. The most common domains were: ‘substance 
28
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 117 
misuse’ (67%), ‘psychological health general (40%), ‘family and social relationships’ (38%), 
‘employment’ (38%), ‘crime’ (36%) and ‘physical health’ (26%).  
When exploring the similarity between the instruments in terms of domains covered, 
we found two main groups of measures: those that focussed only on substance misuse; and 
multidimensional measures focusing on substance misuse and other topics. A similarity tree 
representing these groups is shown in Figure 3. 
 
Figure 3. A similarity tree grouping the 42 outcome measures, based on their proximity in 
terms of domains covered. 
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Comparison between outcome measure domains and patient-relevant problems  
The content matching between the 31 domains and the 54 domains of patient-generated 
problems was performed with satisfactory inter-rater agreement values (Cohen’s kappa between 
raters ranged from .65 to 1.0). Overall, most patient-generated domains (n = 34, 63%) were 
represented by a small proportion (10%) of outcome measures (see Table 3). Moreover, 26% of 
patient-generated domains (n = 14) did not feature in any of the outcome measures. Among the 
unmatched patient-generated domains were topics such as ‘personal development’, 
‘understanding self’, ‘existence’, ‘outlook on life’, ‘moving on’, guilt’, ‘bereavement’ and 
‘dependence on other people’. On the other hand, nearly all 31 domains found in the outcome 
measures were matched, in terms of topics, to at least one patient-generated sub-theme. The 
exceptions were the domains: ‘domestic life’, ‘self-care’, ‘daytime activities’, “technology and 
information’ and ‘acculturation’. We also found that the patient-generated domains of problems 
frequently represented in outcome measures tend to focus on four main areas: interpersonal 
relationships (dimension 1); communication problems (dimension 2); addiction (dimension 3); 
and social problems (dimension 4) (table 4).  
 
 
 
 
Table 3  
Number and percentage of outcome measures featuring the 54 patient-generated sub-theme of problems 
Patient-generated sub-themes 
No. instruments with sub-
theme present (%)  
No. instruments with sub-
theme absent (%) 
Addiction 28 (67) 14 (33)
Relationship difficulties partner - breaking up 15 (38) 27 (64)
Depression/Anxiety 15 (36) 27 (64)
Justice-related problems 15 (36) 27 (64)
Relationship difficulties: family - breaking up 15 (36) 27 (64)
Relationship difficulties: family - worry about another 15 (36) 27 (64)
Relationship difficulties: partner - development 15 (36) 27 (64)
Relationship difficulties: partner - worry about another 15 (36) 27 (64)
Work-related problems 15 (36) 27 (64)
Relationships-general 14 (33) 28 (67)
Relationships difficulties: family-general 13 (31) 29 (69)
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Patient-generated sub-themes 
No. instruments with sub-
theme present (%)  
No. instruments with sub-
theme absent (%) 
Worries about health 10 (24) 32 (76)
Concentration 9 (21) 33 (79)
Socialising 8 (19) 34 (81)
Suicidal thoughts 9 (19) 34 (81)
Coping:daily living 7 (17) 35 (83)
Money worries 7 (17) 35 (83)
Going out/travelling 6 (14) 36 (86)
Relationship difficulties: partner – general 6 (14) 36 (86)
Communication 5 (12) 37 (88)
Attemped Suicide 4 (9) * 38 (91)
Motivation 4 (9) * 38 (91)
Fears/panics 3 (7) * 39 (93)
Being happy 2 (5) * 40 (95)
Emotions – unspecified 2 (5) * 40 (95)
Housing worries 2 (5) * 40 (95)
Loneliness/being alone 2 (5) * 40 (95)
OCD 2 (5) * 40 (95)
Relationship difficulties: partner - conflict 2 (5) * 40 (95)
Sleep problems 2 (5) * 40 (95)
Studies-related problems 2 (5) * 40 (95)
Achievement 1 (2) * 41 (98)
Agression/irritability 1 (2) * 41 (98)
Eating problems 1 (2) * 41 (98)
Relationship diffculties: family – caring 1 (2) * 41 (98)
Relationship difficulties: family - conflict 1 (2) * 41 (98)
Self image/self worth 1 (2) * 41 (98)
Self-acceptance 1 (2) * 41 (98) 
Sexual problems 1 (2) * 41 (98)
Victim of abuse/sexual violence 1 (2) * 41 (98)
Bereavement 0 (0) * 42 (100)
Coping: feelings 0 (0) * 42 (100)
Coping: general 0 (0) * 42 (100)
Dependence on other people 0 (0) * 42 (100)
Existence/existential 0 (0) * 42 (100)
Future 0 (0) * 42 (100)
Global 0 (0) * 42 (100) 
Guilt 0 (0) * 42 (100)
Having positive Outlook 0 (0) * 42 (100)
Having time 0 (0) * 42 (100)
Moving on 0 (0) * 42 (100)
Outlook on life 0 (0) * 42 (100)
Personal development 0 (0) * 42 (100)
Understanding self/events 0 (0) * 42 (100)
Note. The values highlighted with a * represent sub-themes covered by <10% of outcome measures. 
 120 
 
 
 
Ta
bl
e 
4
D
im
en
sio
ns
 (o
f p
at
ie
nt
-g
en
er
at
ed
 su
b-
th
em
es
) c
ov
er
ed
 b
y 
th
e 
ou
tc
om
e 
me
as
ur
es
, b
as
ed
 o
n 
th
e 
mu
lti
pl
e 
co
rr
es
po
nd
en
ce
 a
na
ly
si
s 
V
ar
ia
ble
s (
pa
tie
nt
-g
en
er
at
ed
 s
ub
-th
em
es
)
D
isc
rim
in
at
ion
 
C
on
tri
bu
iti
on
 (%
)
D
isc
rim
in
at
ion
 
Co
nt
rib
uit
ion
 (%
)
D
isc
rim
ina
tio
n 
C
on
tri
bu
itio
n 
(%
)
D
isc
rim
in
at
ion
 
Co
nt
rib
uit
io
n 
(%
)
A
dd
ic
tio
n
.0
0
0.
04
.0
2
0.
67
.4
4
22
.0
4
.1
6
11
.0
6
Co
m
m
un
ic
at
io
n
.0
0
0.
00
.5
9
18
.7
0
.2
5
12
.7
1
.0
8
5.
64
Co
nc
en
tra
tio
n
.2
1
2.
54
.3
6
11
.4
0
.2
5
12
.7
1
.0
2
1.
71
Co
pi
ng
: d
ai
ly
 li
vi
ng
.0
0
0.
02
.4
0
12
.6
1
.1
8
9.
08
.0
0
0.
07
D
ep
re
ss
io
n/
A
nx
ie
ty
.4
6
5.
45
.2
4
7.
59
.0
9
4.
29
.0
0
0.
00
Go
in
g 
ou
t/t
ra
ve
lli
ng
.0
1
0.
14
.6
1
19
.2
8
.2
3
11
.7
5
.0
2
1.
64
Ju
st
ic
e-
re
la
te
d 
pr
ob
le
m
s
.5
0
5.
91
.0
0
0.
06
.0
0
0.
05
.2
4
16
.8
5
M
on
ey
 w
or
rie
s
.4
0
4.
71
.0
5
1.
68
.0
0
0.
10
.1
0
7.
35
Re
la
tio
ns
hi
p 
di
ffi
cu
lti
es
 p
ar
tn
er
 - 
br
ea
ki
ng
 u
p
.8
7
10
.2
9
.0
7
2.
35
.0
1
0.
61
.0
3
1.
93
Re
la
tio
ns
hi
p 
di
ffi
cu
lti
es
: f
am
ily
 - 
br
ea
ki
ng
 u
p
.8
7
10
.2
9
.0
7
2.
35
.0
1
0.
61
.0
3
1.
93
Re
la
tio
ns
hi
p 
di
ffi
cu
lti
es
: f
am
ily
 - 
w
or
ry
 a
bo
ut
 a
no
th
er
.8
7
10
.2
9
.0
7
2.
35
.0
1
0.
61
.0
3
1.
93
Re
la
tio
ns
hi
p 
di
ffi
cu
lti
es
: p
ar
tn
er
 –
 d
ev
el
op
m
en
t
.8
7
10
.2
9
.0
7
2.
35
.0
1
0.
61
.0
3
1.
93
Re
la
tio
ns
hi
p 
di
ffi
cu
lti
es
: p
ar
tn
er
 –
 g
en
er
al
.2
7
3.
18
.0
0
0.
03
.0
3
1.
46
.0
3
2.
00
Re
la
tio
ns
hi
p 
di
ffi
cu
lti
es
: p
ar
tn
er
 - 
w
or
ry
 a
bo
ut
 a
no
th
er
.8
7
10
.3
3
.0
7
2.
35
.0
1
0.
61
.0
3
1.
93
Re
la
tio
ns
hi
ps
 d
iff
ic
ul
tie
s:
 fa
m
ily
-g
en
er
al
.5
3
6.
30
.0
1
0.
25
.0
0
0.
15
.0
3
2.
28
Re
la
tio
ns
hi
ps
-g
en
er
al
.5
8
6.
87
.0
1
0.
35
.0
2
1.
06
.0
0
0.
21
So
ci
al
is
in
g
.1
1
1.
28
.0
9
2.
73
.0
8
4.
19
.3
7
26
.6
2
Su
ic
id
al
 th
ou
gh
ts
.1
9
2.
22
.4
0
12
.7
0
.1
9
9.
48
.1
0
6.
78
W
or
k-
re
la
te
d 
pr
ob
le
m
s
.4
7
5.
53
.0
1
0.
29
.1
3
6.
66
.0
4
2.
50
W
or
rie
s 
ab
ou
t h
ea
lth
.3
7
4.
34
.0
0
0.
00
.0
2
1.
21
.0
8
5.
50
A
ct
iv
e 
to
ta
l 
8.
42
10
0.
00
3.
15
10
0.
00
1.
98
10
0.
00
1.
40
10
0.
00
In
er
tia
 / 
Va
ria
nc
e 
.4
2
.1
6
.1
0
.0
7
1
2
3
4
D
im
en
sio
ns
 121 
Discussion 
This study provides an overview of the measures recommended for outcome 
assessment in substance misuse treatment in Europe. Our goal was to identify the main 
characteristics of these measures; and also to explore the extent to which they covered 
individualised problems that bring patients to substance misuse treatment. In the next 
paragraphs we discuss the lessons derived from our findings.  
 
Lesson 1: Most outcome measures evaluate similar domains and are predominantly 
multidimensional    
In the 1960s professionals felt the need to employ methods to quantify substance use 
related problems that were being overlooked, which resulted in the proliferation of outcome 
tools (Dwyer & Fraser, 2015). Our study reveals that there is considerable duplication of the 
contents of outcome measures with consequent redundancy of measures in terms of topics 
covered. Hence, careful consideration of the domains worth measuring is required before 
selecting an outcome measure (Slade & Thornicroft, 2014).  
Our study revealed that outcome measures used in substance misuse treatment can be 
clustered into two main groups. One group included unidimensional measures focussing on 
substance misuse. This was consistent with the study population and with the fact that most 
outcome studies focus solely on this topic. A second and larger group contained three types of 
measures covering: substance misuse and behaviours associated with this disorder (e.g. 
injection of drugs); substance misuse and psychological health; and domains not directly 
related to substance misuse (e.g. self-esteem). Psychological health was the second most 
commonly identified domain, featuring in nearly half the measures. Given the importance of 
psychological health, these findings suggest that outcome measurement currently adopts a 
strategy to measure patients’ changes from a psychological point of view. These findings show 
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that the “narrow” approach (Bühringer, 2012) that most outcome studies follow is not due to 
the lack of multidimensional tools, because they are already available. It is the paradigm 
underlying outcome measurement that could implement a broader approach by using more 
comprehensive measures. This is consistent with studies where patients in substance misuse 
treatment reported a need to talk about topics that go beyond their drug-related problems 
(Alves, Sales & Ashworth, 2016).  
 
Lesson 2: The domains covered by outcome measures are relevant for patients  
Considering that outcome measures tend to be standardised and expert-driven, we were 
particularly interested in exploring the extent to which they reflected the personalised problems 
of patients in substance misuse treatment. We found that the majority of domains (e.g. 
addiction, work-related problems, relationship difficulties, money worries) covered by 
outcome measures were relevant for patients in substance misuse treatment, because they were 
equivalent to domains of problems reported by patients in free-text items. This had already 
been highlighted by patients in a previous study, who stated that outcome measure targeting 
substance misuse helped them to think about the negative consequences of their addictive 
behaviour (Alves, Sales, & Ashworth, 2016). Moreover, the patient-generated domains 
covered by outcome tools tend to focus on interpersonal and/or social relationships, which are 
concerns reported by 20% of patients in substance misuse treatment (Alves, Sales, Ashworth, 
& Faísca, submitted). This reinforces that outcome measures are tackling topics of interest to 
this population. 
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Lesson 3: The outcome measures available are overlooking areas of concern to this 
population 
 Our study revealed that only 10% of outcome measures contained half or more of the 
patient-generated domains identified by our study. The remaining 90% of measures contained 
few of those domains, which means that most fail to capture the full diversity of patient-
generated themes. Some patient-generated domains overlooked by outcome measures reflected 
specific concerns likely to be experienced by a small minority (e.g. ‘bereavement’). However, 
more universally experienced psychological factors or distressing events such as ‘guilt’, 
‘dependence of other people’ or ‘housing problems’, which are topics of relevance to this 
population, were rarely included in outcome measures. None of the measures included worries 
about the self (e.g. ‘personal development’, ‘existence’, ‘outlook on life’, ‘having time’) even 
though these were frequently reported in individualised measures (Alves, Sales, Ashworth, & 
Faísca, submitted). Some of these topics, namely, ‘self-care’ and ‘outlook on life’, have also 
been identified by patients as topics to be included in the standardised measure SURE (Neale 
et al., 2016). This suggests that patients seeking substance misuse treatment are likely to have 
a greater diversity of concerns than has previously been acknowledged by experts in the process 
of designing outcome measures. For this reason, we suggest the use of a more open-ended 
approach to outcome assessment which elicits a broader range of information from patients.  
 
Implications for outcome assessment in substance misuse treatment  
We believe that our study has provided some insight into the limitations of current 
outcome measures and how we can improve outcome assessment by producing more informed 
(and less contradictory) findings about treatment outcomes. Based on our study of measures 
used in Europe, we recommend that international bodies identify a core-set of outcome criteria 
for use in treatment evaluation, facilitating the selection of outcome tools. However, it is 
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important that both researchers/professionals and patients are engaged with this task. Although 
standardised outcome measures tend to cover relevant domains, they also overlook relevant 
information about individual distress. As Slade & Thornicroft (2014) put it, “any attempt to 
squeeze personal identity into predefined boxes can be justifiably criticised for its loss of 
meaning” (p. 120). This problem could be overcome through the use of a more patient-centred 
approach to outcome assessment, by using individualised measures (see Sales & Alves, 2016, 
for a review about these tools), which allow patients to express their personal problems. We 
advocate that individualised measures are used in combination with existing standardised 
measures, which provide population reference data. If the use of individualised measures is not 
feasible, a standardised PROM designed with a high level of patient input may be a suitable 
alternative. Although “imperfect measures are better than no measures at all” (Scheyett et al, 
2013), the addition of items deemed important by patients has the potential to improve outcome 
assessment.  
 
Limitations 
This study is not without limitations. First, we accept that some outcome measures may 
have been omitted from our study, since we only searched for outcome measures included in 
the EMCDDA database. However, our goal was to confine our search to measures 
recommended by this European agency. Restriction of our search to Europe may have restricted 
our findings although measures have to be culturally applicable (Mann, 2012). A further 
limitation is that our review excluded adolescents, since the patient-generated domains used 
for comparison purposes were derived from an adult population, whose concerns may differ 
from those of younger individuals. We believe, though, that this present study adds up to an 
increasing body of literature showing the importance of multidimensional outcome assessment 
in substance misuse and the inclusion of patient perspectives. Such an approach would 
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acknowledge the multiplicity of problems associated with substance misuse disorder, as well 
as taking into account the concept that recovery is an individual journey.  
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Main findings  
When presenting the background for this manuscript, a question was raised that would 
guide the theoretical and empirical work that followed: are we missing something when we 
measure the outcomes of substance misuse treatment? We also questioned ourselves about how 
could we shift the current paradigm, towards a personalised outcome measurement approach 
that enables patients to contribute with topics of personal relevance.  
 According to what was found, the answer to our main question is that outcome 
measurement is, indeed, potentially missing the opportunity to capture the whole range of 
patient’s problems. Paraphrasing an individual from our focus group, whose quote entitled one 
of our articles, there are things patients want to say but we (i.e. researchers, professionals) do 
not ask. Our proposal to shift the paradigm was the adoption of I-PROMS as a strategy to 
provide patients with freedom to express their personal problems. This strategy yielded 
encouraging findings, demonstrating that I-PROMS were well accepted by patients, allowed 
the identification of topics overlooked by standardised measures and permitted a quantification 
of patient’s personal distress.  
In this section we provide an in depth discussion of what we learned from our project, 
the implications of its findings for practice and future research and a preliminary set of 
recommendations for personalised measurement in substance misuse treatment. Finally, an 
overview of the strengths, limitations and concluding remarks of this project is presented. 
Figure 1 highlights the main conclusions of this work.  
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Figure 1. Summary of main findings from this project.  
 
How was our theoretical proposal to personalise outcome measurement in substance 
misuse treatment received by the scientific community? 
We started our thesis by providing a pragmatic answer to the call of various addiction 
research experts about the need to increase patient involvement in this field (Neale & Strang, 
2015; Orford, 2008). Even though this research project had an empirical scope, the lack of 
guidelines on how to translate this recommendation into practice challenged us to present our 
approach to the scientific community, in a structured and visible manner. Hence, we sought not 
There is an increasing 
number of innovative 
approaches to improve 
patient involvement in 
substance misuse 
treatment.
I-PROMS are perceived 
by patients as helpful for 
their treatment and to 
freely express whatever 
problem they have, related 
or not to substance 
misuse.
I-PROMS capture 
personal problems that 
patients have and that 
standardised outcome 
measures tend to 
overlook.
I-PROMS are practical 
and generate reliable 
scorings of patients' 
distress, even though their 
convergence with 
standardised measures is 
not strong.
Outcome measures in 
substance misuse 
treatment need to become 
more flexible and to 
acknowledge the 
subjectivity of patients.
I-PROMS should be used 
in combination with 
standardised problems 
towards a personalisation 
of outcome measurement. 
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only to explain the framework that was going to be used throughout the project; but also to 
motivate the wider scientific community to contribute with other perspectives about this topic. 
From our point of view, we succeed drawing attention to the need for a greater 
personalisation of outcome measurement in substance misuse treatment. International 
researchers responded directly, and promptly to our call, by building on our proposal with 
further considerations about personalised measurement. An example is the article by Trujols, 
Iraurgi, Battle and Cobos (2015), entitled ‘Towards a genuinely user-centred evaluation of 
harm reduction and drug treatment programmes: a further proposal’. We conceptualised 
standardised measures as tools that are expert-driven and that target a more or less general 
population. Nevertheless, Trujols and his colleagues highlighted that standardised measures 
can also be developed with patient input, covering topics of relevance to a specific patient 
group and using methods such as participatory research (Rose, Evans, Sweeny, & Wykes, 
2011). For instance, the drug-related standardised outcome measure SURE (Neale et al., 2016) 
is an example of a tool whose topics were selected by patients. But even under these 
circumstances, it is still possible that measures contain items of little or no relevance at an 
individual level, which is the greatest advantage of I-PROMS. Nevertheless, the reactions to 
our first article, and the parallel emergence of literature about patient involvement in substance 
misuse treatment, demonstrates how rapidly this field is evolving. It also shows an effort for 
the development of practical solutions to overcoming the poor engagement of patients with 
treatment-related tasks, in an environment of international collaboration and confluence of 
ideas/approaches.  
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Did patients provide relevant input about outcome measures and the outcome 
measurement process?  
Approximately 30-80% of patients with substance misuse disorders experience several 
forms of cognitive impairment, including decreased insight and lower self-efficacy (Copersino 
et al., 2009). The present research did not include an evaluation of patients’ cognitive skills. 
However, we found that patients in this population were not only able to respond to I-PROMS 
and the other standardised measures, but were also capable to think about the impact of these 
measures and what makes outcome measurement a helpful and/or hindering experience. This 
reinforced that, similarly to what occurred in other populations (Crawford et al., 2011; Stone 
& Elliott, 2011), patients with substance misuse disorders should be actively involved in 
treatment-related tasks, including the selection of outcome measures and the decision about 
whether I-PROMS are, or not, a valuable addition to outcome measurement. 
As we listened to patients’ first-hand experiences with our evaluation protocol, we 
learned that certain topics (e.g. suicidal thoughts) were too sensitive and may trigger negative 
emotions. The literature also shows that questionnaires characteristics such as length or 
question wording are likely to affect the quality of individuals’ responses (Ganassali, 2008). 
This does not mean that I-PROMS, or any outcome measure for that matter, should exclude 
distressful topics. In fact, outcome measures that target psychological distress will, 
undoubtedly, tackle situations or symptoms that are unpleasant to reflect about. However, 
precisely because of this, it is important to gather patient’s feedback whilst developing outcome 
measurement protocols. This would not only help us to improve the conditions that make 
outcome measurement a more appreciated experience for patients; but also raise (our) 
awareness and minimise the negative impact of discussing potentially critical issues.  
By gathering patients’ perspectives about I-PROMS, we understood that, like therapists 
and researchers, patients favour the use of these measures as a means of freely expressing their 
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problems. Patients view I-PROMS as an opportunity to talk about significant aspects in their 
lives, without being confined to discussing issues around their substance use disorder. The 
following quote, which partly became the title of the focus group study, is an illustration of 
this: ‘it is not just about the alcohol, we feel bad about many other things in life. My sister 
doesn’t drink alcohol but could answer this too, because everyone has problems’. From a 
normalisation theory approach, an experience such as this can have a positive impact on 
patients’ well-being, by making them feel less stigmatised and closer to the general population 
(Kraynak, 2013). 
 From our research emerged concerns that should be addressed in future studies to ensure 
that I-PROMS do not become hazardous for patients. The first of them is the high level of 
personal exposure that I-PROMS require to be completed. Obviously, talking therapies involve 
information sharing about one’s personal problems in a secure and private setting. Hence, the 
novelty of I-PROMS is not to elicit personalised data; but to collect it in such a way that is 
usable beyond the clinical, one-to-one setting, namely, outcome measurement. Unlike 
standardised measures which allow patients to rate their level of distress in a relatively neutral 
manner, I-PROMS involve disclosure of intimate aspects about their lives and the lives of their 
significant others. Even though patients are free to choose what they want to include in I-
PROMS, the dilemma about omitting or not certain information can be, in itself, a distressful 
experience that should be avoided. Based on this, it is paramount to further explore how 
comfortable patients are in exposing aspects of their private lives for outcome measurement 
purposes. From this point of view, it would be worth investigating to what extent should I-
PROMS be completely open-ended; or to have a hybrid structure by including open and closed 
questions, similarly to PSYCHLOPS. We hypothesise that such hybrid measures would give 
patients a choice to decide which type of information (personalised vs. standardised) they wish 
to share.  
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What did we gain, in terms of qualitative information, from using I-PROMS?  
Knowing that both professionals and patients acknowledge I-PROMS as a good 
strategy to measure treatment outcome is paramount. However, when this project was planned, 
we did not know whether I-PROMS generated qualitative information that was not already 
present in standardised measures.  
As our project has shown, using standardised measures alone may not be enough to 
capture everything that is distressing patients. More specifically, our findings indicate that 
patients seeking treatment for substance misuse are likely to present a great variety of problems, 
ranging from psychosocial situations frequently associated with this population (e.g. justice-
related problems), to more inner conflicts (e.g. being happy). This shows that substance 
misusers are anything but a homogenous patient group and that tools such as I-PROMS are 
needed to take each person’s concerns on board. Hence, even though a greater attention is being 
paid to the personalisation of treatment offered to substance users (e.g. Marsden et al., 2014), 
these initiatives rely on standardised measures which, according to our project, may not be 
enough.  
To acknowledge that patients in this group are individuals with very specific and diverse 
problems creates a need to widen the scope of outcome measurement, so that the whole 
spectrum of patients’ distress may be captured. Previous literature (e.g. Donavan et al., 2012; 
Tiffany, Friedman, Greenfield, Hasin, & Jackson, 2012) is also in support of such a proposal. 
This would not only ensure that outcome measurement reflects the reality of each patient as 
accurately and as comprehensively as possible; but would also allow patients to report more 
problems than those typically addressed in substance misuse treatment (e.g. personal 
development). The present study limited the comparison of I-PROMS with three standardised 
measures only. However, I-PROMS items such as ‘I am afraid to acknowledge my feelings for 
my ex-husband’ or ‘the price of my medication for epilepsy has gone up so I drink to fall 
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asleep’, reported by our sample, indicate that those concerns were unlikely to be part of any 
standardised measure that could have been included.  
By capturing patient’s individuality, I-PROMS are likely to reduce the gap between the 
outcome measurement process and psychological interventions. In other words, I-PROMS 
provide the possibility to measure treatment outcomes based on personal information that 
patients naturally discuss with their therapists and that was used to shape their therapeutic 
journey. Without I-PROMS, this patient-relevant information would undoubtedly be captured 
by clinicians, but could be lost for outcome measurement purposes.  
 There are however challenges in using I-PROMS to capture patient’s individualised 
problems. The first is the ever changing nature of an individual clinical picture. More 
specifically, new problematic situations may emerge in patients’ lives during the course of 
treatment and concerns that were relevant in the beginning of treatment may cease to exist or 
no longer be perceived by patients as a problem. This dynamic structure of patient’s clinical 
situation requires a continuous revaluation to ensure that therapists make informed decisions 
based on patients’ here-and-now problems (Bickman, Kelley, & Athay, 2012). Even though 
this is also true for standardised measures, reassessing individualised problems in I-PROMS 
may imply adjustments in the items’ free-text, or even the introduction or deletion of items. 
There are I-PROMS, such as PQ, that acknowledge the necessity to revise individualised items 
over time. To date, it is unknown how the variations in individualised items impact the 
evaluation of outcome. This means that, at least in I-PROMS, the formulae typically used to 
calculate outcome (i.e. contrasting pre-post treatment item scores) may need to be adjusted, by 
taking into account that not all problems experienced during the intervention existed at 
treatment entry.  
 Capturing the personalised problems of patients is a clear advantage of I-PROMS. As 
Gough and Madill (2012) put it, psychology researchers still have a discomfort with 
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subjectivity and prefer objective and standardised data collection methods to produce valid 
knowledge. It is believed that using I-PROMS is a strategy to give back subjectivity to outcome 
measurement. However, it is important that this growing call for the personalisation of outcome 
measurement do not result in an overuse of I-PROMS. To have a purely subjective approach 
of evaluating treatment outcomes is as undesirable as using standardised measures alone. 
Radicalism should be avoided, regardless of which approach is adopted, and a pluralistic 
perspective of outcome measurement, in particular, and psychological research, in general, is 
to be commended (Gough & Madill, 2012). In extreme situations, using I-PROMS as the only 
means of gathering information about patients may also hamper the progression of health 
research, by hindering the comparison between individuals, the interpretation of data and the 
recruitment of large sample sizes.  
 
Were I-PROMS scorings reliable and valid to quantify patients’ level of distress? 
 To this point, we have learned that, in substance misuse treatment, I-PROMS are 
valuable for patients, and that they are likely to capture qualitative information about patients 
that is overlooked by their standardised counterparts. However, to be adopted as outcome 
measures, I-PROMS need to have the capacity to quantify the patient’s distress.  
As in previous studies (Ashworth et al., 2005; Elliott et al., 2016), we found that both 
PQ and PSYCHLOPS allowed patients to score their individualised problems with a good 
reliability. On validity, even though convergence between PQ and standardised measures was 
weak, moderate correlations between PSYCHLOPS and those same standardised measures 
were found. Overall, these findings were satisfactory because they not only add to the body of 
knowledge about the psychometric properties of these measures, but they also help 
consolidating the status of I-PROMS as tools that serve the purpose of quantitative outcome 
data collection, as their standardised counterparts do.  
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 However, one must interpret these findings with reservations for two reasons. The first 
is that our studies cannot be considered as isolated investigations of this topic, but as part of a 
continuum work towards the understanding of I-PROMS. As Cizek (2013) put it, a single study 
cannot make dichotomous statements about the validity (“valid/invalid”) of an instrument, and 
any judgements about this property should derive from accumulated evidences. From this point 
of view, in the current state of the art, any conclusion about the psychometrics of I-PROMS is 
preliminary, considering that only a limited number of studies has addressed this issue. 
Secondly, it is unknown whether the methodology previously used to study the psychometrics 
of I-PROMS (e.g. Ashworth et al., 2005; Elliott et al., 2016), which we replicated, was the 
most adequate. We followed the quantitative approach that tends to be adopted with 
standardised measures. This focussed on validity (i.e. whether an instrument measures what it 
is supposed to measure) and reliability (i.e. whether an instrument includes items that 
consistently measure the same construct) as the most important criteria to ascertain if an 
instrument is usable or not (Kember & Leung, 2008). But as Barkham (2016) recently pointed 
out, perhaps applying these psychometric standards to I-PROMs is, in a way, contrary to their 
ultimate purpose: to capture the uniqueness of patients.  
As recommended by the literature (Mokkink et al., 2010; Wong, Ong, & Kuek, 2012), 
to measure I-PROMS validity, we contrasted them with gold standard outcome measures to 
understand if they were measuring the same construct. When this comparison involves 
standardised measures only, interpreting the numbers (i.e. Pearson’s correlation coefficients) 
is a relatively direct and objective procedure because the items are fixed and pre-determined. 
However, adding I-PROMS to the equation complicates this task. Considering that the contents 
of I-PROMS items are variable and unpredictable beforehand, it is almost impossible to 
anticipate the topics that will be covered, hindering the selection of relevant standardised 
comparators. Even when generalised measures of psychological distress are chosen, as we did 
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in this project, we cannot guarantee that we are comparing similar constructs. This may have 
been the reason underlying the weak convergence between PQ and other standardised measures 
of psychological distress. Future research should endeavour alternative methods to evaluate the 
validity of I-PROMS, by integrating the scores and the contents of the items in these analysis, 
so that patients’ individuality is not lost to psychometrics.  
To calculate the reliability of I-PROMS, we analysed their internal consistency based 
on Cronbach’s alpha scores. By definition, internal consistency “describes the extent to which 
all the items in a test measure the same concept or construct (...), put simply, the correlation of 
the test with itself” (Tavakol & Dennick, 2011, p. 53). It is generally acknowledged that alpha 
scores > .7 are considered as acceptable in terms of reliability (Bland & Altman, 1997). In our 
sample, this was observed for both PQ and PSYCHLOPS. However, because in I-PROMS each 
individual has a different set of items, any “between subjects” analysis with Cronbach’s alpha 
must be interpreted with caution. To overcome this limitation, Elliott et al. (2016) added a 
method to estimate “within subjects” reliability, by comparing PQ scores of the same individual 
at different points in time, although we could not replicate this due to lack of data. Another 
concern that one faces when estimating the internal consistency of I-PROMS is the 
unpredictability of the number of items generated by individuals. It is known that an 
instrument’s internal consistency increases with its number of items; but in I-PROMS, it is 
possible that individuals generate such a small number of items that either hinder the 
calculation of this parameter, or result in extremely low alpha scores.  
 
Did PQ and PSYCHLOPS generate similar qualitative and quantitative data? 
 PQ and PSYCHLOPS are two of the most popular I-PROMS and both focus on patient’ 
target complaints (Sales & Alves, 2016). Because of this, when integrated in the same 
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evaluation protocol, similar results were expected in the two measures. This is not what our 
research demonstrated.  
 We found that the problems reported by patients in PQ and PSYCHLOPS tended to 
diverge in terms of content, meaning that patients used the two measures to express different 
kind of concerns. As such, we were not surprised to observe a weak correlation between the 
scorings of PQ and PSYCHLOPS during the convergent validity analysis. The reasons for this 
divergence are unknown, but there are strategies that could be adopted to explore this issue. 
On the one hand, one could make use of think-aloud approach (Charters, 2003) to ask patients 
what were the characteristics of the two measures (i.e. self-report vs. interview; unlimited 
number of problems vs. three blank-boxes; open-ended vs. semi-structured requesting two 
problems and one function; only individualised items vs. three individualised and one 
standardised item) that motivated them to provide dissimilar responses to PQ and 
PSYCHLOPS, when simultaneously administered. For instance, as one patient reported in the 
focus group, “we can be more honest by using a pen”, suggesting that, at least for some patients, 
the administration format may have impacted how they responded to each I-PROM. On the 
other hand, it would also be important to investigate individual expectations towards the 
measurement process when both measures are used. In our protocol, patients may have been 
inclined to generate different items in the two measures to avoid repetition. It would be useful 
to develop a set of instructions for I-PROMS to ensure that patients feel as free as possible to 
create any items of their choice, regardless of being repetitive. To achieve this, though, the 
wording of these instructions must be carefully selected to ensure a minimal impact on patients’ 
responses. 
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Were I-PROMS practical to implement in substance misuse treatment settings?   
The fact that patients perceived I-PROMS as advantageous to their treatment, and that 
we had response rates higher than 90%, indicates that these measures can be implemented in 
substance misuse treatment. However, we identified three situations that must be considered 
when discussing the practicability of I-PROMS.  
The first was patients’ preference for outcome measures to be administered by 
therapists, as someone to whom they could confide their problems. It is known that therapists 
perceive I-PROMS as useful for their clinical work (Sales et al., 2007; Sales, Alves, Evans, & 
Elliott, 2014). Putting these results together, we endeavour that I-PROMS practicability could 
be increased if used by therapists as part of their routine therapeutic work, for instance, during 
initial evaluation sessions. Hence, further initiatives are required to train and support therapists 
and clinical staff to implement I-PROMS in their practice. Such initiatives must be delivered 
to emphasise the fact that I-PROMS are not only advantageous, but are also similar, in their 
format, to informal clinical assessments that therapists already do as part of their clinical 
intervention (e.g. asking patients what brought them to therapy, similar to what is performed 
in PQ).  
The second aspect to bear in mind was that approximately half of our sample requested 
that self-report measures, including PSYCHLOPS, to be administered in an oral format. A 
quote from one patient in our sample illustrates this situation: “if we are forced to talk, it is 
better because we end up saying something”. However, this format alteration may not only 
have affected patients’ responses but also the purpose of the instrument in itself. Previous 
literature, in other populations, has been published on this topic. For instance, the study by 
Young, Campbell, Zakanis & Weinstein (2003) showed that measuring insight in 
schizophrenic patients with researcher-administered and self-report questionnaires generated 
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different results. On the other hand, the study by Lopes and collaborators (2009) found that 
evaluating physical health through interviews and self-report methods produced similar data.  
We did not foresee that such a large proportion of patients would ask for PSYCHLOPS 
to be orally administered; hence, our methodology was not planned to address this topic. 
However, finding that its original mode of administration was not practical to half of our 
sample, and that this affected patients’ scores, indicates that this topic needs further 
consideration. This would allow us to understand how the practicability of instruments could 
be improved, as well as the impact on altering the original mode of administration on the quality 
of data collected. For instance, it is unknown whether the psychometrics of a self-report 
measure are preserved when orally administered.  
We also verified that our sample tended to create less items in PQ and PSYCHLOPS 
than other samples (e.g. Elliott et al., 2016). In the case of PSYCHLOPS, where a minimum of 
items is required to compute its total score, this resulted in discarding nearly half of the 
questionnaires for the purposes of quantitative analyses. Ultimately, if I-PROMS fail to devise 
qualitative and quantitative information to evaluate patients’ distress, their practicability as 
outcome measures is questioned. In other words, even if patients agree to participate in the 
measurement process, providing missing or unreliable responses leads to an unnecessary 
burden and waste of human and economic resources. For this reason, future research should 
focus not only on I-PROMS psychometrics, but also on the improvement of their structure, 
exploring what would make them more attractive to patients in substance misuse treatments.  
 
Did outcome measurements in substance misuse treatment take the patient’s subjectivity 
into account?   
The scoping review suggested a disparity of views between patients and experts, by 
showing that the topics of concern elicited by patients were not always represented in expert-
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driven measures. This finding is supported by the literature, with authors such as Trujols and 
collaborators (2011) having demonstrated that patients and clinicians had a different 
perspective about the meaning of clinical improvement.  
The results of our previous studies pointed towards the benefits of using methods that 
capture the patient’s subjectivity, which standardised measures tend to overlook. But these 
observations were drawn from a comparison between two I-PROMS and three standardised 
measures only. Although five outcome measures may seem adequate for a protocol to be 
implemented in naturalistic settings, more generalised conclusions about the panorama of 
outcome measurement in this field could not be derived from these findings. Is there an overall 
tendency for outcome measures to miss aspects of relevance for patients? Was this an artefact, 
or a type II error (i.e. failure to detect an effect that is present), caused by the type and the 
limited number of measures included in our measurement protocol? 
Our review showed that most outcome measures tend to conceptualise addiction as a 
multidisciplinary problem that encompasses several areas of patients’ lives, as many authors 
advocate (Tiffany, Friedman, Greenfield, Hasin, & Jackson, 2012). However, the reality is that 
they tend to be similar in what they address, which makes us question the existence of 
numerous measures (> 40). To overcome this, it would be important that internationally-
relevant bodies, such as the European Monitoring Centre for Drugs and Drug Addiction 
(Europe) or the National Institute on Drugs Abuse (United States of America) could overview 
the existing measures, and ideally reduce the number of those that are recommended for 
outcome measurement. This would not only guide researchers and clinicians selecting the most 
appropriate measures, but would also avoid the parallel, and unnecessary, development of tools 
that tackle equivalent topics.  
The major finding of our review was that the domains addressed by outcome measures 
correspond to real concerns of this patient group, as reported in I-PROMS. This showed that 
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outcome measures for substance misuse treatment are applicable to this population, which is a 
crucial aspect to consider when selecting and using outcome measures (Lambert & Hawkins, 
2004). The problem is that, in line with our previous results, we did not find a single measure 
that matched perfectly all concerns elicited by patients. Even though these results are not 
exhaustive and there may still be other measures that our project overlooked, we believe that 
no measure is likely to capture everything that is distressing a patient. Hence, the challenge is 
not the inadequacy or the lack of outcome measures; but the need to have additional means to 
accommodate for the diversity of human beings and the subjectivity of each clinical case.  
 Our findings, therefore, suggest that we do not need to develop new tools, but instead 
to re-think the strategy that has been used for outcome measurement in this population. In 2013, 
the North American’s Agency for Healthcare Research and Quality published a guiding 
document on how to develop evaluation protocols for research. It stated that the selection of 
outcomes “involves the consideration of multiple stakeholder viewpoints (provider, patient, 
payer, regulatory, industry, academic and societal) and the intended use for decision-making 
of resulting evidence.” (p. 71). To achieve this goal, and because it is impossible to predict the 
nature of each individual’s problems, more flexible tools should be considered. In line with our 
previous studies, this too points out to a more idiographic approach to evaluate the views and 
personal features of patients, which is lacking in substance misuse treatment (Neale & Strang, 
2015). Unfortunately, supporting the use of an idiographic measurement approach, and I-
PROMS in particular, is not enough. Even if these measures are endorsed by national and 
international health agencies, it is difficult to ensure that they are used in practice, unless it is 
a mandatory procedure. We expect, though, that those interested or asked to design outcome 
measurement protocols may explore alternatives to the traditionally used measures and are 
aware of their advantages and limitations, so that informed decision-making takes place.  
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 To sum up, our scoping review was not exhaustive and was limited to the measures that 
are recommended in Europe. Hence, it is possible that broadening the scope of this study would 
have resulted in the selection of different measures, which could have had a higher (or lower) 
convergence with patients’ concerns. It is also true that another sample, with different patients 
and other kind of problems, may have resulted in a different list of patient-generated domains 
to use as comparators. Even so, the unpredictability of human beings and their life 
circumstances still supports the benefits of including I-PROMS in evaluation protocols, as a 
guarantee that such unpredictability can be accommodated. 
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Recommendations for personalised outcome measurement in substance 
misuse treatment   
Overall, we aimed to explore the use of I-PROMS in substance misuse treatment, as a 
strategy to personalise outcome measurement and to involve patients more actively in this 
process. From our findings, we were able to draw a list of preliminary recommendations to 
implement this measurement approach in substance misuse treatment settings, in a such a way 
that is practical, comfortable and meaningful for both therapists and patients.  
 The main recommendation that emerges from our work is that we should involve 
patients in all steps of the outcome measurement process, and also to request their feedback 
about how this process could be improved. This could be achieved through the organisation of 
periodic patient forums in clinical services or groups of service users that collaborate actively 
with addiction researchers. An example of this is the Service User Research Group, based in 
London, (www.kcl.ac.uk/ioppn/depts/addictions/research/SURG/index.aspx), which aims to 
engage patients in “[thinking about] research problems, designing studies, preparing grant 
applications and ultimately conducting and disseminating research”. We suggest that similar 
groups can be created in other locations, including Portugal, where, to our knowledge, these 
kind of initiatives have never been promoted.  
 Another recommendation suggested by our findings is that in substance misuse 
treatment, likewise in mental health in general, it is important to develop evaluation protocols 
that include standardised and individualised outcome measures. According to the studies here 
presented, the complementary use of both kind of measures allows for the collection of 
standardised indicators that can be used for large-scale purposes (e.g. evaluating the success 
rate of a clinical service); as well as taking patients’ idiosyncrasies into account. The protocol 
used in this project is an example of how standardised measures and I-PROMS can be 
combined, but other measures can be selected according to the needs and characteristics of 
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each sample. The list of patient-generated domains that emerged from our thematic analysis 
(third article) together with the review of outcome measures presented in the scoping review 
(fifth article), can be useful resources to help clinicians and researchers selecting the measures 
that best reflect the problems of patients in this population. The review of Sales & Alves (2016) 
provides a full list of I-PROMS available, which can also guide those interested in using 
individualised measures.  
 Moreover, it is preferable to adopt outcome measures that are flexible in their mode of 
administration, that can either be used as oral interviews or written self-report measures. Our 
studies revealed that both formats were welcomed by patients; however, we also found that the 
mode of administration is likely to influence patients’ qualitative and quantitative responses. It 
is unknown why and how the administration format influences patients’ responses (e.g. does 
written-formats offer more privacy? Are interviews a more interactive and humanised 
process?). Before future studies shed light to these questions, we propose that patients are asked 
about their preferred questionnaire format, before evaluation takes place, to ensure that we 
provide them with a setting adjusted to their personal needs. This is particularly important in 
pre-treatment evaluations, where patients tend to be anxious and less able to focus in the 
completion of questionnaires.  
We also suggest that outcome measurement processes are conducted by clinicians or 
any member of the clinical staff who will take part in the patient’s therapeutic journey. As we 
listened to patients in our focus group, we learned that, at least in this sample, they tended to 
prefer having questionnaires administered by their therapists. The extent to which this might 
affect patients’ responses is uncertain, since there is a risk of obtaining socially desirable 
responses (Börger, 2013). However, as patients and therapists actively collaborate in these kind 
of tasks, it is likely that their therapeutic alliance will increase (Flückiger et al., 2012). As such, 
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when looking at this from a cost-benefit approach, we suggest that therapists may still be the 
best choice in terms of outcome measurement delivery.  
It is recommended that future studies explore to what extent I-PROMS are sensitive to 
change in this population, with pre-post outcome studies, and also the concerns of patients that 
emerge, or fade, as soon as they enter the treatment system. This is important because it is 
unknown which kind of data would result from subsequent applications of I-PROMS in this 
patient group. Most patients reported addiction as their main problem; but it is possible that the 
nature, and also the quantity, of patients’ problems vary throughout treatment. A recent review 
has stated that patients’ level of insight and motivation for treatment are poorly documented in 
the literature (Linn-Walton & Maschi, 2015). Nevertheless, it is likely that these change whilst 
patients progress in treatment, consequently affecting their responses to I-PROMS and how 
they perceive their clinical situation. 
Given the vast number of outcome measures available for substance misuse treatment, 
we advocate that national and international policy makers and health managers may work 
towards a greater harmonisation of outcome evaluation practices. This would involve 
developing clear guidance on which topics should be tackled in substance misuse treatment 
outcome measurement, and the instruments that best fit that purpose, based on the literature. It 
is also important to develop initiatives to encourage therapists and researchers to personalise 
outcome measurement as much as possible (for instance, through the use of I-PROMS), ideally 
promoted by health policy makers to ensure its success.  
 Finally, it is imperative that physical/virtual facilities and secure storage methods are 
developed to ensure data protection and patient confidentiality of those completing I-PROMS. 
When patients respond to I-PROMS, it is likely that identifiable data will be shared, such as 
names, locations or dates. This is particularly relevant in a patient group such as substance 
misusers, who may be involved with illegal activities e.g. theft or drug trafficking. Moreover, 
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the rapid advance of information technologies allowed for the development of systems to 
collect and/or store patient data in digital formats, from computer software to mobile 
applications, increasing the cost-effectiveness and feasibility of outcome measurement 
(Locklear et al., n.d., p. 10). Examples of such systems have been created for generalist mental 
health settings, e.g. Contextualised Feedback System (Bickman, Kelley, & Athay, 2012), as 
well as specific populations, e.g. Electronic Patient Reported Outcomes for Cancer Survivors 
(Ashley et al., 2011). Although helpful, the use of these electronic tools posits additional 
challenges in encrypting data, de-identifying information and protecting any patient-
identifiable data with firewalls or any equivalent data security methods (Wilcox et al., 2012).  
Access to personalised information provided in I-PROMS should also be given careful 
consideration. As Smith and Street (2012) pointed out, outcome measurement data can be used 
by individual clinicians, but also by teams, organisations and entire health systems to monitor 
the quality of health care provision. When such large-scale investigations are at stake, it is 
crucial to preserve the patient’s identity, ensuring that data is not used for ill purposes and to 
interfere with individuals’ personal freedom, welfare and/or socioeconomic situation.  
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Strengths and limitations 
Combining all of our studies, we have grounds to suggest that I-PROMS can be a viable 
strategy to collect individualised testimonies of patients in substance misuse treatment, 
allowing a personalisation of outcome measurement.  
Our project was innovative and ground breaking in several ways. To our knowledge, 
this was the first ever application of I-PROMS in substance misuse treatment. This project was, 
therefore, a step further from previous approaches that developed evaluation protocols with 
input from patients, or advocated personalised treatment, but did not collect information at an 
individual level (Marsden et al., 2014; Neale at al., 2016). From this perspective, we have also 
provided a pragmatic solution to the challenge highlighted by addiction researchers that 
outcome measurement in substance misuse treatment should include qualitative, personalised 
information about patients (Orford, 2008; Neale & Strang, 2008). 
We listened to the voices of a population that is often misheard and stigmatised and 
asked them to contribute with their opinion about outcome measures, which is something that 
tends to be decided in a top-down philosophy. To take a deeper step in this direction, we opted 
to conduct our focus group with female patients with alcohol problems in a rural setting, a sub-
population of substance misusers who tends to be even more neglected in this field (Olszewski, 
Giraudon, Hedrich, & Montanari, 2009).  
Even though the combination of qualitative and quantitative data is still under debate, 
mixed-methods designs are being increasingly adopted in healthcare (Östlund, Kidd, 
Wengström, & Rowa-Dewar, 2009). In line with this, this project followed a mixed-methods 
approach, by analysing qualitative and quantitative information generated by the same patients, 
in I-PROMS, and reflecting about the relationship between these two types of information.  
Another strength of our project was the contrast of the qualitative and quantitative 
information derived from two different I-PROMS. There were no reports of such comparison 
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in the literature, and the differences that we found between PQ and PSYCHLOPS suggest that 
this topic deserves further exploration. 
This work has several limitations that must be highlighted as well, the first being the 
absence of post-treatment data. Such data would have allowed for an estimation of further PQ 
and PSYCHLOPS psychometric parameters, such as sensitivity to change and consistency of 
results over time (time-series analysis). Although the collection of post-treatment data was 
planned, the characteristics of the sample prevented it from taking place, and only a very 
limited number of patients were traceable and completed the second evaluation (5 out of 93 
patients). Reasons for missing the second evaluation were patients dropping out of treatment 
and being referred to inpatient therapeutic services in remote regions of the country. A larger 
period assigned to data collection, as well as a larger sample, would have increased the 
likelihood of collecting a bigger sample of post-treatment evaluations. In the context of this 
project, the lack of time, funding and human resources impaired those possibilities.  
The findings were based in items generated by patients in I-PROMs. These items 
corresponded to sentences elicited in patients’ own words. However, the quality of these items 
was not explored and it is possible that certain problems were more clearly explained and better 
formed than others. For instance, problems such as ‘my alcoholism’ were less informative than 
‘I cannot stop drinking’, although both refer to addiction problems. This may have affected the 
results of the thematic analysis, by hindering the judge’s task of categorising the underlying 
theme of each item. To ensure that this limitation is overcome in the future, the quality of the 
items should be evaluated, using a validated and reliable procedure.   
In our naturalistic study, only three standardised measures were contrasted with I-
PROMs. Our findings supported the idea that these standardised missed topics of importance 
to patients. We hypothesize that if other measures, or a larger number of measures, had been 
used, different results could have been achieved. Our biggest concern is that we did not include 
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the measure SURE (Neale et al., 2016) in our protocol. This measure was developed with input 
from patients and, for that reason, it would have been important to contrast it with I-PROMS. 
However, when this measure was released (2016), our data had already been collected. Despite 
these limitations, there was an effort to include measures that addressed topics supported by 
relevant literature; and also to keep the number of measures in the protocol to a minimum, to 
ensure feasibility of the protocol. Also, even if different measures would have produced 
different findings, we believe that we would have reached similar conclusions. Our aim was to 
illustrate how standardised measures have a limited capacity to capture the individuality of 
patients, and to our knowledge, it is unlikely that any existing standardised measure included 
every aspect of a patient’s life that causes him/her with distress.  
Another limitation refers to the number of clinical services and the sample of patients 
that participated in our project. With only four participating research sites, and a sample of 93 
patients, the generalisability of our findings is restricted. This is particularly problematic in our 
qualitative study, which is based in a single focus group, with a very specific population 
(women with alcohol problems). Nevertheless, this inpatient service was the only setting where 
gathering a group of patients available for approximately three hours, at the same day/time, 
was possible. It is expected that future studies can contribute with further data about the use of 
I-PROMs in mental health in general, and in substance misuse treatment, in particular, so that 
more evidence on their advantages and drawbacks can be accumulated. Figure 2 summarises 
the strengths and limitations of this project.  
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Figure 2. Summary of strengths and limitations of this project.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Strengths/Innovations
• Using I-PROMS in substance 
misuse treatment
• Gathering the perspectives of 
stigmatised and devalued patients
• Using a bottom-up approach 
(collaborating with patients) to 
reflect about outcome measures
• Following a mixed-methods 
approach 
• Proposing a pragmatic response to 
the lack of patient involvement with 
treatment
• Comparing two different I-PROMS
• Reviewing a wide range of outcome 
measures recommended for 
substance misuse treatment
Limitations
• Lack of post-treatment evaluations
• Quality of I-PROMS items was not 
evaluated 
• Limited number (n = 3) of 
standardised measures used for 
comparison purposes with I-
PROMS
• Lack of generalisability due to 
small number of services recruited 
(n = 4) for data collection 
• Small sample size (N = 10) used in 
the qualitative study 
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Concluding remarks  
To sum up, this project showed that patients in substance misuse treatment are able to 
contribute with valuable hints about how outcome measurement can be conducted in this field. 
It has revealed that using I-PROMS is a practical method to generate important and 
personalised information about patient’s concerns that traditional, standardised outcome 
measures may overlook. Moreover, I-PROMS were able to produce satisfactory quantitative 
estimates of patient’s level of distress. Our project has also suggested that patients perceive I-
PROMS as measures that enable them to talk freely about their problems, including those that 
were not directly related to substance misuse. When considering a wider range of standardised 
measures, we found further evidence that measures with pre-set items driven by experts do not 
always reflect the problems that patients in this population experience. This work has 
successfully demonstrated that patients can be (more) actively involved in outcome 
measurement, by contributing with data about their own clinical status through the use of I-
PROMS. As a methodology that allows for a personalisation of outcome measurement, I-
PROMS are a potential strategy to help therapists delivering a more patient-centred healthcare 
to those with substance misuse problems, as advocated by scientists and health policy makers. 
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ADDITIONAL MATERIALS  
 
   
 
A questionnaire about you and how you are feeling –  
now that you are starting therapy 
 
Question 1 
 
a Choose the problem that troubles you most.  (Please write it in the box below.) 
  
               
 
b  How much has it affected you over the last week?  (Please tick one box below.) 
 
 0  1  2  3  4  5  
Not at all affected            Severely affected 
             
c How long ago were you first concerned about this problem?  (Please tick one box below.) 
   
Under one month 
 
Between one and three 
months 
 
Over three months 
but under one year 
 
 
One to five years 
 
 
Over five years 
 
                 
 
Question 2 
 
a Choose another problem that troubles you.  (Please write it in the box below.) 
  
               
 
b  How much has it affected you over the last week?  (Please tick one box below.) 
 
   0  1  2  3  4  5    
Not at all affected            Severely affected 
 
c How long ago were you first concerned about this problem?  (Please tick one box below.) 
   
Under one month 
 
Between one and three 
months 
 
Over three months 
but under one year 
 
 
One to five years 
 
 
Over five years 
 
                 
 
Question 3 
 
a Choose one thing that is hard to do because of your problem (or problems).  (Please write it in the box below.) 
  
               
 
b How hard has it been to do this thing over the last week?  (Please tick one box below.) 
 
 0  1  2  3  4  5  
Not at all hard            Very hard 
 
    Question 4 
  
How have you felt in yourself this last week?   (Please tick one box below.) 
 
 0  1  2  3  4  5  
Very good            Very bad 
     
 
 
 
 
 
This questionnaire is called the Psychological Outcome Profiles questionnaire (PSYCHLOPS), Pre-Therapy, Version 5. 
Client ID  
   
See www.psychlops.org  All rights reserved © 2010, Department of Primary Care and Public Health Sciences, King’s College London. 
 
 
 
Therapist Assessment Form – pre therapy 
 
 
To be completed by the therapist and attached to the completed questionnaire. 
            
 clinic / surgery ID   
 client ID or initials   client age or DOB  
            
 therapist ID   
 client gender      
            
 referral date    
  
            
 assessment date   
     
            
 date pre-therapy PSYCHLOPS completed   
     
       
 date of first session (unless same as above)   
     
 
 
             How does the client describe their ethnic group? 
         (Please tick one of the boxes below)      
        
            Asian or Asian British        Chinese or Other ethnic groups       White 
 Bangladeshi     Chinese    British  
 Indian   Irish  
Pakistani     
Other Asian background 
(please specify) 

  Other ethnic group 
(please specify) 
   
Other White background 
(please specify)  
            
            Black or Black British       Mixed background 
 Caribbean 
 
 White & Asian    
   
 African     White & Black African      
    White & Black Caribbean      
 
Other Black background 
(please specify)  client’s first language: 
  
  Other Mixed background 
(please specify) 
 
 
 
 
 
Scoring PSYCHLOPS 
 
 PSYCHLOPS has been designed as a mental health outcome measure. As such, the pre-therapy score is 
compared with subsequent scores (during therapy and post-therapy). The difference is the ‘change score’. 
 All of the responses in PSYCHLOPS are scored on a six point scale ranging from zero to five. The higher the 
value, the more severely the person is affected.   
 Not every question in PSYCHLOPS is used for scoring. Only the questions relating to Problems (Questions 1b 
and 2b), Functioning (Question 3b) and Wellbeing (Question 4) are scored. Other questions provide useful 
information but do not contribute to the change score. 
 The questions used for scoring are indicated with the symbol:          This symbol appears after the scoring 
boxes. The therapist may find it helpful to insert the score inside this symbol. 
 PSYCHLOPS therefore consists of three domains (Problems, Functioning and Wellbeing) and four questions 
which are scored. 
 The maximum PSYCHLOPS score is 20.  
 The maximum score for each question is 5.  
 If both Q1 (Problem 1) and Q2 (Problem 2) have been completed, the total score is: Q1b + Q2b + Q3b + Q4.  
 If Q1 (Problem 1) has been completed and Q2 (Problem 2) has been omitted, the total score is:    
(Q1b x 2) + Q3b + Q4. In other words, the score of Q1b (Problem 1) is doubled. This ensures that the maximum 
PSYCHLOPS score remains 20. 
 
 
Total PSYCHLOPS Pre-Therapy score:     
 
 
PSYCHLOPS, Pre-Therapy, Version 5. 
See www.psychlops.org  All rights reserved © 2010, Department of Primary Care and Public Health Sciences, King’s College London. 
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Simplified Personal Questionnaire Procedure (9/99) 
Robert Elliott, Carol Mack & David A. Shapiro 
University of Toledo 
 
The Personal Questionnaire (PQ) is an expanded target complaint measure which is 
individualized for each client.  It is generated from the PQ Problem Description Form, 
completed by the client during the screening process.  It intended to be a list of 
problems that the client wishes to work on in therapy, stated in the client’s own words. 
 
Materials 
 4” x 6” Index Cards 
 Blank PQ Form (for writing in items) 
 Problem Description Form (completed) 
 
Procedure 
 
1. Generating Items.  The items generated for the PQ should be the most important in 
the client’s view.  However, an attempt should be made to include one or two problems 
from each of the following areas: 
 •Symptoms 
 •Mood 
 •Specific performance/activity (e.g., work) 
 •Relationships 
 •Self-esteem 
This means that if the client does not list a problem in a particular area, the interviewer 
should ask the client if s/he has any difficulties in that area that s/he wants to work on 
in therapy.  If, however, the client does not wish to have an item for this area, the 
researcher does not insist on it. 
 
This part of the procedure should be thought of as a brainstorming session, generating 
as many potential items as possible (around 15 is preferable).  If the client has difficulty 
coming up with 10 problems, the interviewer can use other screening measures as 
sources of possible problems.  For example, if the client has completed the SCL-90-R, the 
interviewer can ask the client about items with “3” or “4” ratings.   
 
2.  Refining the PQ items.  Next, the interviewer helps the client to clarify his/her items 
and, if necessary, to rephrase the goals into problems.  If necessary, the number of items 
is reduced to around 10. 
 
2a. In this part of the procedure, the interviewer begins by writing each problem onto a 
separate index card, revising it in the process.  Refining PQ items is not a mechanical 
procedure, but requires discussion with the client to make sure that the PQ reflects 
Simplified Personal Questionnaire, p. 2 
his/her chief concerns.  It takes careful, patient communication to make sure that the 
PQ items truly reflect the client’s experience of what is problematic. 
 
PQ items should be present problems or difficulties, and should be worded “I feel,” “I 
am,” “I can’t,” “My thinking,” and so on.  It is useful to think of the list as things the 
client wants to change through therapy.  A good PQ item has the following 
characteristics: 
  •It reflects an area of difficulty, rather than a goal (e.g., “I am too shy” 
rather than “I want to be more outgoing”). 
 •It is something that the client wants to work on in therapy. 
 •It refers to a specific problem; that is, general, vague problems are specified. 
  •It refers to a single problem; that is, items referring to multiple problems 
(e.g., “I’m uncomfortable around other people and have trouble talking 
about myself.”) are divided up into multiple items. 
 •It is in the client’s own words, not the interviewer’s. 
 •It is not redundant with another PQ item. 
 
2b. After the interviewer writes down the items, s/he then asks the client if anything 
has been left out, adding further items as needed, until the client feels that the list is 
complete.  
 
2c. The interviewer next reviews the items with the client, asking the client to revise or 
confirm them.  If the client has generated more than 10 items, the interviewer asks the 
client to delete or combine repetitive items.  If there are still more than 10 items, the 
interviewer asks the client is s/he wants to drop any.  The interview should not force 
the client to generate exactly 10 items; but try to obtain 8-12 items where possible.   
 
3. Prioritizing the items.  Next, the interviewer asks the client to sort the index cards 
into order, with the most important concern first, the next most important second, etc.  
The rank order of the item is written on the card. 
 
4. Rating the PQ.  After prioritizing, the interviewer gives the client a blank PQ form 
and the rank-ordered index cards, and asks the client to use the blank form to rate how 
much each problem has bothered him/her during the past week.  These ratings become 
the client’s initial baseline score for the PQ.   
 
4a. Optional: Duration ratings.  In addition, at this first administration of the PQ, the 
interviewer may want to find out how long each problem has bothered the client at 
roughly the same level or higher as it does now, using the Personal Questionnaire 
Duration Form.  This can be useful for establishing a retrospective baseline for the PQ. 
 
5. Prepare the PQ.  Finally, the interviewer types or writes the PQ items onto a blank PQ 
form, making at least 10 copies for future use.  In doing so, it is a good idea to leave 2 
Simplified Personal Questionnaire, p. 3 
spaces blank for the client to add more items later, in case his/her problems shift over 
time.
Simplified Personal Questionnaire, p. 4 
Your initials:                             (Client ID:                         ) 
Today’s date:                              
 
Problem Description Form: Do this one first! 
 
1. Please describe the main problems you are having right now that led you to seek 
treatment. 
 
 
 
 
 
 
 
2. If you are seeking psychotherapy, please list the specific problems or difficulties that 
would like assistance with.  Please feel free to add to your list as you fill out other 
forms. 
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PERSONAL QUESTIONNAIRE  Client ID                                 
Today’s date:                                             
 
Instructions:  Please complete before each session.  Rate each of the following problems 
according to how much it has bothered you during the past seven days, including 
today. 
  
Not 
At 
All  
Ver
y  
Littl
e 
 
Little 
Mod
erate
ly 
Consi
derabl
y 
Very 
Consi
derabl
y 
Maxim
um 
Possibl
e 
1.  
 
1 2 3 4 5 6 7 
2. 
 
1 2 3 4 5 6 7 
3. 
 
1 2 3 4 5 6 7 
4. 
 
1 2 3 4 5 6 7 
5. 
 
1 2 3 4 5 6 7 
6. 
 
1 2 3 4 5 6 7 
7. 
 
1 2 3 4 5 6 7 
8. 
 
1 2 3 4 5 6 7 
9. 
 
1 2 3 4 5 6 7 
10. 
 
1 2 3 4 5 6 7 
Additional Problems: 
11. 
 
1 2 3 4 5 6 7 
12. 
 
1 2 3 4 5 6 7 
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Personal Questionnaire Duration Form      Client ID                         
Today’s date:                            
 
Instructions:  Please rate how long each of your problems has bothered you at roughly 
the same level (or higher) as it does now. 
 less 
than 1 
mont
h 
1 - 5 
mont
hs  
6 - 11 
mont
hs 
1 - 2  
years 
3 - 5 
year
s 
 
6 - 
10 
year
s 
 
more 
than 
10 
years 
1. 1 2 3 4 5 6 7 
2. 1 2 3 4 5 6 7 
3. 1 2 3 4 5 6 7 
4. 1 2 3 4 5 6 7 
5. 1 2 3 4 5 6 7 
6. 1 2 3 4 5 6 7 
7. 1 2 3 4 5 6 7 
8. 1 2 3 4 5 6 7 
9. 1 2 3 4 5 6 7 
10. 1 2 3 4 5 6 7 
11. 1 2 3 4 5 6 7 
12. 1 2 3 4 5 6 7 
 
 
CLINICAL
OUTCOMES in
ROUTINE
EVALUATION 
          OUTCOME
           MEASURE
Male
 Age Female
Stage Completed
S Screening                         Stage
R Referral
A Assessment
F First Therapy Session
P Pre-therapy (unspecified)
D During Therapy
L Last therapy session         Episode
X Follow up 1
Y Follow up 2
IMPORTANT - PLEASE READ THIS FIRST
This form has 34 statements about how you have been OVER THE LAST WEEK.
Please read each statement and think how often you felt that way last week.
Then tick the box which is closest to this.
Please use a dark pen (not pencil) and tick clearly within the boxes.
Over the last week
 1  I have felt terribly alone and isolated 0 1 2 3 4 F
 2  I have felt tense, anxious or nervous 0 1 2 3 4 P
 3  I have felt I have someone to turn to for support when needed 4 3 2 1 0 F
 4  I have felt O.K. about myself 4 3 2 1 0 W
 5  I have felt totally lacking in energy and enthusiasm 0 1 2 3 4 P
 6  I have been physically violent to others 0 1 2 3 4 R
 7  I have felt able to cope when things go wrong 4 3 2 1 0 F
 8  I have been troubled by aches, pains or other physical problems 0 1 2 3 4 P
 9  I have thought of hurting myself 0 1 2 3 4 R
 10  Talking to people has felt too much for me 0 1 2 3 4 F
 11  Tension and anxiety have prevented me doing important things 0 1 2 3 4 P
 12  I have been happy with the things I have done. 4 3 2 1 0 F
 13  I have been disturbed by unwanted thoughts and feelings 0 1 2 3 4 P
 14  I have felt like crying 0 1 2 3 4 W
Please turn over
Site ID
letters only numbers only
Client ID
Therapist ID    numbers only (1)  numbers only (2)
Sub codes  
Date form given
/
D D
/
M M Y Y Y Y
Survey : 151 Page : 1Copyright MHF and CORE System Group.  
On
ly 
Mo
st 
or 
ON
LY
No
t a
t a
ll
Oc
cas
ion
all
y
So
me
tim
es
Of
ten
all
 th
e t
im
e
OF
FIC
E U
SE
Over the last week
 15  I have felt panic or terror 0 1 2 3 4 P
 16  I made plans to end my life 0 1 2 3 4 R
 17  I have felt overwhelmed by my problems 0 1 2 3 4 W
 18  I have had difficulty getting to sleep or staying asleep 0 1 2 3 4 P
 19  I have felt warmth or affection for someone 4 3 2 1 0 F
 20  My problems have been impossible to put to one side 0 1 2 3 4 P
 21  I have been able to do most things I needed to 4 3 2 1 0 F
 22  I have threatened or intimidated another person 0 1 2 3 4 R
 23  I have felt despairing or hopeless 0 1 2 3 4 P
 24  I have thought it would be better if I were dead 0 1 2 3 4 R
 25  I have felt criticised by other people 0 1 2 3 4 F
 26  I have thought I have no friends 0 1 2 3 4 F
 27  I have felt unhappy 0 1 2 3 4 P
 28  Unwanted images or memories have been distressing me 0 1 2 3 4 P
 29  I have been irritable when with other people 0 1 2 3 4 F
 30  I have thought I am to blame for my problems and difficulties 0 1 2 3 4 P
 31  I have felt optimistic about my future 4 3 2 1 0 W
 32  I have achieved the things I wanted to 4 3 2 1 0 F
 33  I have felt humiliated or shamed by other people 0 1 2 3 4 F
 34  I have hurt myself physically or taken dangerous risks with 0 1 2 3 4 R
 my health
THANK YOU FOR YOUR TIME IN COMPLETING THIS QUESTIONNAIRE
Total Scores
Mean Scores
(Total score for each dimension divided by 
number of items completed in that dimension)
(W) (P)               (F) (R) All items All minus R
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P A T I E N T  H E A L T H  Q U E S T I O N N A I R E - 9   
( P H Q - 9 )  
Over the last 2 weeks, how often have you been bothered 
by any of the following problems? 
(Use “✔” to indicate your answer) Not at all 
Several 
days 
More 
than half 
the days 
Nearly 
every 
day 
1. Little interest or pleasure in doing things 0 1 2 3 
2. Feeling down, depressed, or hopeless 0 1 2 3 
3. Trouble falling or staying asleep, or sleeping too much 0 1 2 3 
4. Feeling tired or having little energy 0 1 2 3 
5. Poor appetite or overeating 0 1 2 3 
6. Feeling bad about yourself — or that you are a failure or 
have let yourself or your family down 0 1 2 3 
7. Trouble concentrating on things, such as reading the 
newspaper or watching television 0 1 2 3 
8. Moving or speaking so slowly that other people could have 
noticed. Or the opposite — being so fidgety or restless that 
you have been moving around a lot more than usual 
0 1 2 3 
9. Thoughts that you would be better off dead or of hurting 
yourself in some way 0 1 2 3 
                                                                                                               FOR OFFICE CODING     0      + ______  +  ______  +  _____ 
=Total Score:  ______ 
 
     
If you ticked any problems, how difficult have these problems made it for you to do your work, 
take care of things at home, or get along with other people? 
Not difficult  
at all 
? 
Somewhat  
difficult 
? 
Very  
difficult 
? 
Extremely  
difficult 
? 
 
 
 
 
 
Developed by Drs. Robert L. Spitzer, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant from 
Pfizer Inc. No permission required to reproduce, translate, display or distribute. 
    
  
 
Um questionário sobre si e sobre como se sente –  
agora que está a iniciar a terapia 
 
Pergunta 1 
 
a Qual o problema que mais o preocupa?  (Por favor, escreva na caixa que se segue) 
   
               
b  Quanto é que este problema o afectou ao longo da última semana?  (Por favor, assinale uma das seguintes opções) 
 
 0  1  2  3  4  5  
Não afectou nada            Afectou muitíssimo 
             
c Quando é que se começou a preocupar com este problema?  (Por favor, assinale uma das seguintes opções) 
 
 
 
Menos de 1 mês 
 
 
Entre 1 e 2 meses 
 
 
Entre 3 meses e 1 ano 
 
 
Entre 1 e 5 anos 
 
 
Mais do que 5 anos 
 
                 
Pergunta 2 
 
a Indique outro problema que o preocupa.  (Por favor, escreva na caixa que se segue) 
   
               
b  Quanto é que este problema o afectou ao longo da última semana?  (Por favor, assinale uma das seguintes opções) 
 
   0  1  2  3  4  5    
Não afectou nada            Afectou muitíssimo 
 
c Quando é que se começou a preocupar com este problema?  (Por favor, assinale uma das seguintes opções) 
 
 
 
Menos de 1 mês 
 
 
Entre 1 e 2 meses 
 
 
Entre 3 meses e 1 ano 
 
 
Entre 1 e 5 anos 
 
 
Mais do que 5 anos 
 
                 
Pergunta 3 
 
a Há alguma coisa que se tenha tornado difícil de fazer devido ao seu problema (ou problemas)?  (Por favor, 
escreva na caixa que se segue) 
 
   
               
b Quanto foi difícil durante a última semana?  (Por favor, assinale uma das seguintes opções) 
 
 
 0  1  2  3  4  5  
Nada difícil            Extremamente difícil 
Pergunta 4 
  
Como se tem sentido consigo mesmo durante esta semana?   (Por favor, assinale uma das seguintes opções) 
 
 0  1  2  3  4  5  
Muito bem            Muito mal 
     
 
 
 
 
 
Psychological Outcome Profiles (PSYCHLOPS), Pré-Terapia, Versão Portuguesa 2. www.psychlops.org 
  Todos os direitos reservados © 2013, Universidade de Évora | King’s College London | Cis-IUL, Instituto Universitário de Lisboa (ISCTE-IUL) 
ID Paciente 
 
 1
Procedimento do Questionário Pessoal Simplificado PQ 
Robert Elliott, Mack, & Shapiro (1999) 
Adaptado por Célia Sales, Sónia Gonçalves, Daniel Sousa, Eugénia Fernandes, Isabel Silva,  
Jane Duarte, & Robert Elliott (2007) 
 
O Questionário Pessoal Simplificado (PQ) é um instrumento individualizado de mudança de 
tipo target complaint. Pretende ser uma lista dos pontos que o cliente (ou cada elemento da 
família) deseja trabalhar em terapia, formulados pelas suas próprias palavras. 
O PQ é construído durante uma entrevista individual, cujo procedimento se descreve de 
seguida. 
 
MATERIAL 
 Cartões de cartolina 
 Folha branca 
 Formulário PQ, por preencher (para escrever os itens) 
 Formulário de Duração dos Problemas 
 
PROCEDIMENTO 
 
1. Confidencialidade 
Inicialmente refere-se ao cliente que todos os dados recolhidos na entrevista serão 
confidenciais, ficando cingidos à equipa de investigação que os está a recolher, e à equipa 
terapêutica que trabalhará a partir deles, com o intuito de apoiar decisões clínicas ao longo 
do processo terapêutico. 
 
2. Construir a lista dos itens 
Os itens do PQ devem corresponder aos problemas mais importantes, na perspectiva do 
entrevistado. No entanto, deverá tentar-se a inclusão de 1 ou 2 pontos em cada uma das 
seguintes áreas: 
 * Sintomas 
 * Humor 
 * Nível de actividade geral (trabalho, etc.) 
 * Relações interpessoais 
 * Auto-estima 
 
Se o entrevistado não incluir na sua lista pontos em alguma destas áreas específicas, o 
entrevistador deve perguntar se existem dificuldades em alguns desses domínios, que o 
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cliente deseje trabalhar em terapia. Se tal não acontecer, o investigador não deve insistir na 
questão. 
 
Esta fase do procedimento deve considerar-se como uma sessão de brainstorming, tentando 
gerar-se o máximo de itens possível (15 é o ideal). Este brainstorming pode ser iniciado com 
uma instrução verbal do tipo: 
 
“Queria pedir-lhe que me falasse dos motivos que o trouxeram aqui…” 
 
À medida que o cliente fala, o entrevistador escreve numa folha em branco frases que 
correspondam a queixas ou problemas. 
 
3. Filtrar os itens 
Nesta fase, pretende-se ajudar o entrevistado a clarificar os itens listados anteriormente e, se 
necessário, a redefinir os objectivos em Problemas. Se possível, o número de itens deverá ser 
reduzido para cerca de 10.  
O investigador começa por escrever cada queixa num cartão, confirmando-o com o 
entrevistado. Redefinir os itens não é, nem deverá ser, um procedimento mecanizado, e 
requer que se discuta com o entrevistado para garantir que o PQ reflecte as suas principais 
preocupações. Exige uma comunicação cuidada e paciente, que assegure que os itens 
evidenciam a perspectiva do entrevistado acerca do que é relevante e pertinente para a 
terapia.  
 
Um item bem estruturado deverá possuir determinadas características: 
 * Reflectir uma área de dificuldade ao invés de um objectivo de mudança (por 
exemplo “sou muito tímido” ao invés de “quero ser mais sociável”) 
 * Ser algo que o entrevistado quer trabalhar em terapia 
 * Referir-se a um problema concreto, ou seja, os problemas gerais e vagos devem ser 
especificados 
 * Referir-se a um único ponto, ou seja, itens que se reportam a problemas 
múltiplos/vários pontos (por exemplo, “tenho medo de estar com pessoas e tenho muita 
dificuldade em falar sobre mim”) devem ser divididos de forma a constituírem múltiplos itens 
 * Utilizar as palavras do entrevistado, não do investigador 
 * Não ser redundante em relação a qualquer outro item. 
 
Depois de escritos os problemas, o entrevistador deve confirmar se o entrevistado não tem 
mais nada a acrescentar. 
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4. Priorizar os itens 
O investigador pede ao entrevistado que organize os cartões por ordem decrescente de 
importância dando a seguinte instrução verbal: 
 
“Destes problemas qual é o que lhe causa mais mal-estar?... E a seguir?... E a 
seguir?...” 
(até que todos estejam ordenados) 
 
O número de ordem do item deverá escrever-se no cartão. 
 
5. Classificar o PQ 
Depois de priorizar, o investigador preenche o formulário do PQ, colocando os itens pela 
ordem indicada de importância indicada pelo cliente. Dando o formulário preenchido ao 
entrevista, solicita: 
 
“Pensando em cada problema, indique o nível de mal-estar (ou “quanto mal-estar”) 
que cada um lhe causou na última semana” 
 
Alternativamente, por exemplo, se o entrevistado não souber / não puder ler, o entrevistado 
lê em voz alta o item e pergunta o grau de mal-estar, numa escala de 1 a 7. 
 
O investigador deverá tentar perceber se o entrevistado compreendeu o pedido. Se verificar 
que isto não aconteceu, deve explicá-lo de uma forma o mais claro e simples possível, 
assegurando que a classificação será o mais aproximada possível das preocupações do 
entrevistado. 
 
5a. Opcional: Classificação de Duração 
Na primeira aplicação do PQ, o investigador pode estar interessado em saber há quanto 
tempo cada problema tem vindo a preocupar o entrevistado da mesma forma que o preocupa 
no momento, ou mais. Para obter esta informação, deverá usar o Formulário de Duração PQ. 
Este pode ser usado para estabelecer uma baseline retrospectiva para o PQ. 
 
6. Preparar o PQ 
Finalmente, o investigador escreve os itens do PQ num formulário em branco, fazendo pelo 
menos 10 cópias para uso futuro. Ao fazer esta transcrição, é útil deixar aproximadamente 2 
espaços em branco para que o cliente possa adicionar itens posteriormente, se desejar. 
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(Código do Cliente:                         )                                    Data: ___ / ___ / ______ 
 
 
 
 
Formulário para Descrição do Problema: A preencher em primeiro lugar! 
 
 
 
 
1. Por favor, descreva os principais problemas que o levaram a procurar ajuda.  
 
 
 
 
 
 
 
 
 
 
 
 
2. Por favor, indique os problemas específicos que gostaria que fossem abordados na 
terapia. 
 
 
 5
QUESTIONÁRIO PESSOAL   Data: ___ / ___ / ______   Código Cliente: _________ 
 
Instruções: Por favor, indique o grau de mal-estar que cada problema lhe causou na última semana. Muito obrigado. 
 
 
Nenhum 
Mal-Estar 
Muito Pouco Pouco 
Mal-Estar 
Moderado 
Grande 
Muito 
Grande 
Mal-Estar 
Total 
1. 
 
1 2 3 4 5 6 7 
2. 
 
1 2 3 4 5 6 7 
3. 
 
1 2 3 4 5 6 7 
4. 
 
1 2 3 4 5 6 7 
5. 
 
1 2 3 4 5 6 7 
6. 
 
1 2 3 4 5 6 7 
7. 
 
1 2 3 4 5 6 7 
8. 
 
1 2 3 4 5 6 7 
9. 
 
1 2 3 4 5 6 7 
10. 
 
1 2 3 4 5 6 7 
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QUESTIONÁRIO PESSOAL  Data: ___ / ___ / ______   Código Cliente: _________ 
 
Instruções: Por favor, pense desde quando é que estes problemas lhe causam mal-estar, com a mesma intensidade que indicou no 
quadro anterior, ou com maior intensidade. 
 
 
Menos de 
1 mês 
De 1 a 5 
meses 
De 6 a 11 
meses 
De 1 a 2 
anos 
De 3 a 5 
anos 
De 6 a 10 
anos 
Há mais de 
10 anos 
1. 
 
1 2 3 4 5 6 7 
2. 
 
1 2 3 4 5 6 7 
3. 
 
1 2 3 4 5 6 7 
4. 
 
1 2 3 4 5 6 7 
5. 
 
1 2 3 4 5 6 7 
6. 
 
1 2 3 4 5 6 7 
7. 
 
1 2 3 4 5 6 7 
8. 
 
1 2 3 4 5 6 7 
9. 
 
1 2 3 4 5 6 7 
10. 
 
1 2 3 4 5 6 7 
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QUESTIONÁRIO PESSOAL  Data: ___ / ___ / ______   Código Cliente: _________ 
 
Instruções: Preencher antes de cada sessão. Por favor, indique o grau de mal-estar que cada problema lhe tem causado desde a 
última consulta. Caso existam novos problemas, por favor acrescente-os e indique o grau de mal-estar. Se algum dos problemas já 
não fizer sentido, por favor risque-o na lista. Muito obrigado.  
 
 
Nenhum 
Mal-Estar 
Muito Pouco Pouco 
Mal-Estar 
Moderado 
Grande 
Muito 
Grande 
Mal-Estar 
Total 
1. 
 
1 2 3 4 5 6 7 
2. 
 
1 2 3 4 5 6 7 
3. 
 
1 2 3 4 5 6 7 
4. 
 
1 2 3 4 5 6 7 
5. 
 
1 2 3 4 5 6 7 
6. 
 
1 2 3 4 5 6 7 
7. 
 
1 2 3 4 5 6 7 
8. 
 
1 2 3 4 5 6 7 
9. 
 
1 2 3 4 5 6 7 
10. 
 
1 2 3 4 5 6 7 
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QUESTIONÁRIO SOBRE A SAÚDE DO PACIENTE- 9   
( P H Q - 9 )  
Durante os últimos 14 dias, em quantos foi afectado/a por 
algum dos seguintes problemas? 
(Utilize"✔" para indicar a sua resposta) Nunca 
Em 
vários 
dias 
Em mais 
de 
metade 
do 
número 
de dias 
Em 
quase  
todos os 
dias 
1. Tive pouco interesse ou prazer em fazer coisas 0 1 2 3 
2. Senti desânimo, desalento ou falta de esperança 0 1 2 3 
3. Tive dificuldade em adormecer ou em dormir sem 
interrupções, ou dormi demais 0 1 2 3 
4. Senti cansaço ou falta de energia 0 1 2 3 
5. Tive falta ou excesso de apetite 0 1 2 3 
6. Senti que não gosto de mim próprio/a — ou que sou um(a) 
falhado/a ou me desiludi a mim próprio/a ou à minha 
família 
0 1 2 3 
7. Tive dificuldade em concentrar-me nas coisas, como ao ler o 
jornal ou ver televisão 0 1 2 3 
8. Movimentei-me ou falei tão lentamente que outras pessoas 
poderão ter notado. Ou o oposto: estive agitado/a a ponto 
de andar de um lado para o outro muito mais do que é 
habitual 
0 1 2 3 
9. Pensei que seria melhor estar morto/a, ou em magoar-me a 
mim próprio/a de alguma forma 0 1 2 3 
                                                                                                              FOR OFFICE CODING     0      + ______  +  ______  +  ______ 
=Total Score:  ______ 
 
     
Se indicou alguns problemas, até que ponto é que eles dificultaram o seu trabalho, o cuidar da 
casa ou o lidar com outras pessoas? 
Não  
dificultaram 
? 
Dificultaram um  
pouco 
? 
Dificultaram  
muito 
? 
Dificultaram  
extremamente 
? 
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